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ABSTRACT 
 
A diverse range of cellular functions are influenced by the activity of protein kinase 
B (PKB, also known as Akt). PKB is involved in a number of physiological 
pathways, perturbation of which can lead to pathological conditions. PKB 
activation has been shown to involve binding of its pleckstrin homology (PH) 
domain to PtdIns(3,4)P2 and PtdIns(3,4,5)P3 generated on the inner face of the 
plasma membrane upon receipt of an external hormonal signal.  
To study PKB independently of other inositol-phospholipid binding proteins which 
recognise the same lipid signals, their mutual dependence on the same ligand must 
be broken. It is proposed that this can be achieved by mutating PKB‟s PtdInsP n 
binding PH domain to accept an unnatural ligand. By altering the inositol -
phospholipid head-group to include an additional carboxylic acid substituent, its 
binding to the wild-type PH domains should be inhibited through steric 
compression. Disruption of a salt-bridge in the wall of the binding pocket by point 
mutation of glutamate 17 to alanine, E17A, introduces an additional positively 
charged pocket into the PH domain of PKB, which should bind with the tailored 
lipid, resulting in a polar group exchange receptor-ligand pair. 
To this end, a novel 2-O-acetic acid functionalised analogue of Ins(1,3,4,5)P4 was 
synthesised. The key steps were the protection/deprotection of myo-inositol‟s 
hydroxyls, enabling selective functionalisation of the 2-hydroxyl, and 
phosphorylation of the 1,3,4,5-O positions. Using an allyl ether as a masked form of 
acetic acid allowed a divergent synthetic strategy to be employed to access 
additional 2-O analogues. 
Both the wild-type and the E17A mutant of the PH domain were expressed in order 
to assess ligand binding, and determine whether an ion pair exchange receptor-
ligand interaction occurred. Intrinsic tryptophan fluorescence spectrometry was 
initially used, but was unsuccessful due to denaturing problems arising from 
isolating the protein. Isothermal titration calorimetry suggested binding, but protein 
concentration could not be increased high enough for the binding energy to become 
significantly greater than the energy of mixing.  
The analogues were also tested as potential inositol poly-phosphate phosphatase 
catalytic (IPPc) domain inhibitors. 
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DNA-PK  DNA-dependent protein kinase 
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EI electron impact ionisation 
ELISA  enzyme linked immunosorbent assay 
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EST  expressed sequence tag 
FAB fast atom bombardment 
FAB-MS  fast atom bombardment mass spectrometry 
FYVE  Fab1, YOTB, Vac1, and EEA1 
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Glu/E glutamic acid 
Gly/G  glycine 
GST  glutathione S-transferase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hER human estrogen receptor 
His/H histidine 
HPLC high performance liquid chromatography 
HRP horseradish peroxidase 
Ile/I  isoleucine 
Ins inositol 
InsPn/IPn  inositol poly-phosphate 
IPPc inositol poly-phosphate phosphatase catalytic 
IPTG  isopropyl -D thiogalactoside 
ITC  isothermal titration calorimetry 
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MALDI matrix-assisted laser desorption/ionisation 
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PDK2 3-phosphoinositide-dependent protein kinase-2 
PEPP1 phosphoinositol 3-phosphate binding protein-1 
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Phe/F  phenylalanine 
PHISH  3-phosphoinositide interacting SH2-containing protein 
PI3K  phosphoinositide 3-kinase 
PI5K  phosphoinositide 5-kinase 
PKB  protein kinase B 
PKC  protein kinase C 
PLC phospholipase C 
PLD  phospholipase D  
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ppm parts per million 
Pro/P  proline 
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pTSA para-toluenesulfonic acid 
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Ser/S  serine 
SET single electron transfer 
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SK1  sphingosine kinase-1 
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Src sarcoma 
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Tbdms tert-butyl dimethyl silyl  
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Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 12 - 
1. BACKGROUND  
 
1.1  OBJECTIVES 
 
Protein kinase B (PKB, also known as Akt) participates in the regulation of a 
diverse range of cellular functions. It controls physiological pathways and is a key 
junction point that underlies pathological conditions that arise from perturbation to 
these pathways. PKB activation has been shown to involve binding of its pleckstrin 
homology (PH) domain to specific inositol phospholipids contained within the 
plasma membrane. 11213 PH domains in 9880 proteins have been reported across a 
range of species.
1
 Therefore, in addition to PKB, there are multiple other PH 
domain containing proteins that also interact with the same inositol phospholipids. 
Phosphoinositide-dependent protein kinase-1 (PDK1) is one of these proteins.  In 
conjunction with PKB, PDK1 translocates to the cytoplasmic face of the plasma 
membrane where it then assists in the activation of PKB. This makes dissec tion of 
both PKB‟s activation mechanism and the specific down -stream events it regulates 
very complex. 
In order to study PKB independently of PDK1 it is necessary to break their mutual 
dependence on the same inositol phospholipids. It is proposed that this  can be 
achieved by mutating PKB‟s PH domain to accept an unnatural ligand utilising ion 
pair exchange methodology. By altering the inositol -phospholipid head-group to 
include an additional carboxylic acid substituent, its binding to the wild -type PH 
domains should be inhibited. Using site-directed mutation of E17 to A, an 
additional positively charged pocket can be introduced into the PH domain of PKB, 
which should bind with a tailored lipid.   
To establish an ion pair exchange receptor-ligand interaction, the aim is to form an 
additional attractive interaction between the customised lipid head-group and the 
mutant PH domain. Studying the isolated interaction between the modified inositol 
head-group and the mutant PH domain will allow optimisation of the head-group-
PH domain interaction. A synthetic lipid can then be developed that can then be 
used in combination with the full length PKB mutant expressed  in vivo. It is 
predicted that inserting the unnatural inositol-phospholipid into this system will 
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allow PKB to be studied in isolation, and lead to identification of down-stream 
events that are purely dependent on PKB being activated.  
To comprehend how PKB undergoes activation, it is important to understand how 
inositol phospholipids behave within biological systems. 
 
1.2  INOSITOL PHOSPHOLIPIDS 
 
Inositol phospholipids (PtdInsPn/PIPn) belong to the glycerophospholipid family,
2
 
representing slightly under 10% of the total  cellular levels of phospholipids.
3
 These 
compounds are made up of a sn-1,2-diacyl-glycerol-3-phosphate (phosphatidate) 
unit linked by a phosphodiester bond to a polar head-group. Inositol phospholipids 
are amphipathic; the head-group is hydrophilic and the long-chain fatty acid esters 
are hydrophobic. This amphipathic nature underlies the importance of 
phospholipids to biological membranes.  
Abundant in all biological membranes, phospholipids make up a major component 
of membrane lipids. Membranes constitute a permeability barrier that regulates the 
transmission of information between a cell and its environment.
4
 
Glycerophospholipid nomenclature is determined by the structure of its head -group. 
The main biological properties of the molecule are also a direct result of the head -
group, and modifications of it.  
 
Figure 1. General molecular structure of PtdIns. The phosphatidyl subunit is highlighted in 
red and the myo-inositol head-group in yellow. 
 
Despite the fact inositol phospholipids have been studied since the 1930s,
5
 it was 
not until 1959 that their general structure was confirmed
 
(Figure 1).
6
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Phosphatidylinositol (PtdIns) consists of a phosphatidyl (Ptd) subunit - diacyl 
glycerol (DAG), bound to two long lipophilic saturated or unsaturated fatty acid 
esters - linked by a phosphate ester bond to the 1-O of the cyclohexane hexitol myo-
inositol (Ins). The basic PtdIns structure provides the building block for a collection 
of biologically active compounds. These arise from reversible enzymatic 
phosphorylation and dephosphorylation of the hydroxyls.
7
 Compared to other 
membrane lipids, this makes PtdIns unique.  
Potentially, all five of the free hydroxyl groups could undergo phosphorylation, 
generating a prospective thirty-one mono- and poly- phosphorylated compounds. 
However, within the biological context, only phosphorylation of the 3 -, 4- and 5-
hydroxyls has been documented.
8
 This produces seven phosphorylated PtdInsPn 
species (Figure 2). 
 
Figure 2. Molecular structures of the head-groups of the documented PtdInsPn species 
found in eukaryotic cells. 
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While glycerophospholipids frequently function in a structural capacity, some are 
also actively involved in the intracellular signalling pathways of eukaryotic cells.
9
  
Phosphatidylcholine (PC) undergoes catalytic hydrolysis by phospholipase D 
(PLD), releasing the soluble choline head-group into the cytosol and forming the 
signalling molecule phosphatidic acid (PtdOH) which acts to recruit sphingosine 
kinase 1 (SK1) to the membrane.
10
 Similarly the PtdInsPn family can also act in 
intracellular signalling events. 
 
1.3  INTRACELLULAR SIGNALLING 
 
Within complex organisms, it is vital for the cells to be able to communicate in 
order to sustain each other‟s survival by mutual cooperation. Communication over 
varying distances, from a cell‟s immediate vicinity to approaching the total length 
of the organism, needs to be spanned for successful survival. The predominant 
technique employs hormones, such as neurotransmitters, steroids and a range of 
peptides. 
Due to the hydrophilicity of the majority of intercellular signalling molecules (with 
the significant exception of the steroid family of compounds) they are unable to 
directly cross a cell‟s plasma membrane. So that the signal can be propagated into 
the cell‟s interior, transmembrane proteins that traverse the plasma membrane act as 
receptors on the cell surface. Intracellular signalling events are initiated by 
conformational changes induced by association of the hormone with the extra-
cellular binding pocket of the receptor. These changes transmit the signal to the 
inner leaflet of the plasma membrane. This change is detected at the cytoplasmic 
face of the transmembrane hormone receptor by a signal transducer, initiating a 
sequence of intracellular signalling events that eventually transforms a target 
protein, creating an alteration in the cell‟s behaviour.  
From the membrane‟s inner leaflet, the signal is propagated through the cytosol by a 
combination of: (i) activating an intracellular signalling protein, which can either activate 
the next signalling protein in the signalling cascade, or generate second messengers; and (ii) 
second messengers – molecules of low molecular weight, generated from multiple ligands, 
that relay the signal to other areas within the cell.
11
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In mammalian cells, the most abundant of the doubly phosphorylated PtdInsPn species is 
PtdIns(4,5)P2.
8
 This lipid was first identified in the inositol phosphate signalling pathway as 
a precursor for the formation of the soluble second messenger Ins(1,4,5)P3 and membrane 
bound sn-1,2-diacylglycerol (DAG).
12-14
 However, PtdInsPns also serve in an additional 
capacity, where they directly regulate cell functions. By acting as membrane docking sites 
for reversible recruitment of intracellular signalling proteins and house-keeping proteins 
from the cytosol (Figure 3),
15, 16
 PtdInsPns operate as key elements in signalling cascades.
2
 
 
Figure 3. Phosphoinositide mediators  in the cytosol and cell membrane. Showing the 
synthesis of cytidinediphosphate-diacylglycerol from phosphatidic acid (PtdOH), and its 
reaction with inositol (Ins) to form phosphatidylinositol (PtdIns). The inter -conversions of the 
seven main signalling species are highlighted in white. The soluble inositol phosphates are 
included, demonstrating that the two signalling systems are only connected metabolic ally at 
two points – in the formation of PtdIns, and the cleavage of PtdIns(4,5)P 2 to form the 
secondary messengers Ins(1,4,5)P3 and DAG. 
 
1.4  PLECKSTRIN HOMOLOGY DOMAIN 
 
For a protein to directly interact with PtdInsPn, it must contain a phosphoinositide-
binding domain. Various domains with this attribute have been recognized and 
studied, including ENTH,
17, 18
 FYVE
18, 19
 and PX
18, 20
 domains; however the 
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pleckstrin homology (PH) domain is perhaps the most  widely studied 
phosphoinositide binding region. 
In 1993 the PH domain was originally identified in the PKC substrate pleckstrin.
21
 
Since then PH domains have been identified in many other proteins. PH domain 
containing proteins can be divided into four main categories based on  in vitro 
experiments studying the strength of their affinity for each phosphoinositide 
species.
18, 22, 23
 
Group 1: Proteins containing PH domains that demonstrate highly specific binding 
with PtdIns(3,4,5)P3. 
Group 2: Proteins whose PH domains have high affinity for both PtdIns(4,5)P 2 and 
PtdIns(3,4,5)P3.  
Group 3: Proteins that possess PH domains whose affinity is greatest towards 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3. 
Group 4: The largest of the four groups, it accounts for approximately 85% of all PH 
domain containing proteins.
18
 These proteins exhibit relatively low binding affinities to the 
phosphoinositides, but are capable of binding non-phosphoinositide ligands.
24
 
 
Figure 4. Crystal structures of PH domains from various proteins, highlighting how the -
helix and -barrel motif is conserved across all PH domains. The binding specificity for each 
protein is conferred by the sequence of the three variable loops, VL1, VL2 , and VL3. A 
PKB ;
25
 B Human TAPP1;
26
 C Human Dynamin;
27
 D PEPP1;
28
 E DAPP1.
29
  
 
The PH domain is a structurally conserved module of 100-120 amino acids.
21
 While 
PH domains exhibit low sequence homology, with many sharing only 7 -23% pair-
wise sequence identities, there are significant unifying secondary and tertiary 
structural motifs conserved across all PH domains (Figure 4).
30-32
 They are 
constructed from anti-parallel -strands with -meander motifs making up two near 
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orthogonal -sheets; one sheet is made up of four strands, while the other has three. 
The two -sheets form a -sandwich. Because of the right handed twist commonly 
encountered in -sheets, the two -sheets in the sandwich only have close contact at 
two corners. The other two corners are called the „splayed‟ corners, as they are 
where the two -sheets are furthest from one another. One of the splayed corners is 
capped by a C-terminal amphipathic -helix, the other corner is situated next to the 
three variable loops that link the -strands together- variable loop 1 (VL1) between 
-strands 1 and 2, variable loop 2 (VL2) between -strands 3 and 4, and variable 
loop 3 (VL3) between -strands 6 and 7. These loops are known as variable loops, 
as their structure and length is unique to the protein of interest. It is assumed that 
the variable loops bestow the PH domain‟s specifity for its particular ligand, 
displaying a positively charged interface for the poly-anionic ligands to interact 
with.
33
  
 
1.5  PROTEIN KINASE B  
 
Protein kinase B (PKB, also referred to as Akt), is a serine/threonine kinase that 
was initially discovered in the transforming retrovirus AKT8.
34
 PKB  and PKB  
were identified from a human clone library as the cellular homologues of AKT8‟s 
v-Akt oncogene.
35
 PKB has become the focal point of a great deal research as all 
three mammalian isoforms (PKB , , ) have been identified as key mediators in 
signal transduction pathways. PKB assists in regulating a variety of cellular 
processes such as cell proliferation, glucose metabolism, and gene expression by 
phosphorylating a diverse range of substrates (Figure 5).
36
 
Regulation of apoptotic cell death is also one of PKB‟s functions, deactivating pro -
apoptotic factors by phosphorylation; because of this it plays a critical role in 
certain pathological conditions where the signalling pathways have become 
hyperactive, such as with the progression of ovarian and pancreatic cancers. When 
the tumour suppressor PTEN (phosphatase and tensin homologue deleted on 
chromosome ten) stops functioning correctly,
37
 PKB becomes over activated and 
this leads to unregulated proliferation of cancerous cells.
38, 39
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Figure 5. PKB signalling. Binding of a hormone on the outer leaflet of the cell membrane by RTK induces 
a conformational change which leads to the activation of PI3K. PI3K phosphorylates PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3 – a process which is reversed by PTEN. The increased concentration of PtdIns(3,4,5)P3 
causes co-recruitment of PKB and PDK1 to the inner leaflet of the cell membrane. At the membrane PKB 
undergoes phosphorylation initially by PDK1, and then PDK2 (now believed to be the mTOR/RICTOR 
complex). The di-phosphorylated, fully activated, PKB then helps regulates a diverse range of pathways 
including: Glycolysis, teleomere extension, gene expression, nitric oxide synthesis, glucose uptake, 
apoptosis and cell survival.
40
 
 
Although cancer caused by mutation of PKB had not been previously reported, a 
recent study has shown that an E17K mutation in the PKB PH domain has been 
found responsible for some forms of human breast, ovarian and colorectal cancers.
41
 
This mutation modifies the binding interface between the PH domain and the 
phosphoinositide ligands, leading to PKB becoming localised on the plasma 
membrane without regulation, causing its over-activation and pathological down-
stream signalling. 
Although the three PKB isoforms share common roles, each isoform also exhibits 
individual functionality. PKB  is expressed throughout the body. Its physiological 
roles, revealed by gene ablation in mice, have been identified as placental 
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development, growth and lipogenesis.
42, 43
 PKB  is primarily expressed in insulin-
responsive organs and tissues. It shares several functional roles with PKB , such as 
lipogenesis and growth, but has also been shown to be involved in glucose 
metabolism.
43, 44
 PKB  is the least expressed of the three isoforms, with its highest 
concentration found in the brain. This correlates with it being associated with post-
natal brain growth.
43
 
 
Figure 6. Schematic diagram showing the major features of the three PKB isoforms. Each 
consists of three domains, an N-terminal inositol phospholipid binding PH domain, a kinase 
domain, and a C-terminal regulatory hydrophobic motif. The threonine (T308 in PKB ) and 
serine (S473 in PKB ) undergo phosphorylation to form the active protein. Other sites (also 
highlighted) can undergo phosphorylation, but have been shown to be unimportant for the 
activation of PKB.
45
 
 
PKB is a member of the AGC (cAMP dependent, cGMP dependent, and protein 
kinase C) family of protein kinases. AGC protein kinases all contain sections of 
high sequence homology within their kinase domains and have related functionality.  
The entire crystal structure of PKB has not yet been solved; however the combined 
crystal structures of the individual domains have been used to produce a composite 
structure. In order to gain insight into how PKB functions it is necessary to 
consider its structure which can be separated into three key sections (Figure 6)
46
: (i) 
the N terminal PH domain, (ii) the kinase domain and (iii) the regulatory 
hydrophobic motif at the C terminal.  
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(i) The PH Domain 
PKB has been identified as having a group 3 PH domain exhibiting high and similar 
affinity towards PtdIns(3,4)P2 and PtdIns(3,4,5)P3.
47, 48
  
This affinity arises from the interactions between the inositol head -group and 
residues in the variable loops and protein backbone of the PH domain (Figure 7).
48, 
49
 The 1-phosphate interacts with R23 and the backbone nitrogen of I19. The 3 -
phosphate interacts with K14, R23, R25 and N53; these contacts could account for 
PKB‟s inability to bind PtdIns(4,5)P2.The 4-phosphate of the head-group interacts 
with K14, N53 and R86. The 5-phosphate does not form any interactions with the 
amino acids within the binding pocket, explaining why PtdIns(3,4)P 2 and 
PtdIns(3,4,5)P3 bind with similar affinity.  
 
Figure 7. Sequence alignment of the three PKB isoforms. Highlighting (in red) the residues 
involved in binding PtdIns(3,4)P2 and PtdIns(3,4,5)P3. Dots represent residues the same as 
PKB , dashes represent an omission in the sequence. 
 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 concentrations within the plasma membrane are 
regulated by PI3K (phosphoinositide 3-kinase), PI5K (phosphoinositide 5-kinase) 
and the PtdIns(3,4,5)P3 phosphatases PTEN and SHIP (Src homology 2-containing 
inositol-5-phosphatase).
50
  
PI3K is activated by cell-surface receptor stimulation from an external signal. 
Activated PI3K phosphorylates the 3-hyroxyl of PtdIns(4,5)P2 to form 
PtdIns(3,4,5)P3.
51
 PTEN deactivates this pathway by selectively dephosphorylating 
PtdIns(3,4,5)P3 at the 3-position,
52
 negating the effect of the PI3K (see Figure 5). 
Alternatively the 5 position can be dephosphorylated by SHIP,
53
 creating 
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PtdIns(3,4)P2, removing the lipid from the PTEN inactivation pathway. 
PtdIns(3,4,5)P3 is reformed from PtdIns(3,4)P2 by PI5K mediated phosphorylation. 
When the concentrations of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 on the inner leaflet of 
the plasma membrane reach a threshold level,
54
 PH domain mediated translocation 
of PKB from the cytosol to the membrane‟s cytosolic face occurs. The binding 
interaction between PKB‟s PH domain and the phosphoinositide induces a 
conformational change of its tertiary structure, noticeably in VL2 and at the N -
terminus (Figure 8).
55
 Binding of the PH domain to phosphoinositides frees the 
kinase domain for subsequent phosphorylation. However,  the structural 
reorganisation does not seem to activate the kinase domain towards 
phosphorylation, as it has been shown PH-PKB is constitutionally active when co-
expressed with PDK1.
56
 
 
Figure 8. A Crystal structure of PKB 's PH domain in its apo conformation.
25
 B Crystal 
structure of PKB 's PH domain in its holo conformation, bound to an Ins(1,3,4,5)P 4 
molecule.
57
 Upon binding reordering of the tertiary structure occurs within the viable loops 
and at the N-terminus. 
 
(ii) The Kinase Domain 
While PKB is in its inactive form its PH domain is tightly associated with the 
kinase domain. The PH domain-phosphoinositide interaction dissociates this 
complex and induces a conformational change that prepares the kinase domain for 
phosphorylation.
58
 Located within the kinase domain is the activation segment T-
loop
59
 containing T308 (numbering for PKB ). Phosphorylation of this residue 
induces a second change in conformation, allowing substrate binding to occur and 
raising the rate of catalysis at least 30-fold.
60
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Phosphorylation of T308 is undertaken by 3-phosphoinositide-dependent protein 
kinase-1 (PDK1). PDK1 is also a member of the AGC family of protein kinases. 
The PH domains of PKB and PDK1 both belong to group 3.
48
  
In the cytoplasm PKB and PDK1 interact to form an equilibrium between complexed and 
dissociated states (Figure 9). The complexed state allows co-recruitment, concentrating 
them together at the plasma membrane, permitting the associated, PDK1 to phosphorylate 
T308 rapidly. The phosphorylated kinase domain subsequently has reduced affinity for the 
PH domain, leaving it open for substrate binding.
58
 
 
Figure 9. PKB-PDK1 interaction and PKB activation. Within the cytoplasm PKB and PDK1 
are in dynamic equilibrium between a complexed and dissociated state. Upon conversion of 
PtdIns(4,5)P2 to PtdIns(3,4,5)P3 by PI3K, the complex is recruited by its interaction with 
phosphoinositides (highlighted in red) to the plasma membrane. This shifts the PKB -PDK1 
interaction further towards the associated form (PTEN inhibits this process). PKB‟s PH 
domain interaction with the lipids causes a conformational change, allowing  T308 to be 
accessed and phosphorylated by PDK1 and to be phosphorylated (denoted as yellow 
circles). S473 phosphorylation and loading of ATP leads to PKB dissociating from the 
plasma membrane in its active conformation. PKB is deactivated by dephosphoryla tion of 
T308 and S473. 
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(iii) The Hydrophobic Motif 
A section of twenty-one residues makes up the hydrophobic motif at the C terminus 
of PKB. After the initial T308 activation event, this motif functions as an allosteric 
regulator of the catalytic action of PKB. This regulation occurs through 
phosphorylation of S473. Three theories have been proposed for this second 
phosphorylation event: (a) PKB undergoes autophosphorylation, (b) PDK1 performs 
a second phosphorylation at S473, or (c) it is carried out by a second, as yet 
unidentified distinct serine kinase “PDK2”. Recent publications have proposed a 
strong case for the third option being the mode of phosphorylation, with mTOR -
RICTOR acting as the S473 kinase.
61
 
Phosphorylation of S473 amplifies PKB‟s catalytic rate by a further 7 -10 fold.62 
The difference in observed rate between the mono- and di-phosphorylated species is 
explained by the conformational change the second phosphorylation event triggers. 
Mono-phosphorylated PKB is not locked into its active conformation, but is instead 
in equilibrium with other non-catalytic conformations, with only about 10% of the 
enzyme in an active conformation at any one time. S473 phosphorylation promotes 
extensive reordering of the B and C helices, which induces a hydrophobic groove 
in the N-terminal lobe. Interactions between the hydrophobic motif and the groove 
act to hinder further conformational change and forces the majority of the PKB into 
the active conformation.
62
 
To fully comprehend how PKB operates within a biological system, it is necessary 
to have a range of techniques that allow it to be fully examined.  
 
1.6  GENETIC TECHNIQUES 
 
Dissecting complex biological systems by studying the functions and interactions of 
individual components, can achieve understanding of how organisms operate and 
provide insights into a range of diseases. It can be very difficult to completely 
understand even a small part of such systems because of the numerous participating 
components, how they interact with multiple partners, and how they are regulated.  
Classical genetic techniques have been extremely effective in elucidating pair -wise 
interactions for a wide range of biological processes.
63
 These techniques can be 
divided into two main categories: (i) forward genetics, and (ii) reverse genetics.  
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(i) Forward Genetics 
Forward genetics (Figure 10) aims to identify the gene that underlies a phenotype of 
interest. It is possible to locate and identify the function of a gene by examining the 
effects and positions of mutations (usually deletions) on the phenotype. By mapping 
the mutant gene, the gene‟s position in the genome and structure  can then be 
determined. Once the sequence of the gene has been fully identified, the associated 
phenotype can be linked to the gene with a high level of assurance.
63, 64
  
 
Figure 10. Forward genetic approach. Random mutagenesis is used to create cells with many different 
phenotypes. The mutant exhibiting the phenotype of interest is then selected. By mapping the mutant 
gene, its position in the genome and structure can then be determined. 
 
(ii) Reverse Genetics 
Reverse genetics can be considered the opposite of forward genetics. By generating 
a specific mutation in a gene of unknown function, it is possible to correlate this to 
any resultant phenotype and therefore deduce its function (Figure 11).
63, 65
  
 
Figure 11. Reverse genetic approach. Point mutation a single gene of interest should lead to a change in 
the organism‟s phenotype. By correlating the mutation to the observed phenotype it is possible to deduce 
the genes function. 
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Both approaches have several advantages and disadvantages. The forward approach 
generally provides both a gene and its function, but can be extremely time 
consuming. Since the Human Genome Project
66
 has provided the sequences of all 
30,000 human genes, reverse genetics has become increasingly popular. However, 
for this approach gene redundancy means that many genes may have been disabled 
but without having an observable effect on the phenotype. Also it is not possible to 
dissect the phenotype of mutations lethal to the organism.  
To surmount these limitations alternative techniques have been sought. The use of small 
molecules to probe protein function has been adopted in many strategies; this is essentially 
classical pharmacological screening of small molecule libraries, but more recently has 
become known as chemical genetics.
67
 The basic premise of chemical genetics is that 
inactivation of a protein using a small molecule is functionally equivalent to the genetic 
inactivation of its parent gene by mutation.
68
  
Chemical genetics has several advantages over classical genetic techniques. In 
many cases, the same small molecule can be used across a range of organisms; this 
removes the need to repeatedly generate the same mutation in each new organism. 
Using small molecules also allows temporal control in dynamic processes on short 
timescales (seconds), compared to conditional gene activation (hours/days).   
Reflecting classical genetics, chemical genetics can also be separated into two main fields: 
(i) forward chemical genetics, and (ii) reverse chemical genetics.  
(i) Forward Chemical Genetics 
Similar to forward genetics, in forward chemical genetics when a small molecule is 
added to a cell and elicits a phenotype of interest, it must be affecting a cellular 
pathway (Figure 12).
69
 Unlike classical genetics, the molecule can be added or 
removed, thus acting as a conditional switch, which although very useful in 
classical genetics is very difficult to achieve but in chemical genetics can be facile.  
It also allows for dose graduation and the study of embryonic lethal genetic loci.  
When the protein that the molecule interacts with has been identified, the protein‟s 
function within the system can then be probed using the new chemical switch. 
However, the target protein can be extremely hard to identify and th is can be one of 
the most difficult aspects to forward chemical genetics, particularly if the protein 
has not previously been characterised.  
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Figure 12. Forward chemical genetic approach. Cells are treated with a range of compounds. When a 
compound produces the phenotype of interest it is then necessary to determine the protein which the 
compound interacts with. 
 
 (ii) Reverse Chemical Genetics 
Reverse chemical genetics overcomes some of the problems of the forward 
approach, by starting with a protein of interest, and then identifying a small 
molecule that interacts selectively with it (Figure 13).
68
 The small molecule can 
then be used as a conditional switch to probe the phenotype of the target protein.
  
 
Figure 13. Reverse chemical genetic approach. The protein of interest is screened against a range of 
compounds. When a compound which favourably interacts with the protein is identified it is added to the 
organism to elicit the corresponding phenotype. 
 
To diminish the possibility of the small molecule interacting with non-target 
proteins, and to limit the number of small molecules that need to be investigated, 
the fundamental idea of reverse chemical genetics has been extended to embrace the 
established field of receptor-ligand engineering. 
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Figure 14. Bump-hole engineering. A cavity is introduced within the binding pocket of the 
protein of interest by point mutation. The corresponding sterically enlarged – “bumpy” – 
ligand is synthesised. The mutant protein is still able to bind the natural ligand, but can also 
bind the synthetic “bumpy” ligand. The wild -type protein cannot bind the “bumpy” ligand due 
to steric interactions. 
 
Receptor-ligand engineering uses genetic techniques to create a mutant that expresses a 
protein of interest that can bind a modified ligand. The difficulty is then to find a small 
molecule that is complementary to the mutant protein, yet unable to bind to wild-type 
protein receptors (i.e. orthogonal). This is done through screening of a small library or 
through rational design. 
This general description covers several approaches.
70
 A commonly used technique is steric 
complementation, also known as the „bump-hole‟ method (Figure 14).71, 72 This steric 
technique modifies the shape of the complementary receptor-ligand interface. A ligand is 
created that is too sterically hindered fit into the wild-type receptor, but can interact with the 
engineered receptor into which a complementary cavity has been engineered. A 
characteristic of this technique is that the modified receptor often retains significant affinity 
for the natural ligand. Thus, although the modified ligand is orthogonal to the wild-type 
receptor, the mutant receptor is often not orthogonal to the natural ligand. 
Should mutual orthogonality be desired, so that the modified receptor cannot bind with the 
natural ligand, several additional techniques have been developed. 
One way to overcome this has been to create dual „bump-hole‟ plus „hole-bump‟ 
combinations (Figure 15). Theoretically this provides better substrate selectivity and receptor 
discrimination, due to the further increase in steric interactions.
73
 However, there are two 
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potential difficulties arising from this technique: (i) too many mutations around the receptor 
can lead to over all distortion of the protein binding site and diminished functionality, and 
(ii) creating a „hole‟ in a small molecule is very difficult to achieve without significantly 
distorting it, and therefore diminishing/destroying its specificity for the protein of interest.  
 
Figure 15. Dual bump-hole/hole-bump engineering. Both a cavity and a sterically bulky 
group are introduced within the binding pocket of the protein by point mutation. The 
corresponding ligand with both a steric “bump” and space to accommodate the proteins 
“bump” is synthesised. The mutant protein is not able to bind the natural ligand, but can 
bind the synthetic ligand. The wild-type protein cannot bind the synthetic ligand due to steric 
interactions. 
 
Aside from steric complementation, the other main strategy for creating orthogonal receptor-
ligand pairs is to introduce non-native polar receptor-ligand interactions. These polar 
methods can be utilised to engineer mutually orthogonal pairs. 
One important technique used for molecular recognition depends upon manipulating the 
hydrogen bonding at the receptor-ligand interface. By changing one amino acid, to 
reverse its hydrogen bonding characteristics, it is possible to disrupt recognition of the 
natural ligand by the receptor. A synthetic ligand is prepared that has functionality that is 
complementary to this mutation, then orthogonal ligand-receptor pairs, with reversed 
hydrogen bond patterns, can be created
 
(Figure 16).
74
 
This technique has one main advantage over the steric complementation techniques: It limits 
the extent to which the shape of the receptor-ligand interface is changed, minimising steric 
effects on the engineered complex‟s activity, relative to that of the wild-type. However, this 
technique is difficult to implement as hydrogen bonds are rarely isolated, but form networks. 
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Figure 16. Reversal of hydrogen bond pattern. A hydrogen bonding interaction i s identified 
between the protein and its ligand. Point mutation allows the hydrogen bond donor on the 
protein to be changed to a hydrogen bond acceptor. The corresponding hydrogen bond 
acceptor functionality within the ligand is changed to a hydrogen bond donor in the synthetic 
ligand. The mutant protein is not able to bind the natural ligand, but can bind the synthetic 
ligand. The wild-type protein cannot bind the synthetic ligand. This concept applies equally 
to reversal of hydrogen bond acceptor on the protein and donor on the ligand. 
 
It is also possible to manipulate charged residues around the receptor-ligand interface to 
induce polar interactions. There are four basic techniques: (i) Introduction of new ion pairs 
(Figure 17A) - by engineering a new charged residue into the receptor-ligand interface it is 
possible to disrupt binding of the natural ligand; and, by including complementary 
functionality within the synthetic ligand, form an orthogonal pairing.
75
 (ii) Ion pair 
neutralisation (Figure 17B) - this is the opposite approach to introducing new ion pairs; by 
removing the existing ion pair interactions it is possible to induce discrimination against the 
natural ligand, and increase affinity towards a neutral synthetic ligand.
76
 (iii) Ion pair 
reversal (Figure 17C) - this technique is conceptually the same as reversed hydrogen bond 
patterns, only the magnitude of the electrostatic interactions is significantly larger.
77
 (iv) Ion 
pair exchange (Figure 17D) - this method requires the disruption of an intramolecular 
protein salt bridge, by mutagenesis of one of the charged residues.
78, 79
 This unpaired 
charged residue is stabilised by the formation of an intermolecular salt bridge between the 
receptor and a synthetic ligand to which the complementary half of the salt bridge is fused. 
In all these ion-pair methods the wild-type receptor will have reduced affinity for 
the modified ligand, arising from unnatural steric hinderance or electronic 
interference during binding.  
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Figure 17. A Ion pair creation. A new ion pair interaction is created between the protein and 
its ligand. B Ion pair neutralisation. An existing ion pair interaction between the protein and 
its ligand is removed from the protein-ligand interface. C Ion pair reversal. The polarity of an 
existing ion pair interaction between the protein and its ligand is reversed. D Ion pair 
exchange. An intramolecular interaction within the protein‟s binding pocket is replaced by an 
intermolecular interaction between the protein and its ligand. In all four cases the mutant 
proteins are not able to bind their natural ligand, but can bind their synthetic ligand. The 
wild-type proteins cannot bind the synthetic ligands.  
 
There are also a few other techniques that have recently been developed. Creation of a de 
novo ligand binding site in the receptor-ligand interface requires an additional small 
molecule to be present for the protein to bind its ligand (Figure 18A).
80
 Another new 
approach is to increase the affinity between engineered receptor-ligand pairs by introducing 
functional groups, which could selectively react to form covalent complexes (Figure 18B).
70
 
This overcomes the need to develop ligands with very high affinity and also helps avoid off 
target binding. 
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Figure 18. A Creation of a de novo binding site. An additional binding site for a small 
molecule is engineered into both the protein and its ligand. The small molecule must be 
present for protein-ligand binding. B Engineered reactivity. The protein is functionalised 
near the binding interface. A ligand is synthesised with a group which will react with this 
functional group to form a covalent bond.  
 
It is important that both the advantages and limitations of each technique are fully 
appreciated before deciding upon which approach to employ – it might be necessary 
to utilise a combination of techniques in order for the biological pathway to be fully 
dissected. 
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2. PROPOSED RESEARCH  
 
It has been shown that PKB is a signalling kinase that regulates a diverse range of 
cellular functions. However, it has been difficult to elucidate all of its biological 
behaviour due to the dependence of both PKB and PDK1 on the same signalling 
phosphoinositides. Therefore, it is necessary to break the relationship between the 
two species in order to scrutinise the individual components of PKB‟s activation 
pathway. Classical genetic techniques have been able to provide a lot of 
information about this pathway, but additional techniques are required for it to be 
fully understood. To achieve this, it has been proposed that the reverse chemical 
genetics technique of receptor-ligand engineering is employed. 
Bump-hole engineering has had wide success in the case of Src family of kinases. 
Src kinases are involved in a range of signal transduction pathways within the cell - 
influencing processes such as growth, differentiation, adhesion and transcription. 
Being able to selectively activate an individual member of the family provides 
valuable information about its function.  
Liu et al. developed an ATP analogue – N6-(benzyl) ATP (Figure 19B) – that was 
preferentially bound by the I338G mutant of the v-Src kinase.
81
 Due to the high 
degree of sequence homology within the kinase domain of the Src family, applying 
the equivalent mutation to different Src proteins
72
 makes it possible to utilise the 
same compound to study a range of different proteins. 
In order to apply this methodology to PKB it is necessary to identify a suitable site 
for mutation within the PH domain. The main prerequisites for choosing which site 
to mutate are: (i) The residue must be on the surface of the binding in terface so that 
a cavity is formed to accommodate the synthetic ligand; (ii) The residue must not 
be structurally important, so that the tertiary structure of the protein is maintained; 
and (iii) The residue should not be functionally important as mutation  would then 
be likely to lead to reduced affinity for the ligand.  
Taking this all into consideration, locating a suitable site for mutation within the 
PH domain is difficult due to the high degree of structural residues within the 
receptor pocket. An additional problem in the case of PKB is that bump-hole 
engineered receptors tend to discriminate poorly between the natural and synthetic 
ligand, so would not help to separate the effects of PKB from PDK1, as they share 
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the same natural ligands. This could be overcome by adopting the dual bump-
hole/hole-bump approach, but would require identifying a second site for mutation.  
 
Figure 19. A The structure of natural ATP. B N
6
-(benzyl) ATP. The benzyl group 
(highlighted in yellow) provides the steric „bump‟ in the  synthetic ligand complementary to 
the „hole‟ created by the I338G mutation in v-Src kinase. 
 
Because the steric complementation techniques are unsuitable in this situation, an 
alternative technique needs to be applied. Polar techniques require careful 
consideration of the receptor-ligand interface in order to identify potential sites for 
mutation. Study of the crystal structures of the apo and holo forms of the PH 
domain of PKB  reveal an intramolecular salt bridge (Figure 20). Located on the 
surface of the phosphoinositide ligand binding interface, the salt bridge is formed 
between E17 and R86 upon ligand binding. Because of this it could be ideal for 
polar group exchange receptor-ligand engineering.  
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Figure 20. Close up of PKB ‟s PH domain bound to Ins(1,3,4,5)P 4.
57
 The E17-R86 salt 
bridge is shown as a ball-and-stick representation to illustrate the residues‟ proximity, and 
relative orientation, to the bound Ins(1,3,4,5)P 4 molecule. 
 
Shi and Koh
78
 and Tedesco et al.
79
 have both reported previous success with polar 
group exchange receptor-ligand engineering of estrogen to selectively regulate gene 
expression. 
From the co-crystal structure of the estradiol-bound form of human estrogen 
receptor (hER), it was seen that hydrogen bonding holds the 3-hydroxyl of estrogen 
next to an intramolecular E353-R394 salt bridge adjacent to the ligand-binding 
pocket (Figure 21A). The intramolecular salt bridge was disrupted by the E353A 
mutation; a carboxylate functionalized ligand acted in lieu of the glutamic acid to 
form an intermolecular salt bridge (Figure 21B). The E353A mutation is favoured 
over the E353G mutation, as while glycine is a smaller residue, its use can decrease 
the structural rigidity of the protein, and lead to mis-folding of the protein. 
The mutant hER had a greatly reduced affinity for the natural ligand. However, the 
synthetic ligand can induce a transcriptional response in hER(E353A) expressing 
cells, creating a tool that can be used for remote regulation of gene expression.  
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Figure 21. A The natural interactions between the binding residues in hER and the E2 
molecule. B The ion pair exchange receptor-ligand engineered interaction between the 
hER(E353A) mutant and the E2 analogue ES7.  
 
The identification of a similar, suitably located, intramolecular salt bridge, between 
E17 and R86 (highlighted in red in Figure 22) in the PKB  PH domain, suggests 
polar group exchange receptor-ligand engineering is a suitable technique for 
studying PKB. These residues are conserved across all three isoforms, allowing the 
potential for using polar group exchange receptor-ligand engineering to help 
differentiate the roles of PKB ,  and . 
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Figure 22. Protein sequence of PKB  PH domain, highlighting (in red) the E17 and R86 
residues involved in formation of the salt bridge.  
 
Theoretically either side of the salt bridge could be removed through point mutation. 
There are several reasons why the E17A mutation is favoured over the R86A 
mutation: (i) The R86 residue is involved in recognition of the 4 -phosphate,
48
 so 
mutagenesis could lead to reduced affinity between the mutant domain and the 
synthetic ligand; (ii) creating a carboxyl ligand is potentially less synthetically 
challenging than the corresponding guanidine or amine functionality; and (iii) The 
protonated amine or guanidine functionality might reduce attraction to the interior 
of the binding pocket due to the cationic surface presented by the variable loops.  In 
contrast to the E17K mutation, it is anticipated that the E17A mutant will have 
substantially reduced activity because, complementary to the known R86A mutant, 
this mutant also lacks one half of the key salt-bridge that is formed in the active 
conformation.  
 
Figure 23. A E17–R86 salt bridge. B Effect of proposed E17A mutation and its interaction 
with a functionalized ligand. 
 
Point mutation to convert the E17 residue (Figure 23A) into an alanine residue 
disrupts the intramolecular salt bridge. Including a glutamic acid -like carboxylate 
group within a synthetic ligand can provide complementary binding to the R86 
residue (Figure 23B).  
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It is rationalised that this would be a favourable pairing due to several key points. 
The wild-type PH domain will not be able to bind the synthetic ligand because of 
unfavourable steric and electrostatic interactions with the additional 
functionalisation on the ligand. The mutant PH domain should discriminate against 
binding to the natural lipid; although natural PtdIns(3,4,5)P 3 should be not be 
disfavoured for steric reasons, it is hypothesized that binding of PtdIns(3,4,5)P 3 
will not induce the loop remodelling that normally occurs between the natural 
ligand and the wild-type PH domain due to the mutant PH domains‟ incapability to 
form an internal salt bridge. The additional polar interaction between the synthetic 
ligand and the R86 residue should form a functional orthogonal receptor -ligand pair 
due to the alterations conferring increased selectivity. However, whether  the 
unnatural protein-ligand pairing will have as high (or greater) an affinity for each 
other as the natural pair is uncertain. Although there will clearly be a new strong 
polar association in the artificial complex, this will be counter-balanced by the need 
to desolvate the exposed polar groups during binding. The total free energy for this 
will consist of enthalpic and entropic components individually far greater than for 
the natural pairing. Hence it is impossible to predict the structure of the optimum 
ligand, and it is expected that a second generation of ligands will be required.  
PKB‟s dependence on natural phosphoinositide lipids will be removed by the 
introduction of the mutant PH domain, breaking the link between PKB and PDK1 
activation.  
Rational design suggests that the synthetic ligand should retain as many functional 
similarities to the natural ligand as possible in order to preserve the maximum 
number of original molecular contacts and maintain high affinity and specificity in 
the engineered system. 
The affinity between PKB‟s PH domain and PtdIns(3,4,5)P 3 underlies recruitment 
to the plasma membrane; the association between the natural ligand and the wild -
type receptor is specific for the phosphorylation pattern on the inositol head-group. 
In the engineered ligand it is essential that the distribution of phosphate groups is 
retained. Ins(1,3,4,5)P4 is known - in vitro - to compete with PtdIns(3,4,5)P3 for 
binding to PKB‟s PH domain.82 Therefore syntheses will initially focus on the head-
group. The 1-phosphate mimics the phosphodiester linkage in the natural lipid. The 
3- and 4-phosphates are directly involved in recognition by the PH domain. The 5 -
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phosphate is thought to be unimportant for binding as both Ins(3,4)P 2 and 
Ins(3,4,5)P3 are bound with similar affinity.  
 
Figure 24. The relative spatial distribution of the E17 and R86 residues, and Ins(1,3,4,5)P4 molecule 
based on the X-ray crystal structure
57
. Showing the distance between the  carbon of the E17 carboxylate 
and the central carbon of the R86 guanidine (5.31 Å), and the distance between 2-O of Ins(1,3,4,5)P4 and 
the central carbon of the R86 guanidine (5.52 Å).  
 
This leaves either the hydroxyls at the 2- and 6-positions, or the inositol ring, for 
functionalisation. The choice of functional group is dictated by the E17A mutation 
that requires the engineered ligand to contain a carboxylate similar to the glutamic 
acid side chain, so that it can form a replacement intermolecular salt bridge with the 
remaining R86 residue.  
The X-ray crystal structure of Ins(1,3,4,5)P4 bound to the wild-type receptor shows 
that the orientation adopted by Ins(1,3,4,5)P 4 means it presents its 2-hydroxyl and 
protons in the 4- and 6-positions towards the binding interface.  
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Assuming the chosen centre is functionalized with an acetic acid group, then the 
distances of the 2-O, 4-C and 6-C to the central carbon of the R86 guanidine 
correspond to the distance between the  carbon of the E17 carboxylate and the 
central carbon of the R86 guanidine. The distance between the  carbon of the E17 
carboxylate and the central carbon of the R86 guanidine is 5.31 Å.  The distances 
for the 2-O, 4-C and 6-C of Ins(1,3,4,5)P4 are 5.52 Å, 4.86 Å and 5.59 Å 
respectively (Figure 24). Therefore for the functionalized ligand - assuming a 
similar distance should be maintained so that normal binding of the phosphates 
occurs - this discounts the 4 position. When considering the remaining two sit es, 
the difference in bond length between carbon-carbon bonds and oxygen-carbon 
bonds needs to be taken into account. As oxygen-carbon bonds tend to be longer, 
functionalisation of the 2-O should provide the best interaction. This is re-enforced 
by consideration of how the 6-C acetic acid would bind the mutant. Assuming the 
synthetic ligand adopts the same orientation with the mutant domain as the natural 
ligand with the wild-type domain, then the 6-C acetic acid would need to bind 
across the face of the inositol ring, resulting in unfavourable steric interactions with 
the 4-CH. Therefore, the first generation of engineered ligands will be of the 
structure 1 (Figure 25). 
 
Figure 25. Proposed structure for target molecule. Ins(1,3,4,5)P4 with additional acetic acid 
moiety attached to the 2-O (highlighted in yellow).  
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3. BIO-PHYSICAL TECHNIQUES  
.  
A range of bio-physical techniques have been developed to study protein-protein 
and protein-ligand interactions. Each technique has its advantages and limitations 
concerning the type and quality of information derived from each experiment. 
These techniques can be used at several stages in developing an engineered 
receptor-ligand pair. 
Initially, receptor-ligand engineering is assisted by having a good structural 
understanding of the target protein to identify potential sites for mutation. This 
information can be established from either X-ray crystallography or from structural 
calculations based upon nuclear magnetic resonance (NMR) spec troscopy. X-ray 
crystallography offers high resolution structures, but proteins can be difficult to 
crystallise, and it can be questionable whether the solid state data reflect the 
protein‟s conformation in solution. NMR spectroscopy generates a composite 
structure from various solution conformations. Because of this, specific folds will 
only be observable if the data from the various structures converge, if this does not 
occur the conformation will be unresolved.
83
 
Later in the process - once a potential receptor-ligand pair has been produced - 
there is a range of techniques that can be used to probe whether they interact, and to 
what extent.
84
 Commonly used techniques are circular dichroism (CD),
85
 dual 
polarisation interferometry,
86
 fluorescence spectroscopy
87
 and isothermal titration 
calorimetry (ITC).
88
 The choice of technique is dependent upon the type of data 
required. 
PKB ‟s PH domain has previously been studied using intrinsic tryptophan 
fluorescence spectroscopy.
82
 
 
3.1  INTRINSIC TRYPTOPHAN FLUORESCENCE 
SPECTROSCOPY 
 
The basic intrinsic tryptophan fluorescence spectroscopy experiment requires single 
wavelength excitation of tryptophan. The resulting fluorescence – measured at 90° 
to the path of excitation to minimise incidental light from the excitation source – is 
then measured using a photo detector (Figure 26).  
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Figure 26. Simple schematic of a fluorescence spectrometer. Emissions from the excitation 
source pass through a monochromator. The photons excite the sample in the cell, and the 
resulting fluorescence is passed through a second monochromator and then measured by a 
photo detector. 
 
There are 3 amino acid residues that are naturally fluorescent: tryptophan (W), 
tyrosine (Y) and phenylalanine (F). Each residue can be excited at a different 
wavelength, allowing selective excitation and hence detection. The W residues are 
excited in the 290-305 nm wavelength range. W is unusual as, unlike the F and Y 
residues, its fluorescence parameters are especially sensitive to the environment it 
is in. This means that, as long as there is a suitably placed W residue, it is possible 
to study conformational changes arising from protein-ligand interactions. 
W‟s ability to act as an environmentally-sensitive fluorophore mainly occurs due to 
photon absorption causing a large redistribution of electron density across its indole 
ring system. Studies have shown that excitation leads to a large  increase in the 
dipole moment of the excited indole, creating a localised non-equilibrium state in 
the environment surrounding the residue. This arises from loss of electron density 
from the N 1 and C  atoms and a corresponding increase at the C 3, C 2, and C 2 
atoms of the indole ring (Figure 27).
89
 The same type of redistribution is not 
observed in F or Y residues as their side chains possess higher order symmetry than 
the indole ring. 
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Figure 27. Indole ring of tryptophan residue, showing the numbering system and the areas 
of increased and decreased electron density resulting from excitation of the ring system.  
 
The shape and maxima ( max) of the steady-state tryptophan fluorescence spectrum 
are energetic parameters that represent the energy gap between the excited and 
ground state of W (Figure 28). Photon absorption causes excitation from the 
electronic ground state to one of the vibrational states of in the electronic excited 
state. Relaxation of the vibrational states occurs until the lowest energy level of the 
electronic excited state is reached, at which point fluorescence occurs when the 
electron returns to its ground state with a corresponding photon emission.
90
  
 
Figure 28. Jablonski diagram showing single electron excitation of Tryptophan to its excited 
state, and the corresponding relaxation back to its ground state through photon emission.  
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The polarity, flexibility and chemical nature of the environment surrounding the W 
residue influences how the environment adjusts to the redistribu tion of electron 
density upon excitation. Because of this a combination of different universal and 
specific interactions can occur with the excited state, resulting in additional 
modifications to the spacing between the energy levels of the excited and ground 
states. Hence the steady-state fluorescence spectrum highlights changes in the 
protein‟s tryptophan environments.  
The main universal interaction occurs due to the redistribution of electron density 
in the indole ring inducing dipole-dipole relaxation of the surrounding protein 
groups and solvent molecules.
91
 This relaxation process causes lowering of the 
energy of the excited state and therefore causes lengthening of the observed max in 
the fluorescence spectra. The scale of the difference between the wavelength of 
absorption and observed fluorescence is influenced by several factors: (i) the 
magnitude of the dipole difference between the ground and excited states; (ii) the 
refractive index and dielectric constant of the environment; and (iii) the lifetime of 
fluorescence when compared to the time of dipole relaxation of the W and its 
surrounding dielectric. 
This also explains why the Y and F residues are insensitive to their surroundings, as 
the differences between the dipoles of their ground and excited states are essentially 
zero. 
This effect does not solely explain the shift  in fluorescence; the W residue also can 
undergo specific interactions with a few select groups in its surrounding 
environment. These can be due to charge transfer reactions or from the formation of 
weak hydrogen bonds. Specific interactions can also give rise to significant shifts in 
the emission spectra.
90
 
Besides max, the other important parameter that can be extracted from the steady-
state fluorescence spectrum is the quantum yield (q) – the efficiency of conversion 
of photons absorbed into fluorescence. This varies from around 0.4 to the limits of 
detectability.  
Used together max and q can be used to characterise the environment a W residue is 
in. However, while this gives some information about the environment the 
tryptophans occupy, taken on its own this does not explain how quantitative data 
can be determined for protein-ligand interactions. 
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In order to acquire this type of data there are some pre-requisites for the protein-
ligand interaction: (i) that binding of the ligand induces a conformational change in 
the protein; or (ii) that the presence of the ligand causes a change to the universal 
or specific interactions within the environment of the binding pocket; and (iii) that 
there is at least one suitably placed W residue that experiences this shift in 
environment, leading to either quenching or enhancement of the fluorescence.  
This is best illustrated by example: M. Frech et al. used intrinsic tryptophan 
fluorescence spectroscopy to determine the stoichiometry (n) and dissociation 
constant (Kd) for PKB ‟s PH domain interacting with various inositol phosphates 
and phosphoinositides.
82
 As already discussed, upon binding of PtdIns(3,4,5)P 3, 
PKB‟s PH domain undergoes a conformational change. This is reflected by a 
corresponding change in the steady-state tryptophan fluorescence spectrum (Figure 
29). 
 
Figure 29. Fluorescence spectra of PKB ‟s PH domain with, and without, addition of 
dioctanoyl PtdIns(3,4,5)P3. Excitation was carried out at 290 nm. The higher curve is the 
emission spectrum of the PH domain alone; the lower curve is the emission spectrum of the 
PH domain in the presence of an excess of dioctanoyl PtdIns(3,4,5)P 3. The emissions are 
expressed in arbitrary units.
92
 
 
The protein was excited at 290 nm, and a corresponding emission max is observed 
at 345 nm. Addition of excess ligand led to quenching of the signal by ~30%, but 
no change in the value of max. PKB ‟s PH domain contains four W residues – 
W11, W22, W80 and W98. Unpublished mutational studies carried out by Dr. P. 
Free in the Gaffney group suggest that only the W80 significantly contributes to the 
observed quenching in the fluorescence spectrum upon ligand addition – 
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corresponding to W80 undergoing the greatest degree of reorientation of upon 
ligand binding, as seen by comparing X-ray crystal structures.
25, 57
 
 
Figure 30. A Titration of the PKB ‟s PH domain with sequentially increased concentration of 
dioctanoyl PtdIns(3,4,5)P3. Excitation carried out at 290 nm, and emission measured at 345 
nm. B Scatchard plot of the data from A.
92
 
 
Once the max values of the bound and unbound states have been determined (in this 
case they are the same), the next step is to carry out a titration, plotting the change 
in fluorescence intensity ( F) against the relative amount of ligand added to 
protein. This gives a graph where the F values tend towards FMAX at high ligand 
concentrations (Figure 30A). A non-linear fit to a hyperbolic function is used to 
determine the FMAX value.  
 
F/ FMAX = n – Kd{( F/ FMAX)/[PtdIns(3,4,5)P3]} (eq. 1) 
 Scatchard plot of eq. 1 is then employed to analyse the data,
93
 plotting the 
relative change in the difference between F and FMAX per increase in ligand 
concentration against the relative change in the difference between F and FMAX 
(Figure 30B). The linear fit of this data set gives both the binding stoichiometry for 
the interaction (n) – the intercept on the y axis – and Kd is given by the slope of the 
line. 
In the case of PKB ‟s PH domain binding dioctanoyl PtdIns(3,4,5)P3 this gives the 
binding stoichiometry as 1:0.92 for the PH domain-PtdIns(3,4,5)P3 complex, which 
shows good agreement with the expected value of 1:1, and a Kd of 0.40 (±0.03) M. 
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While intrinsic tryptophan fluorescence spectroscopy is known to work for the 
wild-type PH domain of PKB , to probe a mutant PH domain requires that a similar 
response is observed upon binding to a synthetic ligand. While a positive result is 
proof of concept, a negative result will not necessarily mean binding is not 
occurring. Because the formation of the intramolecular salt bridge is being 
disrupted, it is possible that even with ligand binding, the conformational change 
observed in the wild-type protein will not occur in the mutant.  
Hence a second technique is required to either verify a positive result, or establish a 
negative result as genuine. ITC is a potential technique to give this verification.  
 
3.2  ISOTHERMAL TITRATION CALORIMETRY 
 
Isothermal titration calorimetry (ITC), like intrinsic tryptophan fluorescence 
spectroscopy, is a technique that can be used to determine the Kd and binding 
stoichiometry (n) of a protein-ligand interaction. Additionally, it determines the 
enthalpy changes ( H) of the interaction. Since the interaction is studied at a 
controlled temperature, it is also then possible to use Kd, n and H to calculate the 
Gibbs free energy change ( G) and the entropy change ( S). Because of this ITC is 
the only bio-physical technique that can determine all of these parameters with a 
single experiment, and nearly completely characterise the thermodynamic 
properties of the interaction.  
The standard experimental equipment (MicroCal VP-ITC MicroCalorimeter) 
(Figure 31) is formed of two identical coin shaped cells fashioned from the highly 
efficient heat conducting metal Hastelloy® alloy C-276.
94
 The cells are then 
encased in an adiabatic jacket. This allows thermostatted heating/cooling to 
maintain equal constant temperature between the two cells. The differential power 
(DP) signal between the reference cell and the sample cell is the power required to 
maintain temperature equilibrium, and is measured using sensitive 
thermopile/thermocouple circuits. This signal is calibrated electrically by applying 
a known amount of power through a resistive heater element positioned on the cell. 
When the ligand is titrated into a solution of its macromolecular receptor it is 
typically accompanied by the evolution of heat within the sample cell. This results 
in a negative change in the DP as less power is needed due to the heat contribution 
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from the exothermic chemical interactions. For endothermic reactions the opposite 
is true.  
 
Figure 31. Schematic diagram of the MicroCal VP-ITC MicroCalorimeter. The reference and 
sample cells are surrounded by an adiabatic jacket. The syringe/stirrer is computer 
controlled. 
 
Raw data from the experiment is displayed as a series of spikes of heat flow 
(power) - each spike a consequence of an injection of ligand (Figure 32A). Because 
DP has units of power ( cal/s), the time integral of the spike gives a measurement 
of H. The amount of binding is directly proportional to the heat which is absorbed 
or released, with the heat signal diminishing to only the background heat of dilution 
as the macromolecule becomes saturated with ligand. 
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Figure 32. Representative ITC data. A Raw ITC data. Twenty injections of ligand solution 
added to a solution of macromolecule in the sample ITC cell  B Binding isotherm. The area 
of each injection spike equals the total heat released from that injection. A plot of the 
integrated heat against the molar ratio of ligand added to macromolecule - the binding 
isotherm for the interaction - is acquired. A non-linear least squares fit gives a best fit 
curve (in red) from which the thermodynamic parameters can be determined.
94
 
 
Once the raw data has been collected, Origin® software is used to analyse the data. 
An iterative mathematical curve fitting process – a non-linear least squares fit – is 
used to create a curve through the plotted integrated peak areas. The type of 
equation created is dependent upon the type of interaction being observed. The 
mathematical parameters of the binding isotherm are then used to determine n, Kd, 
and H. In the case of the “one set of sites” model (APPENDIX A), as for the 
example below (Figure 32B), n is the point of inflection of the curve. Kd is the 
inverse of the slope at the point of inflection. H is the difference between HMIN 
and HMAX.  
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Figure 33. Plot of ITC isotherms for various values of c: At low values the isotherm is a near 
horizontal line. As c increases the isoform takes on a sigmoid form. At high values of c the 
isotherm takes on a rectangular form. 
 
The shape of the binding isotherm is determined by the parameter c. c is a unitless 
constant, defined by eq.2:  
 
c = ([Mtot]n)/Kd  (eq. 2) 
 
Where [Mtot] is the total macromolecule concentration at the start of the experiment, 
n the stoichiometry parameter, and Kd the disassociation constant. Since n and Kd 
are constant for any given interaction, [M tot] is the only parameter that can be 
varied. If the initial [M tot] is very low (i.e. c ≤ 0.1), then the isotherm is essentially 
featureless, appearing as a near horizontal line (Figure 33), making characterisation 
of the interaction‟s thermodynamic properties impracticable. As [M tot] is increased 
the equivalence point begins to be defined, and the calculated H converges 
towards the true value of H. At very high concentrations of M tot (i.e. c > 5000), 
there is very tight binding, and the isotherm takes on a rectangular form with the 
sharp drop occurring precisely at n and its height exactly corresponding to H. 
However it is not then possible to accurately determine the Kd value for the 
interaction. This gives rise to an “experimental window” for determining Kd, where 
c is high enough for the isotherm to have definition, yet low enough so that Kd can 
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be extracted from the curve fit. It has been experimentally determined that the 
middle of the window 5 ≤ c ≤ 500 is ideal for measuring Kd.  
However, Kd is not the only parameter required when designing an ITC experiment. 
It is also necessary to have some understanding of the expected H value. This 
arises from the limitations in the sensitivity of the ITC equipment. For accurate 
measurements at least 3-5 μcal of heat should be evolved/absorbed within the 
sample cell with each injection. Hence, while ITC can be a very powerful 
technique, with the potential to characterise many thermodynamic parameters with 
a single experiment, it is limited by the need to have a strong enough understanding 
of the interaction so that a reasonable estimate of Kd and H can be made before 
starting the experiment. These estimates are needed to ensure [M tot] is high enough 
so that the heat evolved/absorbed is accurately observable. This is why ITC is often 
used in parallel with intrinsic tryptophan fluorescence spectroscopy as it 
independently provides a Kd value, which can then be fed into the calculations to 
determine the required [Mtot] for the ITC experiments. 
One advantage of ITC, when compared to intrinsic tryptophan fluorescence 
spectroscopy, is that it does not require suitably placed W residues within the 
protein in order to study an interaction. This means that ITC can be used to study a 
wider range of interactions inaccessible to intrinsic tryptophan fluorescence 
spectroscopy. However, if there is a suitable W residue, intrinsic tryptophan 
fluorescence spectroscopy is a significantly more sensitive technique, allowing 
much lower concentrations of protein and ligand to be used per experiment. 
Because of this, interactions with very high Kd values can be studied, which would 
not be possible using classical ITC techniques as the requisite [M tot] would be 
unobtainable.   
While ITC has not previously been used to study the PKB  PH domain‟s 
interactions with inositol phosphates/phosphoinositides, it has been used to study 
other PH domains. Kavran et al. studied several different PH domains using – 
amongst other techniques – ITC.95 One of the PH domains studied was that of EST 
(expressed sequence tag) 684797. ITC of its PH domain titrated into solutions of 
Ins(1,3,4)P3, Ins(1,4,5)P3 and Ins(1,3,4,5)P4 produced three binding isotherms 
(Figure 34). All three inositol phosphates show binding to the EST 684797 PH 
domain. However both Ins(1,3,4)P3 and Ins(1,3,4,5)P4 exhibit higher H and lower 
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Kd than Ins(1,4,5)P3, placing it in group 3 (section 1.4) similar to PKB‟s PH 
domain. EST 684797 has subsequently been identified as the B cell antigen receptor 
(BCR) downstream signalling regulator DAPP1 (dual adaptor of phosphotyrosine 
and 3-phosphoinositides),
96
 also known as PHISH (3-phosphoinositide interacting 
SH2-containing protein) or Bam32 (B cell adaptor molecule of 32 kDa). While its 
PH domain is in the same group as PKBs, they only share ~18% pair -wise sequence 
identity. This would account for the differences in the X-ray crystal structures of 
each domains holo conformation when binding Ins(1,3,4,5)P4. The inositol ring is 
rotated approximately 45° in the plane of the ring between the two structures; 
additionally the ring is closer to the core of the PH domain in the case of PKB.
48
 
 
Figure 34. ITC results of inositol phosphates binding the EST 684797 PH domain. 50 mM 
PH domain titrated into 5 mM solutions of Ins(1,3,4,5)P 4 (■), Ins(1,3,4)P3 ( ), or Ins(1,4,5)P3 
(∆) , at 25°C. Best fits curves assume a single class of binding site. Kd for Ins(1,4,5)P3 > 1 
M, Ins(1,3,4,5)P4 = 43 nm and Ins(1,3,4)P3 = 49 nM, in a 1:1 interaction. H values 
measured at 25°C: Ins(1,3,4,5)P4 = 28.3 kcal/mol and Ins(1,3,4)P3 = 24.9 kcal/mol.
97
 
 
This shows how ITC can be used to probe a PH domain‟s interaction with inositol 
phosphates, and should be transferable for studying the interactions of both wild -
type and mutant PKB  PH domains with natural and functionalised inositol 
phosphates.
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4. SYNTHESES OF PHOSPHORYLATED MYO-
INOSITOL DERIVATIVES 
 
A range of biological processes have been shown to be influenced by 
phosphorylated myo-inositol and inositol phospholipid compounds. This has created 
demand for a wide range of synthetic derivatives and analogues.  
There are five main issues that arise when considering the synthesis of the 
Ins(1,3,4,5)P4 analogue 1: (i) Choice of starting material; (ii) enantiomeric purity; 
(iii) how to achieve the desired functionalisation at the 2-O position; (iv) 
phosphorylation technique; and (v) choice of protecting groups.  
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The first two points can be taken - to some extent - in parallel. Inositol derivatives 
have been synthesised from a variety of sources (Scheme 1).
98-113
 Most commonly 
used is myo-inositol itself (2) and other naturally occurring cyclitols (3 and 4). 
However, carbohydrates (5-9), chiral acids (10), and benzene derivatives (11) have 
also been employed.  Chiral, non-racemic, compounds (5-10) provide routes to 
optically active inositol derivatives, but, compared to myo-inositol, require several 
additional reactions to establish the myo-stereochemistry of the incipient hydroxyls 
around the 6-membered ring. The choice of starting material therefore depends on 
the importance of chirality versus yield and minimal number of synthetic steps.  
Neither in vitro nor in vivo studies of the L-enantiomers of Ins(1,3,4)P3 and 
Ins(1,3,4,5)P4 interacting with the PH domain of PKB have been reported. However 
studies of the PH domain of PDK1 binding a range of PtdInsP n suggest that the PH 
domain of PKB should exhibit a high level of discrimination between the D- and L-
enantiomers of both Ins(1,3,4,5)P4 and Ins(1,3,4)P3.
114
 If this holds true for the 
E17A mutant PH domain of PKB then there is no immediate need for a chiral 
synthesis of 1 – the D-enantiomer will bind, but the L-enantiomer will not do so to 
any significant extent. This premise can be verified by the biophysical studies for 
this project – both intrinsic tryptophan fluorescence spectroscopy and isothermal 
titration calorimetry give a constant of stoichiometry. Using a racemic mixture, 
assuming that only the D-enantiomer interacts, should give an n value of 2, as only 
half the mixture partakes in the interactions. An n value significantly lower than 2 
would show that both enantiomers are interacting, and that both isomers should be 
investigated in their own rights.  
If enantiomeric purity is not of prime importance then myo-inositol, is an ideal 
starting point for preparing inositol polyphosphate analogues, as the correct 
stereochemistry is already in place around the 6-membered ring. This is re-enforced 
by retrosynthetic analysis of the target molecule.  
 
4.1 RETROSYNTHETIC ANALYSIS 
 
The first consideration in the retrosynthetic analysis of 1 (Scheme 2) is the creation of the 
phosphate moieties. Free phosphates are difficult to handle, and their protected forms are 
sensitive to nucleophiles, so they should only be formed in the final step of the synthesis to 
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avoid unwanted side reactions. Because of the need for myo-inositol and inositol 
phospholipid derivatives and analogues, a variety of polyol phosphorylation 
techniques have been investigated. 
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4.2 PHOSPHORYLATION 
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Phosphorylating reagents can be split into two main classes: (i) P(III), and (ii) P(V) 
reagents (Figure 35). P(V) reagents react to form phosphate triesters directly, so the 
products are already in the desired oxidation state. P(III) reagents can react via 
several different routes to form either an intermediate phosphite triester – which 
then requires oxidation to the P(V) state – or a phosphate triester, if the oxidant is 
also the activator.  
The one-step formation of phosphate triesters from phosphites requires the presence 
of an oxidising agent such as I2, or pyridinium bromide perbromide (PBP). I2 
oxidises the P(III) reagent in situ to form a P(V) phosphoryl iodide intermediate 
(25) which then react with the alcohol.
115
 PBP reacts with the P(III) reagent to form 
a bromophosphonium salt intermediate (27), which then reacts with the alcohol to 
form the phosphate triester via a bromophosphorane
116
 (Scheme 3). 
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Scheme 3. Phosphorylation reaction mechanisms for the reaction of trialkyl phosphites with 
an alcohol, with either I2 or PBP as an oxidising reagent . 
 
The main issue that arises with phosphorylation of inositol polyols, and helps 
dictate the choice of reagent, is the phosphate/phosphite triester‟s ability to migrate 
(Scheme 4). Attack on the P(III/V) centre by an adjacent alcohol leads to the 
formation of cyclic intermediate 30. This cyclic intermediate (after oxidation if via the 
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phosphite) is then hydrolysed during work up to form a mixture of phosphodiester salts 31 
and 32, so decreasing the yield of the desired product.  
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Scheme 4. Phosphate/phosphite triester migration mechanism. 
 
Phosphate triesters are less sensitive to nucleophilic attack than their phosphite counterparts, 
so when phosphorylating a diol the absolute rate of formation of 30 would be expected to be 
slower for the phosphate than for the corresponding phosphite triester. This would appear to 
make it advantageous to use P(V) reagents compared to P(III) reagents. However P(V) 
reagents are much less reactive than the corresponding P(III) species, so the rate of 
phosphorylation of the second, now more hindered, alcohol is much slower for P(V) than for 
the P(III) reagents. Consequently, the ratio of the rate of formation of 30 to its rate of 
phosphorylation, is much greater for P(V) than P(III) reagents. Hence P(III) reagents can 
often be used for phosphorylation where P(V) reagents are unsuccessful. This is the reason 
why P(III) reagents have become favoured for inositol chemistry. 
Additionally, while the P(V) compound tetrabenzyl pyrophosphate (TBPP, 20) - with 
sodium hydride and catalytic imidazole or 18-crown-6 in THF - effected 
tetraphosphorylation in the first reported synthesis of Ins(1,3,4,5)P4,
117
 it requires full 
conversion of the hydroxyls into alkoxides. However, many phosphoinositide related targets 
contain functional groups sensitive to these strongly basic conditions (e.g. fatty acid esters). 
Hence they have been almost completely superseded by P(III) reagents in more recently 
reported synthesises.
118
 P(III) reagents can be split into two sub-groups: 
Phosphorochloridites and phosphoramidites. 
Phosphorochloridites have been widely employed in the synthesis of phosphorylated 
peptides and oligonucleotides. They have also been used for the preparation of poly-
phosphorylated inositols - di(2-cyanoethyl)phosphorochloridite (15) was used to establish 
the phosphoryl centres in the total synthesis of PtdIns(3,4,5)P3.
119
 However, in the case of 
dialkyl/diaryl phosphorochloridite reagents, it has been shown that product purity is a 
function of the purity of the reagent, and the phosphorochloridites can disproportionate over 
time, leading to variable yields.
120
 Because of this the less reactive phosphoramidites have 
become favoured.  
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By themselves phosphoramidites do not phosphitylate hydroxyls. In order for the reaction to 
proceed, the phosphoramidite reagent needs to be activated by protonation (Scheme 5). 
There are several reagents that can achieve this, but the most commonly employed is the 
weakly acidic 1-H-tetrazole (34, pKa ca. 5). Tetrazole protonates the amide nitrogen and the 
tetrazolide anion then displaces the ammonium leaving group. The activatied P(III) centre is 
next attacked by the weakly nucleophilic alcohol (35) to form a phosphite triester (36); the 
tetrazole released at this stage forms a salt with the more basic dialkylamine (pKa ca. 10) 
liberated in the initial activation.  
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Scheme 5. Mechanism of alcohol phosphitylation by phosphoramidite.  
 
Once formed, the phosphite triester needs to be oxidized to form the desired phosphate. The 
most commonly used oxidising agents are mCPBA,
118
 
t
BuOOH
119
 or I2/water.
121
 mCPBA 
has been shown to give cleaner oxidations of dibenzylphosphite triesters,
122
 while 
t
BuOOH 
has been favoured for di(2-cyanoethyl)phosphites, so the choice of oxidising agents is 
dependent upon the protecting groups used in the phosphorylating reagent, and the other 
functional groups present (e.g. double bonds are not epoxidised by 
t
BuOOH). 
The free phosphate is subsequently formed by removal of the protecting group.  
 
4.3 PROTECTING GROUPS 
 
Protecting group strategies play a central role in the synthesis of phosphorylated myo-
inositol and inositol phospholipid compounds. The choices of protecting groups 
influence every stage of the synthesis.  
To minimize the number of synthetic steps to target 1, it would be simplest if the 
protecting groups for the phosphates (PGP) could be removed by the same 
conditions as for the protecting group on the 6-O (PG6). To make a suitable choice 
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for these protecting groups, how the 2,6-O substitution pattern of the tetrol might 
be established should be considered. 
No reactions have been reported for selective 2-O-alkylation of myo-inositol, and 
this axial ring substituent is the least reactive of the six hydroxyls. Therefore, for 
the synthesis of the 2-O acetic acid Ins(1,3,4,5)P4 derivate 1, a protecting group 
strategy is required that isolates the 2-hydroxyl for functionalisation.  
OH
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HO
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RO
a R = CMe2
b R = C6H10
c R = D-Camphor
2
(i) or (ii) or (iii)
OH
OHHO
OH
OHHO
 
Scheme 6. (i) 2,2-dimethoxypropane, TsOH, DMSO, 110 °C; (ii) 1,1-dimethoxycyclohaxane, 
TsOH, DMSO, 110 °C; (iii) D-Camphor dimethyl acetal (2 eq.), DMSO, conc. H2SO4, 68-70 °C 
 
Acetal chemistry has been widely employed in the synthesis of inositol derivatives 
to protect 1,2-diols.
123-125
 However the regioselectivity of these reactions – forming 
a 1(3),2-acetal (Scheme 6) – makes them unsuitable for the synthesis of 1 without 
the inclusion of additional deprotection and functionalisation steps. Several 
alternative protecting groups have been utilised that leave the 2-hydroxyl 
accessible.
126-128
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Scheme 7. (i) TipdsCl2, pyridine, RT; (ii) 2,2,3,3-tetramethoxybutane, trimethyl 
orthoformate, CSA, MeOH, 70 °C; (iii) 42, CSA, DMF, 100 °C.  
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The reaction of myo-inositol with an excess of either 1,3-dichloro-1,1,3,3-
tetraisopropyl disiloxane (TipdsCl2), or with 2,2,3,3-tetramethoxybutane and 
trimethyl orthoformate in the presence of catalytic camphorsulfonic acid (CSA),  
produce myo-inositol based 2,5-diols (39 and 40). Alternatively the reaction with 
bis-dihydropyran (42) produces a 1(3),2-diol (41).  
Orthoesters also provide a route to isolate the 2-hydroxyl for functionalisation. 
Orthoester formation results in the simultaneous protection of the 1 -, 3- and 5-
hydroxyls, creating a 2,4,6-triol (43).
129
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b R = Me, orthoacetate
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Scheme 8. (i) (EtO)3CH, DMF, TsOH, 100 °C; (ii) (EtO)3CCH3, DMF, TsOH, 100 °C;  
(iii) (MeO)3CPh, DMSO, pTSA, 100 °C. 
 
Both types of diol and the orthoesters fulfill the initial prerequisite for synthesising 
1. The choice between them is dictated by the 1,3,4,5 phosphorylation pattern of the 
target compound. Deprotection of functionalized Tipds or bis(butane-2,3-diacetal) 
compounds would subsequently require selective reprotection of the 6-hydroxyl 
before phosphorylation. The same would also be true for the 1(3),2 -diol based 
compounds. However this reprotection step would not be necessary in the case of 
the orthoesters.  
The first reported synthesis of a myo-inositol orthoester (Scheme 9) was in 1966, 
when Luk‟yanov and Tolkachev claimed to have synthesised an orthoformate of 
myo-inositol. However subsequent research by Lee and Kishi showed that while 
they probably achieved the protection, they mis-assigned its structure (44).
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Scheme 9. (i) (EtO)3CH, DMF, TsOH, 100 °C. 
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Myo-inositol orthoesters are formed by exchanging myo-inositol with either the 
trimethyl- or triethyl-orthoester of the corresponding carboxylic acid under 
catalytic acidic conditions. Because the six hydroxyls have similar reactivity, the 
protecting group can initially react with any of the hydroxyls. Orthoester exchange 
around the inositol ring leads to a series of intermediate structures that equilibrate 
to the thermodynamically most favoured structure – the 1,3,5-O-triester (43).  
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Scheme 10. Reaction mechanism for the acid hydrolysis cleavage of orthoesters.  
 
Using this protecting group influences the choice of PG6 and PGP, as PG6 must be orthogonal 
to the deprotection conditions of the orthoester. Using either 4:1 trifluoroacetic acid (TFA)-
water,
130
 or refluxing hydrochloric acid in methanol,
131
 causes acid hydrolysis of orthoesters 
(Scheme 10). Potter et al. formed a mixture of 1- and 3-O benzoate carboxyl esters by acid 
hydrolysis to deprotect inositol-2,6-O-dibenzyl orthobenzoate.
132
 Since none of the 5-O 
benzoate ester was observed, this implies that acid hydrolysis of orthoesters proceeds via 
initial scission of the bond to the 5-O. This is followed by largely unselective cleavage of the 
bond to either the 1- or 3-O, to give a mixture of 1-and 3-O acylated intermediates (48). In 
the case of the orthoformates, these acyl intermediates then undergo spontaneous hydrolysis 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 62 - 
so that all three hydroxyls are revealed. If an orthoester with a more stable corresponding 
acyl ester is used then it is possible to isolate this intermediate for the synthesis of 
compounds such as Ins(1,4,5)P3 and PtdIns(3,4,5)P3. Alternatively the acyl group can then 
be displaced by nucleophilic attack to recover all three hydroxyls. 
Studies of the rates of hydrolysis of 2,4,10-trioxaadamantanes suggest that, if the same holds 
true for inositol orthoesters, substitution at the orthoester bridgehead influences the rate of 
hydrolysis.
133
 The rate determining step is the ring-flip of the cyclohexane ring (46) into the 
boat conformation (47). This change in conformation allows water to access the 
carboxonium ion for hydrolysis to occur. Since the stability of the carboxonium ion 
increases with the size of bridgehead substituent, there is a corresponding decrease in the 
rate of hydrolysis. 
Since the immediate precursor to the target 1 will need to be protected on the 6-O, PG6 must 
be stable to strong acid conditions. Furthermore if R1≠H, it will also need to withstand the 
subsequent nucleophilic displacement of the acyl ester after initial hydrolysis of the 
orthoester. 
 
4.4 INOSITOL ORTHOESTER CHEMISTRY 
 
4.4.1 Functionalisation 
 
As well as protecting the 1-, 3- and 5-hydroxyls, the orthoester imposes an 
adamantane-like structure upon the compound. This forces the 2-hydroxyl into an 
equatorial orientation relative to the carbocycle, and the 4- and 6-hydroxyls to 
adopt axial dispositions. This creates a reactivity differential between the 2 - and 4-
/6- hydroxyls. Taking advantage of this difference has allowed the development of 
techniques to selectively react either: (i) just the equatorial 2-hydroxyl, (ii) just an 
axial 4(6)-hydroxyl, (iii) both the 2- and 4(6)-hydroxyls simultaneously, or (iv) 
both axial hydroxyls simultaneously.  
As a general rule, the regioselectivity of functionalisat ion of myo-inositol 
orthoesters is controlled by the strength of base used in the reaction. Using a mild 
base (Scheme 11), such as pyridine or imidazole, leads to selective reaction of the 
2-hydroxyl. However these bases can only generally be used to enable 
functionalisation with acyl, sulfonyl or silyl protecting groups, but not alkylation. 
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Acylation with one equivalent of reagent in pyridine is selective for the 2 -hydroxyl. 
The reaction proceeds via a bulky but reactive acyl pyridinium ion intermediate. 
Because the hydroxyl group is mostly un-ionised in the reaction transition state, 
product formation is governed by steric factors, leading to preferential acylation of 
the least hindered 2-hydroxyl.
134
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Scheme 11. Synthesis of 2-O-benzoyl-myo-inositol-1,3,5-orthoesters. (i) BzCl, pyridine.  
 
With one equivalent of a reactive alkylating agents, bases such as Et 3N are 
sufficient. Otherwise metal hydrides need to be used. However these bases lead to 
the 4(6)-hydroxyl being favoured due to the stabilisation of the axial alkoxide by 
neighbouring group participation from the other axial hydroxyl (Scheme 12).
135
 The 
4(6)-alkoxide is stabilised by a hydrogen bonding interaction with the 6(4) -
hydroxyl, combined with chelation in the case of metal ion containing bases, of the 
metal cation in the di-axial 4,6-O pocket. Since the 2-alkoxide would not be 
similarly stabilised, these conditions lead to selective functionalisation of the 4(6) -
hydroxyl. 
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Scheme 12. Sythesis of 4(6)-O-benzoyl-myo-inositol-1,3,5-orthoformate. (i) BzBr, NaH (1 eq.). 
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Scheme 13. Selective di-functionalisation of myo-inositol-1,3,5-orthoesters. (i) R
2
X, strong 
base; (ii) R
2
X, mild base; (iii) R
3
X, strong base; (iv) R
3
X, mild base. 
 
A di-substituted compound is formed by increasing the number of equivalents of reagents to 
2. The substitution pattern of the product is again defined by choice of base. Consideration 
of Scheme 13 explains these patterns if R2=R3. When using a weak base the reaction 
proceeds by route BE, initially forming intermediate 54. The second equivalent of reagent 
then reacts with one of the axial hydroxyls for selective formation of the unsymmetrical 
alcohol 55a. Selectivity is diminished by using a stronger base. Functionalisation can follow 
either route AC – to form the symmetrical alcohol 53a – or route AD – to create the 
unsymmetrical alcohol 55a.  
The ratio of 53a:55a is determined by several factors. The presence of a group on the 4(6)-O 
means the formation of the second alkoxide ion cannot be stabilised by intramolecular 
hydrogen bonding,
136
 decreasing the selectivity for the second axial hydroxyl and increasing 
the yield of 55a. 1,3-Diaxial steric interactions, especially with bulky reagents, increase the 
level of 55a formed. If metal ion containing bases are used, the choice of ion can increase 
selectivity for the 6(4)-hydroxyl; the small Li
+
 cation binds more tightly in the 4,6-O pocket 
than Na
+
,
137
 increasing the chelation effect and favouring 53a.  
If the substitution reactions are separated into individual steps, the chemistry creates 
compounds with different functional groups on each oxygen atom.  
Because of the symmetrical nature of 54, the product of reacting the 4,6-diol under either 
weak or strongly basic conditions (route E) can only break this symmetry.  
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The unsymmetrical diol (52) can be functionalised in one of two ways; (i) using a weak base 
(route D) favours the 2-hydroxyl in the same manner as for the triol (43); (ii) the use of 
strong bases has the same problems with selectivity as for the one-pot di-functionalisation, 
creating a mixture of 53b and 55b. 
Both diols 52 and 54 can be exhaustively di-functionalised, depending on the desired 
functionality, using both weak or strong base and an excess of reagent. Similarly the already 
di-substituted compounds (53 and 55) can be functionalised at their remaining hydroxyl in 
the same way, to create a fully protected myo-inositol. 
 
4.4.2 Reductive orthoester removal 
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Scheme 14. Reaction mechanism for DIBAL-H reduction of orthoesters.  
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As already discussed, the orthoesters can be cleaved by acid hydrolysis. However there are 
two other main routes that have been developed for manipulating orthoesters: (i) reduction 
with diisobutyl aluminium hydride (DIBAL-H), or (ii) using Grignard reagents or trimethyl 
aluminium to insert an alkyl group into the C-O bond. 
DIBAL-H offers greater control of the intermediate products that can be generated when 
compared to acid hydrolysis (Scheme 14 vs. Scheme 10). Using 2 equivalents of DIBAL-
H selectively generates a bridging 1,3-O acetal (56).
138
 Similar to acid hydrolysis of 
orthoesters the 5-O reacts preferentially,
139
 but in this case it is clearly due to being the least 
sterically hindered of the three orthoester oxygens.
140
 This acetal can then be hydrolysed to 
form 49. Using an excess of DIBAL-H inserts a second hydride, but this time unselectively, 
leading to the formation of a mixture of the 1- and 3-O isomers of the ether (57).
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Scheme 19. Reaction mechanism for Grignard reagent reduction of orthoesters.  
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 67 - 
Use of limiting Grignard reagents or trimethyl aluminium to cleave myo-inositol orthoesters 
also generates a bridging acetal. Unlike DIBAL-H, where the 1,3-O acetal is preferentially 
formed, these reagents create a 1(3),5-O acetal (58). In the case of trimethyl aluminium, this 
difference in region-selectivity has been attributed to its smaller steric bulk compared to 
DIBAL-H allowing it to access the more sterically hindered 3(1)-O. With Grignard reagents, 
their activation and orientation of attack is dictated by the chelation of a magnesium ion in 
the myo-inositol-1,2,3-O-trioxa pocket (Scheme 15).
138
  
Using an excess of Grignard reagent leads to the generation of a 5-O-alkyl derivative (59). 
Both these techniques can be used to create the desired tetrol 49. However acid hydrolysis, 
particularly of the orthoformate, provides the most efficient route as it requires the fewest 
synthetic steps. 
 
4.5 PROPOSED SYNTHETIC ROUTE 
 
Combining the retrosynthetic analysis to the 2,6-O substituted tetrol 14 (Scheme 2) with the 
chemistry of inositol orthoesters, suggests a synthetic route to the Ins(1,3,4,5)P4 analogue 1 
(Scheme 16).  
Since direct alkylation of the 2-O is not possible, the longer route via temporary protection – 
i.e. using a protecting group that controls regiochemistry, but which is not retained up to the 
final global deprotection – of the 4-hydroxyl needs to be adopted. The orthoester dictates 
the selection of subsequent protecting groups. Strongly basic conditions can be used 
to set up the desired substitution pattern, in which PG6 could be an alkyl, acyl or 
sulfonyl group. As a permanent protecting group – i.e. a group that is retained up to the 
final global deprotection step – it must be stable to the strong acid conditions used to 
remove the orthoester and, if R1≠H, the subsequent nucleophilic displacement of the 
R
1 acyl ester. It must also be stable to the deprotection conditions for PG4.  
This discounts acyl protecting groups for the role of PG6 as they would be displaced during 
removal of the orthoester (R1≠H). Because of this alkyl reagents, particularly allyl and 
benzyl (Bn) groups, have been widely employed for this purpose due to their stability 
towards both acidic and basic conditions. The criteria for PG4 are less stringent. As a 
temporary protecting group the main requirement is that its removal does not affect PG6. 
Using an acid labile protecting group would allow for a one-pot deprotection to form the 
tetrol (14) directly from the fully protected inositol (62). 
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The choice of protecting group for the phosphates is influenced by PG6. By using a group 
with a deprotection compatible with that of PG6, a final one-pot global deprotection can be 
used. Although base labile groups such as cyanoethyl could be used in a two-step final 
unblocking, the obvious choice is for PG6=PGP=Bn to provide a one-pot global deprotection. 
Alternatively, other groups susceptible to reductive conditions can be used [e.g. 
benzyloxymethyl (BOM) or para-methoxybenzyl (Pmb)]. To minimise the steric 
interactions when trying to phosphitylate multiple hydroxyls, the phosphoramidite N,N-
diethylamino-5,6-benzo-1,3,2-dioxaphosphepane (section 4.2, 19), with a bridging protecting 
group, has been developed.
142
 
The choice of R2 initially seems quite simple, as direct formation of the 2-O acetic acid is 
possible using chloroacetic acid. However this would need to be protected during the 
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phosphorylation step. Additionally it does not allow alternative analogues from a 
divergent synthetic strategy to be explored. Using an allyl group as a masked form 
of the acid would allow the potential synthesis of a wide range of compounds.  
 
4.6 MANIPULATIONS OF ALLYL GROUPS 
 
Although allyl ethers are most commonly used as protecting groups, they can also be used as 
a form of masked functionality. The desired acetic acid functionality can be generated by a 
variety of techniques (Scheme 17), either in a “one-pot” reaction or via isolation of the 
aldehyde intermediate 66. 
O
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(ii)
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64
65
66  
Scheme 17. (i) Direct oxidation of an allyl ether to an acetic acid; (ii) oxidation of the ally l 
ether to an aldehyde; (iii) oxidation of the aldehyde to an acetic acid.  
 
However, the double bond of the allyl group need not only be oxidised but can be converted 
into a diverse range of other functionalities as well. The range of chemistry that can be 
applied means that, at least in theory, nearly any commonly utilised functionality should be 
accessible. In addition to the aldehyde and acid functionalities it is also possible to directly 
access: alcohols, ethers, 1,2-diols, 1,2-halohydrins, 1,2-dihalides, halides, and the products 
of pericyclic reactions such as cyclopropanes.
143
 Further compounds can then be synthesised 
from these intermediates. 
The simplest inter-conversion is the reduction of the double bond to give a propyl group 67. 
Alternatively using the acetaldehyde 66, with subsequent reduction instead of oxidation, 
allows access to the 2-hydroxyethyl ether 68. Ins(1,3,4,5)P4 analogues with these 
functionalities at the 2-O substituent can act as control molecules for the receptor-ligand 
engineering studies, testing the effectiveness of a polar group exchange interaction instead 
of steric complementation. The alcohol also allows for the formation of further analogues. 
Using the Mitsunobu reaction, the alcohol can be replaced by a wide range of nucleophiles 
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(69). The alcohol can also undergo further substitution reactions, such as PEGylation 
(Scheme 18). 
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Scheme 18. Manipulations of the al lyl group. (i) Reduction of allyl; (ii) oxidation of the allyl 
to an aldehyde; (iii) reduction of aldehyde to hydroxyethyl; (iv) Mitsunobu reaction; (v) 
PEGylation. 
 
Longer carbon chain lengths can also be accessed from the allyl ether. Hydroboration-
oxidation of the allyl ether forms a 3-hydroxypropyl ether (71). The alcohol can be 
manipulated as for the 2-hydroxyethyl ether above, or can be oxidised to the aldehyde (72) 
or carboxylic acid (73, Scheme 19). The organoborane also increases the options for 
functionalisation, allowing the introduction of halides and amines, or can be used in carbon-
carbon bond forming reactions.
144
 
O
64
O
71
Hydroxypropyl versions of 
compounds accessed 
from hydroxyethyl
O
72
O
(i)
(ii)
OH
O
73
(iii)
O
OH
 
Scheme 19. (i) Hydroboration/oxidation; (ii) oxidation of hydroxypropyl to the aldehyde; (iii) 
oxidation to propionic acid.  
 
From the allyl ether the chain length might be extended even further by the use of olefin 
metathesis with the Grubbs or Schrock catalysts (Scheme 20).
145
 A suitable choice of R 
group allows a wide range of further functionalities to be introduced. 
O
64
O
74
R
R
Grubbs/Schrock
catalyst  
Scheme 20. Cross-metathesis reaction. 
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This demonstrates that using an allyl group to form the acetic acid functionality on the 2-O 
creates a versatile synthetic route that can be readily adapted to create a library of 2-O 
substituted Ins(1,3,4,5)P4 analogues. 
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5. CHEMISTRY RESULTS & DISCUSSION  
 
5.1 MRes RESEARCH   
 
This section summarises the research undertaken during the MRes year of the 4 
year MRes/PhD, for which an MRes qualification was awarded.
146
 It is included to 
provide background information relevant to the subsequent PhD research.  
The first consideration for the synthesis of 1 is the choice of the primary protecting 
group. The orthoformate affords the shorter synthetic route - requiring only a single 
step deprotection. It also provides a higher degree of freedom with the choices for 
subsequent protecting groups - since there is no nucleophilic deprotection step, it is 
possible for PG6=acyl. However this needs to be weighed against the flexibility of 
the synthetic route.  
A divergent strategy allows for a range of compounds to be synthesised from a 
shared intermediate. Acidic hydrolysis of a substituted orthoester allows selective 
conversion to the 1-O acyl derivative. This can then be used as an intermediate in 
the synthesis of PtdInsPn analogues. DIBAL-H reduction of orthobenzoates forms a 
mixture of the 1- and 3-O Bn compounds. Consideration of the proposed synthetic 
route (see section 4.5) suggests that if PG6=Bn, then the 3-O Bn provides a succinct 
route to the Ins(1,4,5)P3 analogues. Because of this the orthobenzoate was chosen 
over the orthoformate, and the Bn group was picked as PG6. Giving the 2-O-
functionalised 6-O-benzyl-myo-inositol-1,3,5-orthobezoate (75) as a key 
intermediate target molecule (Figure 36). 
O
O
O
R
2
O
PG
6
O
OH
R
1
63 75
O
O
O
R
2
O
BnO
OH
Ph
 
Figure 36. Key intermediate target molecule 6-O-benzyl-myo-inositol-1,3,5-orthobezoate. 
 
Acid catalysed reaction of myo-inositol with trimethyl orthobenzoate (Scheme 
21)
147
 can be carried out in either dimethylformamide
117
 or dimethyl sulfoxide.
129
 
Published studies of the formation of other orthoesters have reported that the 
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reaction in DMF gives a cleaner product.
135
 However in the case of the 
orthobenzoates, previous work in the Gaffney group gave better results when 
DMSO was used.  
O
O
O
OH
HO
HO
Ph
43c
[58%]
2
(i)
OH
OHHO
OH
OHHO
 
Scheme 21. Synthesis of myo-inositol-1,3,5-O-orthobenzoate. (i) 1.5 eq. (MeO)3CPh,  
cat. TSA, DMSO, 100 °C. 
 
Recrystalisation of triol (43c) from ethyl acetate allowed it to be obtained in high 
purity and with a reasonable yield. Rather than isolating the triol it was decided to 
take the crude the myo-inositol orthobenzoate on to the next step. This acted to 
increase the overall yield for the entire synthesis, since it avoided product loss due 
to the recrystalisation procedure. Reacting the crude t riol (43c) with one equivalent 
of NaH in DMF selectively formed the 6-alkoxide ion. Subsequent addition of BnBr 
(Scheme 22) gave a racemic mixture of the asymmetric diol (76) in good yield and 
as the only isolatable compound.  
2
(i)
OH
OHHO
OH
OHHO
O
O
O
OH
HO
BnO
Ph
76
[90%]
O
O
O
OH
HO
HO
Ph
43c
(ii)
 
Scheme 22. Synthesis of 6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate.  
(i) 1.5 eq. (MeO)3CPh, cat. TSA, DMSO, 100 °C; (ii) 1 eq. NaH, 1 eq. BnBr, DMF.  
 
The next step was to use a temporary protecting group to protect the 4-hydroxyl. The 
protecting group needs to be either acid labile – so that it can removed during acid 
hydrolysis of the orthoester – or removable by another means that is orthogonal to the other 
functionalities present. para-Methoxybenzyl (Pmb) has previously been used in inositol 
syntheses and fulfils both these requirements.
148
 The Pmb protecting group can either be 
                                                 
 All compounds in this synthesis are a racemic mixture. For ease of nomenclature all subsequent numbering 
will be as for the single biologically active D-enantiomer of myo-inositol. 
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removed by acidic hydrolysis or by single electron transfer (SET) reagents such as ceric 
ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ).
149
 
Reacting 76 with one equivalent of NaH formed a mixture of the desired 4-O-, the 
2-O- and the di-substituted 2,4-O-Pmb ether derivatives. Using a range of 
protecting groups Devaraj et al. showed that selectivity for the alkylation of the 4-
hydroxyl can be increased by chelating the 4-alkoxide with the smaller lithium 
ion.
137
 This study did not include the Pmb group. Trying to reproduce their 
observed selectivity alkylating with this protecting group did not prove successful, 
and a similar yield of each product was observed as for using NaH. In an attempt to 
improve this, the order of substitution was reversed (Scheme 23). 
O
O
O
OH
HO
BnO
Ph
76 [90%]O
O
O
OH
HO
HO
Ph
43c
(i)
O
O
O
OPmb
HO
HO
Ph
77 [42%]
O
O
O
OPmb
HO
BnO
Ph
78
(ii) [60%]
(i) [58%](ii)
 
Scheme 23. Dual synthetic routes for the preparation of 4-O-para-methoxybenzyl-6-O-
benzyl-myo-inositol-1,3,5-O-orthobenzoate. (i) 1 eq. NaH, 1 eq. BnBr, DMF; (ii) 1 eq. NaH,  
1 eq. PmbCl, DMF. 
 
Product Yield (%) 
myo-inositol-1,3,5-O-orthobenzoate 21 
2-O-para-methoxybenzyl-myo-inositol-1,3,5-O-orthobenzoate 13 
4-O-para-methoxybenzyl-myo-inositol-1,3,5-O-orthobenzoate 42 
di-para-methoxybenzylated compounds 17 
2,4,6-O-tri-para-methoxybenzyl-myo-inositol-1,3,5-O-
orthobenzoate 
2 
Non-reclaimed material 5 
Table 1. Yields of mono-, di- and tri- substituted products from  para-methoxybenzylation of 
myo-inositol-1,3,5-O-orthobenzoate. 
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It was hoped that first reacting 43c with one equivalent of NaH and PmbCl would 
selectively form the 4-O-Pmb ether. Then using one equivalent of BuLi and BnBr, 
this should exhibit similar selectivity for the formation of the 6-O Bn ether as 
reported by Devaraj et al. When the mono-alkylation of triol 43c with PmbCl was 
attempted, it failed to reproduce the selectivity and yield achieved in the 
corresponding benzylation reaction. A mixture of the mono-, di- and tri- para-
methoxybenzylated myo-inositol orthoesters formed (Table 1), as well as unreacted 
starting material. Since PmbCl is more reactive than the reagents that Devaraj et al. 
used, the combination of results from the para-methoxybenzylation reactions imply 
that it is not as dependent on the stabilised alkoxide ion as other alkylations in 
order to react.  
Comparisons of the cumulative yields established that the initial route (benzylation 
followed by para-methoxybenzylation) gave the most efficient route to 78 
(cumulative yield of 54% versus 24% for the alternative route) . 
The final step to fully functionalise the inositol ring is to introduce the masked acid 
group. The allyl functionality was chosen as it has the potential for divergent 
synthesis to create several other alternative final inositol phosphate analogues (see 
section 4.6). Since there is only one alcohol left to functionalise, reacting 78 with an 
excess of NaH and allyl bromide, cleanly produced 79 in high yield (Scheme 24).  
O
O
O
OPmb
O
BnO
Ph
79
[95%]
O
O
O
OPmb
HO
BnO
Ph
78
(i)
 
Scheme 24. Synthesis of 2-O-allyl-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-
orthobenzoate. (i) 1.5 eq. NaH, 1.5 eq. allylBr, DMF. 
 
The next synthetic step was to oxidise the allyl ether to the carboxylic acid functionality 
(Scheme 25). A range of different reagents were employed to try to achieve this. Direct 
formation was attempted first. Treating alkenes with ozone produces a highly reactive 
mol-ozonide, which undergoes a rapid rearrangement to form an ozonide. Treatment 
with hydrogen peroxide causes oxidation of the ozonide into the corresponding 
ketone or carboxylic acid species.
150
 A reductive work-up with dimethyl sulfide 
creates two aldehydes. However, both reactions gave a mixture of products, with 
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only trace amounts of the desired acid present. An alternative method that has been 
employed to convert allyl functionality into an acetic acid is to use sodium 
periodate with a ruthenium catalyst.
151, 152
 However, no reaction was observed, so a 
stepwise approach was adopted instead.  
Osmium tetraoxide cis-dihydroxylated the alkene (81). Using excess oxidant (N-
methylmorpholine-N-oxide, NMO) regenerated the OsO4, so only catalytic levels 
were required.
153
 Sodium periodate was then used to cleave the diol
154
 to create 
aldehyde 82. It was then necessary to oxidise the aldehyde to the acid. Several 
different oxidising reagents were tested: Potassium permanganate oxidised the 
aldehyde, but secondary oxidation at the benzyl ether was also observed; silver 
oxide
155
 showed no sign of reaction, as did oxone.
156
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BnO
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Scheme 25. Routes to 2-O-acetic acid-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-
1,3,5-O-orthobenzoate. (i) Direct formation of the 2-O-acetic acid moiety from the allyl ether, 
ozonolysis with oxidative work-up; (ii) formation of the 2-O-acetaldehyde moiety from the 
allyl ether, ozonolysis with reductive work-up; (iii) 3 eq. NMO, cat. OsO4, 9:1 acetone-water; 
(iv) 4:1 THF-sat. aq. NaIO4 solution; (v) oxidation of the aldehyde to the 2-O-acetic acid 
moiety. 
 
Due to the problems with oxidising the aldehyde, it was decided that direct 
alkylation with chloroacetic acid (Scheme 26) would be used so that synthesis of the 
primary synthetic target (1) could be investigated in parallel to resolving these 
issues. This method proceeded as a relatively clean reaction to give desired acid 80; 
however, due to difficulties handling the acid, it was decided to protect the acid and 
form the methyl ester 83. 
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80
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Ph
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[100%]
(ii)
O
OMe
Scheme 26. Synthesis of 2-O-acetic acid-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-
orthobenzoate and its conversion to its methyl ester. (i) 2.2 eq. NaH, 1 eq. chloroacetic acid, DMF;  
(ii) 0.1 eq. TSA, MeOH. 
 
R
O
H
OMe
H
O
Hemiacetal
hydrolysis
+
87 88 89
O
O
CN
CN
Cl
Cl
85
R
O
OMe
84
O
O
-
CN
CN
Cl
Cl
R
O
O
+
Me
H H
OH
O
-
CN
CN
Cl
Cl
R
O
O
+
Me
OH
O
-
CN
CN
Cl
Cl
R
O
OMe
H OH
SET
H-atom
transfer
H2O
 
Scheme 27. Mechanism for SET deprotection of Pmb ethers by DDQ.  
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Once the fully functionalised  myo-inositol had been produced, the next step was to 
deprotect the 1-, 3-, 4-, and 5-O positions to regenerate the free hydroxyls ready for 
phosphorylation. The standard orthoester deprotection conditions were employed,
130
 
as the strongly acidic conditions should allow a „one-pot‟ reaction that would also 
cleave the Pmb ether
157
 and return the methyl ester to a carboxylic acid. However 
preliminary attempts using 4:1 TFA-water gave a complex mixture of products. In 
order to minimise the potential for side reactions it was decided to remove the Pmb 
group prior to orthoester deprotection. DDQ (85) can be used to selectively remove Pmb 
ethers in the presence of Bn ethers due to their differences in reactivity. This difference 
arises from the para-methoxy substituent on the benzyl group being able to stabilise the 
intermediate cation after H-atom transfer, leading to reaction times of minutes (for Pmb) 
rather than days (for Bn).  
Treating alcohol 90 from Pmb deprotection with acid initially seemed promising, 
with negative ion FAB-MS showing a peak at m/z=431 corresponding to the 
formation of the isomeric benzoate ester. Subsequent treatment with sodium 
methoxide removed the benzoyl ester, but the target compound (91) could not be 
isolated, and instead a mixture of compounds was formed (Scheme 28), believed to 
derive from intramolecular esterification (92). Attempts at reforming the acid 
functionality were unsuccessful.  
O
O
O
OPmb
O
BnO
Ph
80
O
O
O
O
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O
BnO
Ph
90
[69%]
O
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O
OHHO
OBnHO
OH
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(ii),(iii)
(ii),(iii)
X
X
O
OHO
OBnHO
OH
92 [98%]
O
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(ii),(iii)
 
Scheme 28. (i) DDQ SET Pmb cleavage: 4 eq. DDQ, 10:1 DCM-water; (ii) 4:1 TFA-water; 
(iii) MeONa, MeOH. 
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A dual approach was decided upon to overcome these difficulties: (i) the orthoester 
removal conditions needed to be properly established in isolation from the acid 
functionality, and (ii) further study of the allyl ether as a potential route to the acid 
was pursued. To cover the first point it was decided that the natural Ins(1,3,4,5)P4 
would be synthesised using the same strategies as employed for the synthetic 
ligand. Allyl ethers are stable towards the orthoester deprotection conditions, so 
transforming the allyl ether into the acetic acid after phosphorylation of the  tetrol 
would allow the acid to be formed without the risk of intramolecular esterification.  
 
5.2 PhD RESEARCH 
 
5.2.1 Synthesis of myo-inositol tetrol precursor to Ins(1,3,4,5)P4 
 
The synthesis of Ins(1,3,4,5)P4 serves two purposes: (i) It allows the deprotection of the 
orthobenzoate to be studied without the complication of the acid functionality, and (ii) it can 
be used as a control molecule for the receptor-ligand binding studies. 
Billington et al. developed a synthetic route to Ins(1,3,4,5)P4 from myo-inositol 
orthoformate.
135
 It was decided to use a modified form of the synthesis to establish reaction 
conditions for the modified ligand.  
O
O
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OAllyl
HO
HO
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Scheme 29. Synthesis of 4-O-allyl-myo-inositol-1,3,5-O-orthobenzoate and 2,6-O-dibenzyl-4-O-allyl-
myo-inositol-1,3,5-O-orthobenzoate. (i) 1 eq. NaH, 1 eq. allylBr, DMF; (ii) 3 eq. NaH, 3 eq. BnBr, DMF. 
 
Direct di-benzylation of the orthoformate triol has been reported to produce an unfavourable 
1:5 mixture of the 2,6- and 4,6-O-diethers.
158
 The first step is therefore to protect the 4-
hydroxyl so that only the 2,6-O-dibenzyl ether is formed. Pmb has already been shown to 
display poor selectivity for only the 4-O position; therefore an alternative temporary 
protecting group was required. Since the 2-O is not functionalised in the natural product, the 
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allyl group can be used in this role. Allylation followed by benzylation of the inositol 
orthobenzoate gave the fully protected inositol (94) in good yield (Scheme 29).  
There are several methods by which the allyl ether can be deprotected, but the chosen 
method must be orthogonal to the other protecting groups. Gigg et al. showed that allyl 
ethers of a wide range of myo-inositol compounds may be removed using a relay strategy.
159
 
The allyl ether is activated for deprotection by isomerising it to the Z-1-propenyl ether with 
potassium tert-butoxide (
t
BuOK) in DMSO at elevated temperatures.
160
 Isomerisation places 
the double bond into conjugation with the oxygen atom, creating an enol ether that can then 
be removed under acid hydrolytic conditions to expose the free hydroxyl (Scheme 30). 
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Scheme 30. Synthesis of 2,6-O-dibenzyl-myo-inositol-1,3,5-O-orthobenzoate via 
isomerisation of the allyl ether with 
t
BuOK, and the sebsequent removal of the Z-1-propenyl 
ether under mildly acidic conditions. 
 
Although there was the potential for a „one-pot‟ reaction to hydrolyse both the 1-propenyl 
ether (95) and the orthobenzoate using acidic hydrolysis conditions, this was not employed 
as it would be counter-productive for determining optimum deprotection conditions for the 
orthobenzoate. Hence the dibenzyl orthobenzoate 96 was isolated first, and then subjected to 
the literature 4:1 TFA-water acid hydrolysis conditions.  
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Scheme 31. Synthesis of 2,6-O-dibenzyl-myo-inositol. (i) 4:1 TFA-water; (ii) MeONa, MeOH. 
 
Acidic hydrolysis gave a mixture of the 1- and 3-O benzoyl esters. The crude reaction 
mixture was evaporated to dryness and then taken up in dry methanol. Sodium methoxide 
was added until pH 11 was obtained. This induced transesterification of the benzoyl ester, 
leading to the formation of the putative sodium salt of 2,6-O-dibenzyl-myo-inositol and 
methyl benzoate 100 (Scheme 31). To achieve good yields, the reaction mixture was 
neutralised with hydrochloric acid to convert any inositol alkoxide ions into the tetrol (99), 
with sodium chloride byproduct. It was discovered that 99 could then be obtained in a 
quantitative yield, and high purity, using a two step process: (i) after evaporating to dryness, 
the crude mixture was partitioned between chloroform and water. Because of the 
hydrophilicity of the tetrol (99), it joins the NaCl in the aqueous phase, while methyl 
benzoate (100) moves into the organic phase. (ii) The aqueous phase was then evaporated to 
dryness, and taken up in dry MeOH. The NaCl formed a precipitate, while the tetrol 
dissolved in the supernatant, allowing filtration to isolate the product with no requirement 
for further purification.  
While the 2,6-O-dibenzyl-myo-inositol was being prepared, alternative uses for dibenzyl 
orthobenzoate compound 96 were explored. 
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5.2.2 Synthesis of myo-inositol triol precursor to Ins(1,4,5)P3  
 
O
O
O
OH
BnO
BnO
Ph
96
(i) OO
O
OR
BnO
BnO
Ph
101a R=Tbdms [76%]
101b R=Tbdps [84%]  
Scheme 32. Synthesis of 2,6-O-dibenzyl-4-O-(tert-butyldimethylsilyl) and (tert-
butyldiphenylsilyl)-myo-inositol-1,3,5-O-orthobenzoate. (i) 1.5 eq. RCl, 2.2 eq. imidazole,  
1 eq. Et3N, DMF, 100 °C. 
 
 
The 4-O tert-butyl diphenyl silyl (Tbdps) and tert-butyl dimethyl silyl (Tbdms) 
derivatives were synthesised by silylation of the remaining axial hydroxyl of 96 
(Scheme 32). Both reactions proceeded with complete conversion of the hydroxyl to 
the corresponding silyl ether; however the Tbdps derivative (101b) was 
contaminated with TbdpsOH, which could not be readily removed by flash 
chromatography. This was overcome by the discovery that the TbdpsOH could be 
sublimed from the product mixture at low pressure and high tempera ture, to leave a 
pure sample of the fully protected orthobenzoate 101b.  
102a R=Tbdms [40%]
102b R=Tbdps [42%]
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Scheme 33. Synthesis of 1,2,6-O-tribenzyl-myo-inositol and 2,3,6-O-tribenzyl-myo-inositol. 
(i) 3.5 eq. DIBAL-H, DCM; (ii) 4.75 eq. TBAF, THF. This reaction sequence was carried out 
by J. Swarbrick. 
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These compounds were synthesised for collaborative work with Joanna Swarbrick, 
to investigate the ability of a range of sterically bulky substituents to influence the 
regioselectivity of DIBAL-H reduction of myo-inositol orthobenzoate 
compounds.
141
 Treating silyl ethers 101a or 101b with excess DIBAL-H led to the 
reduction of the orthobenzoate to a benzyl ether. In both cases a 5:4 mixture of the 
1-O Bn (102) and 3-O Bn (103) compounds was created. The fact that there was no 
difference between the ratios of products obtained from these two compounds was 
attributed to repulsion between the bulky 4-O-silyl ether and the 5-O-DIBAL 
adduct. This forces the inositol ring into an inverted chair -like conformation similar 
to the orthoester, which acts to reduce the contrast between the steric environments 
at the 1- and 3-O as the distance between the silyl 4-O and 3-O acetal linkage is 
increased (Scheme 34).
161
  
These compounds were separated by flash chromatography, and then reacted with 
tert-butyl ammonium fluoride (TBAF) to remove the silyl group (Scheme 33, 
reaction sequence carried out by J. Swarbrick.). Triol 105 has the correct regiochemistry 
to be a precursor for the synthesis of Ins(1,4,5)P3. Like Ins(1,3,4,5)P4, this will also 
be used as a control molecule for the receptor-ligand binding studies. 
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Scheme 34. Rationale for the observed poor selectivity of DIBAL-H reduction of 101. For the 
reaction mechanism see Scheme 14. The chair-like conformation of 107 means there is 
poor discrimination between the 1-O and 3-O and DIBAL-H can co-ordinate to either oxygen 
equally. 
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5.2.3 Synthesis of 2-O-allyl-6-O-benzyl-myo-inositol 
 
O
O
O
OPmb
AllylO
BnO
Ph
79
(i) OO
O
OH
AllylO
BnO
Ph
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[72%]
OAllyl
OHHO
OH
OBnHO
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Scheme 35. Synthesis of 2-allyl-6-O-benzyl-myo-inositol. (i) 4 eq. CAN, 9:1 MeCN-water  
(ii) 4:1 TFA-water; (iii) MeONa, 1:1 CHCl3-MeOH. 
 
Having established suitable conditions for the synthesis of the Ins(1,3,4,5)P 4 
precursor 2,6-O-dibenzyl-myo-inositol (99), the same approach was used for the 
synthesis of 2-O-allyl-6-O-benzyl-myo-inositol (109). The first step was to remove 
the Pmb group from the fully protected allyl compound (79). CAN removes the Pmb 
group by a SET mechanism similar to DDQ (see Scheme 27), but was found to give 
the higher yield of the two reagents. This was ascribed to the differences in the 
work-up procedures for the two reactions. Using the conditions developed for 
dibenzyl ether 99, the orthobenzoate of inositol alcohol 108 was deprotected to 
cleanly form 2-O-allyl-6-O-benzyl-myo-inositol 109 (Scheme 35).  
Once these conditions had been confirmed as a practical route to 109, it was decided 
to revisit the „one-pot‟ option to shorten the number of synthetic steps, and 
potentially increase the overall yield. The initial attempt adopted the same 
conditions as were previously used for orthobenzoate deprotection: the acidic step 
seemed to proceed as expected, but when preparing the crude mixture for the 
methoxide treatment, it formed a gum which was not soluble in methanol. Since this 
was not observed in the other deprotections it was attributed to the Pmb group. The 
gum could either be formed of debris from the removal of the Pmb group, or by 
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other unwanted by-products. To establish which option was true, a suitable solvent 
was needed to dissolve the gum. Working through the standard solvents in the 
laboratory showed it to be most soluble in chloroform. The second step of the 
deprotection was thus modified so that the crude mixture was taken up in  1:1 
chloroform-methanol. Although treating chloroform with sodium methoxide risked 
the formation of dichlorocarbene,
162
 a test reaction gave only the expected products. 
Using the work-up established for the previous deprotections removed the Pmb 
debris into the organic phase, along with the methyl benzoate, and gave the tetrol 
(109) in quantitative yield, and in high purity. 
 
5.2.4 Phosphorylation 
 
The 2-O-allyl-6-O-benzyl-myo-inositol, 2,6-O-dibenzyl-myo-inositol and 2,3,6-O-
tribenzyl-myo-inositol were all then ready for phosphorylation. Baudin et al. used 
N,N-diisopropyldibenzyl phosphoramidite (section 4.2, 17) in the synthesis of 
Ins(1,3,4,5)P4.
163
 Using this reagent, activated with 1-H-tetrazole (34), allows the 
phosphitylation of polyols under mild conditions. Subsequent oxidation of the P(III) 
centre creates a dibenzyl phospho-triester. Since both the alcohol of the final 
product and the phosphates are benzyl protected, this allows for a single „one -pot‟ 
global deprotection strategy to be employed to create the target compound. It was 
decided that the synthesis of Ins(1,3,4,5)P4 would again be used to establish 
conditions for synthesising the 2-O-acetic acid derivative (1).  
The first step was to synthesise the activating agent. Using a Sandmeyer reaction, 
5-aminotetrazole monohydrate (110) was treated with hypophosphorous acid and 
sodium nitrite in an aqueous solution. This initially converts the amine into a 
nitrosamine (111). The acid then converts the nitrosamine into a diazonium ion 
(112). Via a radical mechanism the hypophosphorous acid then  operates as a 
reducing agent to remove the diazonium ion and form 34 (Scheme 36).
164
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Scheme 36. Sandmeyer reaction for the preparation of 1-H-tetrazole from 5-aminotetrazole. 
 
1-H-Tetrazole (34) was initially separated from the crude reaction mixture by 
trituration in ethyl acetate. The crude heterocycle was then purified by sublimation, 
using a Kugelröhr heater and a drying piston. Due to the explosive nature of 34 
(decomposes rapidly and explosively if heated above its melting point of 155 -157 
ºC),
165
 careful control of pressure (~0.01 mmHg) and temperature (< 130 °C) was 
required to safely control the deposition of the purified 1-H-tetrazole. Additionally 
only small samples of the crude 1-H-tetrazole (< 2 g) were purified each time in a 
purpose-built high-pressure laboratory. 
Reaction of 2,6-O-dibenzyl-myo-inositol tetrol 99 with N,N-diisopropyldibenzyl 
phosphoramidite 17 activated by 1-H-tetrazole 34 in acetonitrile-dichloromethane 
created the intermediate tetrakis-phosphite 113. The N,N-diisopropyldibenzyl 
phosphoramidite was first dissolved in DCM and then added dropwise to the 
solution in order to avoid increased viscosity during activation of the 
phosphitylating reagent. It was then necessary to oxidise the P(III) centres up to 
phosphates. The choice of oxidising reagent was influenced by the functionality in 
the target molecule. For 114 either mCPBA
118
 or 
t
BuOOH
119
 can be used (Scheme 
37), with mCPBA being the better choice since it has been shown to give a cleaner 
reaction. However in the case of the 2-O-allyl derivative there is the potential for 
additional epoxidation of the double bond in the allyl group.  
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Scheme 37. Polyphosphitylation of 2,6-O-dibenzyl-myo-inositol. (i) 14 eq. 1-H-tetrazole,  
7 eq. 17, 5:2 MeCN-DCM; (ii) 14 eq. 
t
BuOOH; (iii) 14 eq. mCPBA. 
 
A 
 
B 
  
 
Figure 37. 
31
P-NMR spectra of the crude product mixture from the synthesis of 1,3,4,5-O-
tetrakis(dibenzylphosphoryl)-2,6-O-dibenzyl-myo-inositol (Scheme 37). A Oxidation with 
t
BuOOH. B Oxidation with mCPBA. 
 
The tetrakis-phosphitylated myo-inositol compound 113 was oxidised using both 
mCPBA and 
t
BuOOH. The crude reaction mixtures were then compared by proton 
decoupled 
31
P-NMR which showed the mCPBA oxidation (Figure 37B) to be 
significantly cleaner, with the four expected peaks from the product clearly visible 
(-0.05, -0.29, -0.47, -0.80 ppm), and the additional peaks derived from the excess 
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phosphitylating reagent. The reaction with 
t
BuOOH (Figure 37A) exhibited a 
considerable number of extra peaks, arising from side reactions. TLC also implied 
that, in the case of the 
t
BuOOH reaction, separation by flash chromatography would 
prove difficult. It was therefore decided to use mCPBA if possible for all the 
oxidation steps. Oxidation with mCPBA is assumed to occur through a concerted 
mechanism similar to the “butterfly mechanism” familiar from its reaction with 
olefins (Scheme 38). 
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Scheme 38. Mechanism for the oxidation of phosphite triesters with mCPBA. 
 
The final step in the synthesis of Ins(1,3,4,5)P4 was the global deprotection of the 
fully benzyl protected precursor 114 (Scheme 39). A wide range of procedures have 
been developed for the cleavage of benzyl ethers and phosphate esters. The most 
commonly employed in the synthesis of inositol poly-phosphates are 
hydrogenolysis conditions using a Pd based catalyst.
166-168
  Attempted deprotection 
using catalytic 10% Pd on carbon under a 60 psi  atmosphere of H2 only partially 
removed the benzyl groups, giving a mixture of products. Instead Pd-black (Pd 
nanoparticles) in tert-butanol-water under ambient pressure of hydrogen,
169
 plus 8 
equivalents of NaHCO3 was used to successfully unblock precursor 114. The 
hydrogen carbonate was added to the reaction in order to neutralise the free acids 
that are generated during the deprotection, preventing a decrease in pH that can lead 
to cyclisation and migration of the phosphates.
170
 
After filtration to remove solids, any chelated Pd
2+
 was removed by passing a 
concentrated aqueous solution of the Ins(1,3,4,5)P4 through a DOWEX 50WX8-200 
H
+
 column. Acidic fractions from the column were combined and then neutralised 
with aqueous ammonia before evaporating to dryness to give the Ins(1,3,4,5)P 4 
ammonium salt (115) in a quantitative yield.  
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Scheme 39. Global deprotection of 1,3,4,5-O-tetrakis(dibenzylphosphoryl)-2,6-O-dibenzyl-
myo-inositol. (i) 20 eq. Pd-black, 1 atm. H2, 8 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
Using the conditions established in the synthesis of Ins(1,3,4,5)P 4, Ins(1,4,5)P3 117 
was synthesised from the 2,3,6-O-tribenzyl-myo-inositol 105 (Scheme 40). 
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Scheme 40. Synthesis of Ins(1,4,5)P4 from 2,3,6-O-tribenzyl-myo-inositol. (i) 10 eq.  
1-H-tetrazole, 7 eq. 17, 5:2 MeCN-DCM; (ii) 6.5 eq. mCPBA; (iii) 15 eq. Pd-black, 1 atm. H2, 
6 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
Because of the potential for the allyl ether being epoxidised by mCPBA during the 
oxidation of the P(III) centres, oxidation with 
t
BuOOH was attempted first. The 
same problems were experienced using this reagent as for the Ins(1,3,4,5)P 4 
precursor; however a small sample of the desired product 118 was isolated. Using 
the established mCPBA conditions, phosphorylation of the 2-O-allyl-6-O-benzyl-
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myo-inositol was then attempted (Scheme 41). Since the 
1
H-NMR spectra of the 
product from this reaction are complex, it was not possible to be certain that this 
material was purely allyl tetraphosphate 118, and was not contaminated with 
epoxide 119. For this reason, the allyl ether was explicitly further oxidised with 
mCPBA to convert all the vinyl functionality to the diastereomeric epoxides. 
Notably, epoxide 119 was separable from the starting allyl ether by TLC, and it was 
found that this second oxidation took considerably longer than the phosphite 
oxidation reaction. Thus, using the epoxide, it was possible to carefu lly monitor the 
oxidation step by TLC. The reaction was quenched once full conversion from the 
tetrakis-phosphites to -phosphates was achieved, but before epoxide formation 
became detectable. Following the reaction in this manner meant that the desired 
1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-inositol 118 
was formed, with NMR confirming that there was no formation of the epoxidised 
side product 119. 
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Scheme 41. Phosphorylation of 2-O-allyl-6-O-benzyl-myo-inositol. (i) 14 eq. 1-H-tetrazole,  
7 eq. 17, 5:2 MeCN-DCM; (ii) 14 eq. mCPBA, 1 h; (iii) 14 eq. 
t
BuOOH; (iv) 3 eq. mCPBA, 
CHCl3, overnight. 
 
Hydrogenolysis of 118 using the previously established conditions (Scheme 42) 
removed the benzyl protecting groups as expected, and also reduced the allyl ether 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 91 - 
to a propyl moiety. This compound is useful for the receptor-ligand binding studies 
as the propyl group should enter the binding pocket in the same way as the acid. 
However, since it is not charged there can be no polar group exchange interaction. 
Hence, 120 acts as a control molecule to explore whether binding of 1 is due to 
polar interactions rather than steric complementation.  
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Scheme 42. Global deprotection and reduction of the allyl ether to form 2-O-propyl-
Ins(1,3,4,5)P4. (i) 20 eq. Pd-black, 1 atm. H2, 8 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
It was now possible to explore potential routes to the 2-O-acetic acid from the allyl 
ether 118. 
 
5.2.5 2-O-Acetic acid formation 
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Scheme 43. Oxidation of the allyl ether: (i) to the 2-O-acetic acid by ozonolysis with an 
oxidative work-up, and (ii) to the 2-O-acetaldehyde by ozonolysis with a reductive work -up. 
 
It was decided to initially revisit ozonolysis as a way of accessing the acetic acid 
moiety (Scheme 43). Using an oxidative work-up should provide a direct route to 
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the acid (121).
150
 Mass spectrometry of the crude product mixture from this reaction 
revealed the presence of the desired product. However 
31
P-NMR showed the 
presence of several additional phosphorylated species, and there was poor mass 
recovery, so a stepwise approach was attempted instead. Ozonolysis with a 
reductive work-up to form the aldehyde 122 appeared to proceed more cleanly, and 
provided a pure enough sample to explore its oxidation up to the acid. However, 
once more the mass recovery was poor. It was then noted that ozonolysis has been 
reported to remove benzyl ethers (Scheme 44).
171
 Although the conditions reported 
(0ºC) are far more forcing than those used here (-78ºC), the benzyl phosphate esters 
may be more reactive than benzyl ethers as the benzyl C-H is more polarised by the 
electron withdrawing phospho-triester. Partial deprotection of the phosphates would 
then explain the poor mass recovery, as any product could have been water -soluble, 
and would certainly have a low Rf. Therefore an alternative approach was needed.  
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Scheme 44. Mechanism for the cleavage of benzyl ethers with ozone.  
 
Based on the earlier attempts to oxidize allyl ethers during the MRes phase of this 
research, osmium tetraoxide was used to catalyse the cis-dihydroxylation of the 
allyl ether of tetraphosphate 118. Sodium periodate was then used to oxidatively 
cleave the glycer-1-yl diol, to create aldehyde 122 successfully and with good mass 
recovery (Scheme 45). These two reactions were telescoped in order to minimise 
compound lost during any intermediate work-up.  
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Scheme 45. Stepwise formation of the 2-O-acetaldehyde. (i) 3 eq. NMO, cat. OsO4,  
9:1 acetone-water; (ii) 3:1 dioxane-sat. aq. NaIO4. 
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A mild oxidising agent is required to convert the aldehyde into the acid without 
concomitant side reactions with the other functionalities around the inositol ring. 
Poly-phospho-triesters are particularly sensitive to nucleophiles, so care needs to be 
taken when choosing a suitable reagent. The Pinnick reaction is a very mild 
oxidation of aldehydes to carboxylic acids, which uses sodium chlorite in a sodium 
dihydrogen phosphate buffered solution in the presence of 2-methyl-2-butene.
172
 
The sodium chlorite acts as the oxidising agent, while the 2-methyl-2-butene acts as 
a chlorine scavenger. Treatment of aldehyde 122 with the Pinnick reagents readily 
converted it into the desired nona-benzyl protected 2-O-acetic acid Ins(1,3,4,5)P4 
derivative (121, Scheme 46). 
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Scheme 46. Synthesis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl) -2-O-acetic acid-6-O-
benzyl-myo-inositol.
173
 Pinnick conditions: NaClO2, aq. NaH2PO4, 2-methyl-2-butene, 
t
BuOH. 
 
The final step was the global deprotection to remove the benzyl groups. This was 
carried out under the same conditions as for Ins(1,3,4,5)P4, and gave 2-O-acetic 
acid-myo-inositol-1,3,4,5-O-tetraphosphate 1 in quantitative yield (Scheme 47). 
31
P-
NMR originally exhibited 8 peaks, suggesting two species. This was attributed to the 
protonated and deprotonated forms of the acid. Addition of deuterated acetic acid to the 
deuterium oxide NMR solvent caused the secondary peaks to disappear as the 2-O-acetic 
acid was converted into only its protonated form. 
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Scheme 47. Global deprotection to form 2-O-acetic acid-Ins(1,3,4,5)P4. (i) 20 eq. Pd-black, 
1 atm. H2, 8 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
5.2.6 Synthesis 2-O-(2-hydroxyethyl) derived ligands 
 
Using acetaldehyde tetraphosphate 122, the synthesis of alternative Ins(1,3,4,5)P4 
analogues was explored. It was hoped that the aldehyde 122 could be reduced to the 
corresponding alcohol 128 (Scheme 48) which could then be activated under 
Mitsunobu conditions to be displaced by a range of nucleophiles. The choice of 
reducing agent was important so that the phosphates were not reduced. Sodium 
borohydride (NaBH4) was considered too nucleophilic a reducing agent, so milder 
reagents were studied. Sodium cyanoborohydride is familiar for converting imines 
to amines under mildly acidic conditions.
174
 However it can also be used to reduce 
aldehydes and ketones.
174
 The reaction required careful monitoring because leaving 
the reaction too long led to overreaction, with trace levels H-phosphonates 
observable in the 
31
P-NMR spectrum of the crude product. However, too short a 
time and the reaction does not go too completion, but reaction progress is d ifficult 
to monitor by TLC. Although a range of solvent systems were investigated, 
obtaining a good separation of the spots corresponding to starting aldehyde 122 and 
alcohol 128 was not achieved. Thus a chemoselective stain was used to estimate the 
extent of reaction. 2,4-Dinitrophenylhydrazine (2,4-DNP) selectively stains 
compounds containing aldehyde or ketone moieties, to give an orange spot. 
Following the decrease in intensity, and eventual disappearance, of this spot 
allowed the reaction to be quenched when all of the starting aldehyde had been 
consumed. 
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Scheme 48. Reduction of the 2-O-acetaldehyde to a 2-O-(2-hydroxyethyl) ether.  
(i) 1 eq. NaBH3CN, acetic acid, MeOH. 
 
Hydroxyethyl tetraphosphate 128 was then globally deprotected to give the 2-O-(2-
hydroxyethyl)-myo-inositol-1,3,4,5-O-tetraphosphate 129 (Scheme 49). Similar to the propyl 
analogue (120), this compound was also designed to act as a control molecule to establish if 
any observed interaction between 1 and the E17A mutant of the PH domain of PKB could be 
due to polar interactions rather than steric complementation. 
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Scheme 49. Global deprotection to form 2-O-(2-hydroxyethyl)-Ins(1,3,4,5)P4.  
(i) 20 eq. Pd-black, 1 atm. H2, 8 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
Conversion of the hydroxyl of the nona-benzyl derivative 128 to nitrogen based 
functionalities was now addressed. The first target considered was 2-O-(2-aminoethyl)-myo-
inositol-1,3,4,5-O-tetraphosphate 139. The E17K mutant of PKB ‟s PH domain41 suggests 
that the presence of a positively charged functionality on the ligand could elicit an 
interaction with the E17A mutant. Additionally, although the R86A mutant was discounted 
as being the less favourable of the two possible polar group exchange mutations (see section 
2), the 2-aminoethyl derivative is also a potential ligand if the initially preferred E17A 
interaction is unsuccessful. 
Amines can be synthesised by hydrogenolysis of an azide precursor. The most common 
approach for the conversion of hydroxyls into azides involves a two step protocol: (i) 
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Transforming the alcohol into a suitable leaving group, such as a sulfonate or halide; then 
(ii) displacement of the leaving group by nucleophilic substitution with the azide anion.
175
 
When this was attempted with the 2-hydroxyethyl tetrakisphosphate 128, the mesylate (130) 
was successfully formed, although in low yield (31%). Subsequent displacement of the 
mesylate by sodium azide was not observed (Scheme 50). Forcing conditions significantly 
above room temperature were not employed to drive the azidation due to concerns over the 
stability of the protected phosphates.  
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Scheme 50. Attempted routes for azidation of the 2-O-(2-hydroxyethyl) ether. (i) 1.5 eq. MsCl, pyridine; 
(ii) 3.3 eq. NaN3, 2 eq. NaHCO3, 1:2 DMF-water; (iii) 1.3 eq. DIAD, 1.2 eq. Ph3P, 1.2 eq. DPPA (132), 
THF. 
 
Alternative routes to the azide were explored in parallel to the mesylation experiments. 
Alkyl azides can be formed in a single reaction using a modification of the Mitsunobu 
reaction. The Mitsunobu reaction is commonly used to convert primary and secondary 
alcohols into a wide variety of other functionalities.
176
 The alcohol is first activated in situ as 
a leaving group by reacting it with a phosphonium intermediate generated from 
triphenylphosphine (PPh3) and diethyl azodicarboxylate (DEAD) or the less toxic 
diisopropyl azodicarboxylate (DIAD, 133), and is then displaced by a nucleophile with a 
pKa of 10 or less (Scheme 51). This approach has been employed to produce azides using 
hydrazoic acid (HN3) as the acidic nucleophile, but HN3 is a volatile and extremely 
explosive liquid at room temperature and pressure, as well as being highly toxic. Therefore a 
related route was required that did not use HN3.  
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Diphenylphosphoryl azide (DPPA, 132) has been used in Mitsunobu azidations as an 
alternative source for the azide ion.
177, 178
 The success of Mitsunobu reactions has been 
shown to be highly dependent upon the order of addition. First the DIAD was added to a 
solution of PPh3 in tetrahydrofuran (THF) to form the betaine intermediate 134. Then the 
hydroxyethyl compound (128) was added to the solution, converting the alcohol into a 
leaving group. Finally the DPPA was added to the solution, where the azide ion displaced 
the leaving group and formed the 2-O-(2-azidoethyl) compound (131, 48%).  
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Scheme 51. Reaction mechanism for the modified Mitsunobu azidation reaction.R is the 
nona-benzyl functionalised inositol ring.  
 
Hydrogenolysis of fully protected 2-azidoethyl tetrakisphosphate 131 served two roles: As 
with the other ligands it globally deprotected the benzyl ethers, but in addition to this it also 
reduced the azide to an amine. Mass spectrometry of the isolated product showed the 
major peak to be the desired molecular ion. 
31
P-NMR of the sodium chelated 
compound showed four peaks, but the Ins-H signals all occur in the region 3.5-4.5 
ppm, and the overlap made designation of individual resonances difficult. 
Previously, conversion of the sodium salt to an ammonium salt overcame this 
problem. However in this case the 
1
H-NMR was broad and the 
31
P-NMR suggested 
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the presence of multiple phosphorylated species. These were attributed to the 
compound being in several different protonation and metal chelation states.  
O
OO
O
OHO
138
P
O
-
O
P
O
O
-
P
O
O
-
P
O
-
O
(i) O
-
O
-
-
O
O
-
O
OO
O
OBnO
131
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn
8Na
+
N3 NH2
 
Scheme 52. Global deprotection to form 2-O-(2-aminoethyl)-Ins(1,3,4,5)P4.  
(i) 20 eq. Pd-black, 1 atm. H2, 8 eq. NaHCO3, 6:1 
t
BuOH-water. 
 
Based on the success of the Mitsunobu reaction it was decided to also synthesise the 
guanidinium based analogue. To insert the guanidinium functionality into the compound, a 
suitably protected form of this group must first be synthesised so that only one of the 
nitrogen centres undergoes reaction, and the product is easily handleable. Dodd and 
Kozikowski reported the synthesis of a range of protected guanidines from the 
corresponding protected S-methylisothiourea for use in Mitsunobu reactions.
179
 
Consideration of the available starting materials, and the conditions used in the final 
deprotection, suggested the carboxybenzyl (Cbz) protected form (140) as being the most 
suitable, as the hydrogenolysis step would also be expected to deprotect it.  
SMeCbzN
NCbz
(i)
NH2CbzN
NCbz
O
O
H H
Cbz =
139 140
[80%]  
Scheme 53. Synthesis of N,N’-bis(benzyloxycarbonyl)guanidine. (i) NH3, MeOH. 
 
Reacting isothiourea 139 with ammonia in methanol rapidly formed the desired bis-Cbz 
guanidine 140 (Scheme 53). In an improvement on the published procedure, this was easily 
isolated by recrystalisation of the crude product in dichloromethane-methanol. Using the 
conditions already established for the Mitsunobu azidation, the protected guanidinium (140) 
was reacted with hydroxyethyl ether 128 (Scheme 54). 
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O
O
OBn
128
P
O
OBn
OBn
OH
O
O
OBn
141
[40%]
P
O
OBn
OBn
N
(i)
NCbzCbzN
H
H
 
Scheme 54. (i) 1.3 eq. DIAD, 1.2 eq. Ph3P, 1.2 eq. N,N’-bis(benzyloxycarbonyl)guanidine, THF. 
 
While the 
1
H and 
31
P-NMR of the crude reaction mixture showed full conversion of the 
hydroxyethyl ether (128) to the protected guanidine (141), all attempts at purifying the 
product were unsuccessful. TLC showed only one spot after flash chromatography, but 
31
P-
NMR showed trace amounts of other phosphorus species attributable to side reactions. 
Additional purification using high performance liquid chromatography (HPLC) failed to 
fully remove these impurities. Because of this the final global deprotection (Scheme 55) 
was not attempted. 
O
OO
O
OHO
142
P
O
-
O
P
O
O
-
P
O
O
-
P
O
-
O
(i) O
-
O
-
-
O
O
-
O
OO
O
OBnO
141
P
O
BnO
P
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P
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N N
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H
H
NHH2N
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Scheme 55. Proposed global deprotection. (i)  20 eq. Pd-black, 1 atm. H2, 10 eq. NaHCO3, 
6:1 
t
BuOH-water. 
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5.3 CHARACTERISATION OF THE SYNTHETIC LIGANDS 
 
5.3.1 myo-Inositol orthobenzoates 
 
1
2
3
4
5
6
O
O
O
OH
HO
BnO
Ph
HH
76  
Figure 37. Structure of 76 with the “w” 
4
J1,5  coupling highlighted in red. There are three 
other “w” couplings between the five equatorial protons - 
4
J1,3,  
4
J3,5 and  
4
J4,6. 
 
Inositol 
proton 
3
J 
coupling 
Number of additional  
4
J “w” couplings 
Observed 
Splitting 
Pattern 
 
1 dd 2 (
4
J1,3, 
4
J1,5) 
dq 
(3, 1.5 Hz) 
pt (t1)
21400 21450 21500
0
5000000
10000000
 
2 t 0 
t 
(1.5 Hz) 
pt (t1)
9850 9900
0
50000000
100000000
150000000
 
3 dd 2 (
4
J1,3, 
4
J3,5) 
dq 
(3, 1.5 Hz) 
pt (t1)
21400 21450 21500
0
5000000
10000000
 
4 t 1 (
4
J4,6) 
td 
(3, 1.5 Hz) 
pt (t1)
21000 21050 21100 21150 21200
-5000000
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
 
5 t 2(
4
J1,5, 
4
J3,5) 
tt 
(3, 1.5 Hz) 
pt (t1)
9460 9470 9480 9490 9500 9510 9520 9530
-10000000
0
10000000
20000000
30000000
40000000
50000000
60000000
70000000
80000000
 
6 t 1 (
4
J4,6) 
td 
(3, 1.5 Hz) 
pt (t1)
21000 21050 21100 21150 21200
-5000000
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
 
Table 2. Expected splitting patterns for each Ins-H based on 
3
J coupling, and observed 
splitting pattern because of long range “w” couplings.  
 
Orthoesters fix the inositol ring into a rigid conformation. Like myo-inositol itself, 
the inositol orthobenzoate (43c) possesses h symmetry. Alkylation of the 4-O 
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breaks this symmetry. The combination of a fixed conformation and the lack of 
symmetry often allow the substitution patterns around the inositol ring of 
orthoesters to be unambiguously defined by nuclear magnetic resonance (NMR). 
Not only does NMR strongly reflect the altered stereochemistry of 76 compared to 
inositol orthobenzoate 43c, the asymmetry places all six hydroxyls in different 
chemical environments. The restricted conformation means that up to four long 
range 4-bond “w” couplings can be observed (Figure 37). The actual and observed 
couplings are dependent upon similarities in chemical environments, and the 
resolution of the NMR machine used.  
This is demonstrated by considering each inositol proton in turn (Table 2). Ins 1-H 
is split by the equatorial Ins 6-H (~3 Hz) and the axial Ins 2-H (~1.5 Hz). This 
would be expected to give a double doublet (dd). However, the additional long 
range 
4
J1,3 and 
4
J1,5 “w” coupling further split the signal for Ins 1-H (~1.5 Hz). This 
would be expected to give a double double double doublet (dddd), but because 
4
J1,3≈
4
J1,5≈
3
J1,2, and the NMR machine cannot resolve the slight differences that 
exist, so a double quartet (dq) is usually observed. The same argument can be 
applied to Ins 3-H. Ins 2-H is the only inositol proton in an axial position, so there 
is no potential for “w” coupling. This means it only experiences coupling (~1.5 Hz) 
to Ins 1-H and Ins 3-H, and since 
3
J1,2≈
3
J2,3 an apparent triplet (t) is observed.  
In the case of Ins 4-H, it is split by the equatorial Ins 3-H and Ins 5-H. Since its 
geometrical relationships to both these protons are very similar 
3
J3,4≈
3
J4,5 and this 
gives an apparent t (~3 Hz). The additional 
4
J4,6 “w” coupling (~1.5 Hz) in 
asymmetrical orthoesters then splits this into a triple doublet ( td). Very similar 
geometry also explains the observed splitting pattern for Ins 6-H. The Ins 5-H is 
observed as a triple triplet (tt). This arises from 
3
J4,5≈
3
J5,6 (~3 Hz) creating a large 
initial t, and then 
4
J1,5≈
4
J3,5 (~1.5 Hz) which splits each peak further leading to the 
formation of an observed tt. 
If the NMR is carried out in DMSO, it is possible to also observe any free hydroxyl as a d 
around 5 ppm. The d arises from coupling (~6 Hz) between the proton of the alcohol and 
the adjacent proton on the inositol ring. In the case of 76 this means Ins 2-H is further split 
into a double triplet (dt) and the Ins 4-H becomes a double triple doublet (dtd), enabling 
differentiation between the Ins 4- and 6-H. 
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5.3.2 Allyl ethers 
 
The 
1
H-NMR spectra of allyl compounds (Figure 38) exhibit a characteristic ABMXY 
splitting pattern (Table 3). HA and HB give a complex signal. Each proton is split into a d by 
geminal coupling to the other (~13 Hz). This d is then split again by HM (~5 Hz) to create a 
dd. Finally there is long range couplings to HX and HY (~1.5 Hz), creating two sets of double 
double triplets (ddt). Because HA and HB are in similar chemical environments their signals 
occur at a similar chemical shift, with the roofing effect further complicating the pattern of 
observed peaks. HM is split into a d from trans coupling to HX (~17 Hz), into a d from cis 
coupling to HY (~10 Hz), and into a further t by coupling to HA and HB (~5 Hz), creating an 
observable ddt. Similarly HX and HY both produce ddt or a dq from 
3
J coupling to HM, vinylic 
geminal coupling to each other (~1.5 Hz) and then long range coupling to HA an HB (~1.5 
Hz). 
O
Hx
HY
HM
HA HB
 
Figure 38. Structure of an allyl ether with each proton designated in the ABMXY 
nomenclature. 
 
Proton Coupling 
Observed 
Splitting Pattern 
 
A 
2
JA,B, 
3
JA,M, 
4
JA,X ≈ 
4
JA,Y 
ddt  
(13, 5, 1.5 Hz) 
 B 
2
JA,B, 
3
JB,M, 
4
JB,X ≈ 
4
JB,Y 
ddt  
(13, 5, 1.5 Hz) 
M 
3
JA,M ≈ 
3
JB,M, 
3
JM,X, 
3
JM,Y 
ddt 
(17, 10, 5 Hz) 
 
X 
2
JX,Y, 
3
JM,X, 
4
JA,X ≈ 
4
JB,X 
ddt/dq 
(17, 1.5, 1.5 Hz) 
 
Y 
2
JX,Y, 
3
JM,Y, 
4
JA,Y ≈ 
4
JB,Y
 
ddt/dq 
(10, 1.5, 1.5 Hz) 
 
Table 3. Observed splitting pattern arising from allyl ether ABMXY splitting pattern, with real 
1
H-NMR examples. 
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5.3.3 Inositol tetrols 
 
Removal of the orthobenzoate protecting group creates an inositol tetrol (Figure 39). Since 
the conformation is no longer fixed by the protecting group, the compound adopts the lowest 
energy conformation – a chair conformation with the 1-, 3-, 4- and 5-hydroxyls and 6-O 
substituent positioned equatorially, and the 2-O substituent in an axial position. Compared to 
the inositol orthoester conformation, the inositol protons are now in different environments.  
99 R=Bn
109 R=allyl
3
4
5
6
1
2
OR
OHHO
OH
OBnHO
 
Figure 39. Structure of myo-inositol tetrol. 
 
Inositol 
proton 
3
J coupling Observed Splitting Pattern  
1 
3
J1,2, 
3
J1,6 
dd 
(10, 2.5 Hz) 
 
2 
3
J1,2 ≈ 
3
J2,3 
t 
(2.5 Hz) 
 
3 
3
J2,3, 
3
J3,4 
dd 
(10, 2.5 Hz) 
 
4 
3
J3,4 ≈ 
3
J4,5 
t 
(10 Hz) 
 5 
3
J4,5 ≈ 
3
J5,6 
t 
(10 Hz) 
6 
3
J1,6 ≈ 
3
J5,6 
t 
(10 Hz) 
 
Table 4. Observed proton splitting patterns for inositol tetrols due to  
3
J couplings. The 
representative peaks are taken from real spectra, because of this in some cases peaks 
overlap. To assist visualising the splitting patterns the red lines illustrate where an obscured 
peak would be expected to occur.  
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The Ins 1-H is initially split into a d by the anti-periplanar 
3
J1,6 coupling (~10 Hz). 
This d is then split by the smaller gauche 
3
J1,2 coupling (~2.5 Hz) to form a dd. The 
Ins 2-H is split onto an observed t due to two approximately equal gauche 
3
J 
couplings. The Ins 3-H forms a dd for the same geometric reasons as the Ins 1-H. 
The Ins 4-H, Ins 5-H and Ins 6-H inositol protons all give an observed t. The 
protons are split by two approximately equal anti-periplanar 
3
J couplings (~10 Hz). 
 
5.3.4 Inositol poly-phosphates 
 
The introduction of the P atoms into the myo-inositol compounds provides a useful 
analytical tool for confirming the substitution pattern around the myo-inositol ring. 
31
P has a spin ½ nucleus and is the only stable phosphorus isotope, so is 100% 
abundant. 
31
P-NMR confirms the number of phosphates on the ring. Additionally, 3-
bond 
1
H-
31
P coupling is observed in the 
1
H-NMR spectra, and 
13
C-
31
P coupling is 
observed in the 
13
C-NMR spectra. This additional coupling assists in confirming the 
regiochemistry of phosphorylation in the final compounds (Table 5). The 
1
H-
31
P 
coupling is similar enough in magnitude to the myo-inositol anti-periplanar 
3
JHH 
constant that the observed splitting pattern is increased by an order of one. Thus, 
observed in the range of Ins(1,3,4,5)P4 derivatives prepared above, the Ins 1-H is 
initially split into a d by the anti-periplanar 
3
J1,6 coupling (~10 Hz), now forms a t 
due to the additional 
3
JPH coupling. This t is then split by the smaller gauche 
3
J1,2 
coupling (~2.5 Hz) to form a td. Since the 2-O is not phosphorylated, the Ins 2-H 
experiences no 
3
JPH coupling, resulting in only a t (~2.5 Hz) as observed for the 
tetrols, from the two approximately equal gauche 
3
JHH couplings. The Ins 3-H forms 
a td for the same reasons as the Ins 1-H. Both the Ins 4-H and Ins 5-H inositol 
protons give quartets (q); in each case the proton is split into a t by two 
approximately equal anti-periplanar 
3
JHH couplings (~10 Hz), and then into the q by 
the 
3
JPH coupling. Like the Ins 2-H, the Ins 6-H does not experience 
3
JPH coupling, 
so only a t from the two anti-periplanar 
3
JHH couplings (~10 Hz) is seen.  
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Inositol 
proton 
JHH 
coupling 
3
JPH couplings 
Observed Splitting 
Pattern 
 
1 
3
J1,2, 
3
J1,6 
3
JPH ≈ 
3
J1,6 
td 
(10, 2.5 Hz) 
 
2 
3
J1,2 ≈ 
3
J2,3 - 
t 
(2.5 Hz) 
 
3 
3
J2,3, 
3
J3,4 
3
JPH ≈ 
3
J3,4 
td 
(10, 2.5 Hz) 
 
4 
3
J3,4 ≈ 
3
J4,5 
3
JPH ≈ 
3
J3,4 ≈ 
3
J4,5 
q 
(10 Hz) 
 
5 
3
J4,5 ≈ 
3
J5,6 
3
JPH ≈ 
3
J4,5 ≈ 
3
J5,6 
q 
(10 Hz) 
 
6 
3
J1,6 ≈ 
3
J5,6 
- 
t 
(10 Hz) 
 
Table 5. Observed proton splitting patterns in Ins(1,3,4,5)P 4, its 2-O functionalised 
analogues and their fully protected precursors, due to  JHH and 
3
JPH couplings. The 
representative peaks are taken from real spectra, because of this in some cases peaks 
overlap. To assist visualising the splitting patterns the red lines illustrate where an obscured 
peak would be expected to occur.  
 
When combined with 2-D correlation spectroscopy (COSY) 
1
H-NMR, the splitting 
patterns arising from the presence of 
31
P allows unambiguous designation of each 
peak. While the 
3
JPH coupling is useful in the final compounds, it is rather less so 
for the benzyl protected forms where the CH2s of eight of the benzyl ethers also 
experience this coupling. Since these protons resonate in a similar range to the 
inositol protons (3.5-4.5 ppm) the additional coupling acts to further complicate 
already complex spectra.  
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Inositol 
carbon 
2
JPC coupling 
3
JPC coupling 
Observed 
Splitting Pattern 
1 
2
J1-P,1-C - d  
2 - -  s 
3 
2
J3-P,3-C 
3
J4-P,3-C dd 
4 
2
J4-P,4-C 
3
J3-P,4-C, 
3
J5-P,4-C dt or ddd 
5 
2
J5-P,5-C 
3
J4-P,5-C dd 
6 - 
3
J1-P,6-C, 
3
J5-P,6-C dd 
Table 6. Observed 
13
C splitting patterns in Ins(1,3,4,5)P 4, and its 2-O functionalised 
analogues due to 
2
JPC and 
3
JPC couplings. 
 
In addition to the 
1
H-
31
P couplings in 
1
H-NMR, 
13
C-NMR exhibits 
13
C-
31
P coupling 
for both the protected and deprotected families of phosphorylated compounds. Both 
2
JPC and 
3
JPC couplings can be observed in these spectra. Similar to the 
1
H-
31
P 
couplings, when the complications arising from the presence of the benzyl 
protecting groups are removed, these couplings can also provide a convenient 
analytical technique for assigning each of the inositol carbons (Table 6). Ins 1-C is 
split by short range 
2
JPC coupling (~5.5 Hz) to the phosphorus attached to the 1-O, 
giving rises to a d. In the case of the Ins 2-C a t or dd would be expected from the 
two longer range 
3
J1-P,2-C and 
3
J3-P,2-C couplings. However, only a singlet (s) peak is 
observed, a fact that is not easily explained by a  Karplus relationship, which for JPC 
coupling is not fully understood. A dd is observed for the Ins 3-C signal, first from 
splitting due to 
2
J3-P,3-C coupling (~6 Hz) then additional splitting arising from a 
smaller 
3
J4-P,3-C coupling (~2 Hz). Ins 4-C is observed as either a dt or a ddd, since 
it is split by the 
2
J4-P,4-C coupling (~6 Hz), and then by two 
3
JPC couplings (~3.5 
Hz). The Ins 5-C again exhibits a dd for the same reasons as the Ins 3-C. The Ins 6-C is 
split by two unequal 
3
JPC couplings (~6 Hz and ~2.5 Hz) so forms a dd. 
These general relationships were verified by 2-D NMR techniques such as 
heteronuclear single quantum correlation (HSQC) 
1
H-
13
C-NMR.  
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Inositol 
carbon 
115 
Ins(1,3,4,5)P4 
1 
2-O- 
acetic acid 
120 
2-O- 
propyl 
129 
2-O- 
(2-hydroxyethyl)  
1 5.5 Hz 5.3 Hz 5.4 Hz 5.4 Hz 
2 - - - - 
3 5.6, 2.1 Hz 5.8, 2.0 Hz 5.9, 2.1 Hz 6.0, 1.9 Hz 
4 6.7, 4.1, 2.5 Hz 5.9, 4.6 Hz 6.0, 3.3 Hz 5.8, 2.9 Hz 
5 6.0, 3.1 Hz 6.2, 3.1 Hz 6.8, 3.0 Hz 6.3, 2.8 Hz 
6 5.8, 2.8 Hz 5.2, 2.2 Hz 6.3, 2.8 Hz 6.0, 2.8 Hz 
Table 7. JPC coupling constants for Ins(1,3,4,5)P4 and its 2-O functionalised analogues. 
 
Having confirmed that the target compounds had been correctly synthesised, the 
final consideration was the effect of functionalizing the 2-O on the conformation of 
the inositol ring. Although there have not been any published studies that 
specifically identify the relationship between the magnitude of the 
2
JPC and
 3
JPC 
coupling constants and the conformation of the myo-inositol ring, a relationship 
between these two parameters has been established for studying the conformation of 
nucleic acids (NA).
180
 Assuming that a similar relationship does exist for the myo-
inositol compounds, it is reasonable to assume that compounds sharing similar 
2
JPC 
and
 3
JPC coupling constants also share a similar conformation, and this assumpti on 
is reinforced by the 
1
H-NMR. Comparing these values for the three synthetic 
ligands to those of Ins(1,3,4,5)P4 (Table 7) shows that all three compounds share 
similar values to the natural ligand, with only the 2-O-acetic acid exhibiting slight 
variances. Because of this, combined with the 
1
H-NMR data, it appears that 
substitution at the 2-O does not cause the myo-inositol ring to adopt a significantly 
different conformation to Ins(1,3,4,5)P4, which could reduce binding to the PH 
domain of PKB. 
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6. PROTEIN EXPRESSION AND BIO-PHYSICAL  
TESTING  
 
6.1 PROTEIN EXPRESSION 
 
Once the synthesis of the ligands had been achieved, samples of the wild -type and 
E17A mutant of the PH domain of PKB  were required for bio-physical testing to 
study any receptor-ligand interactions which maybe occurring.  
Bacterial plasmids naturally occur in Escherichia coli (E. coli). They are self-
replicating, circular, extrachromosonal DNA molecules that can confer  new 
characteristics to the bacteria, such as antibiotic resistance or production of 
restriction enzymes. Because of this, engineered plasmids are often used for the 
production of unnatural proteins.  
It is possible to express target proteins by introducing a plasmid containing the 
sequence for the desired protein  into E. coli. A versatile technique for the 
expression, purification and detection of fusion proteins is the glutathione -S-
transferase (GST) gene fusion system. By inserting a gene or gene fragment into the 
multiple cloning site (MCS) of a pGEX vector (Figure 40) it is possible to construct 
GST fusion proteins for synthesis in  E.coli. The vector can be split into five main 
regions:  
(i) The tac promoter (Ptac): This is a hybrid promoter, constructed from sequences 
of the trp and the lac UV5 promoters, to induce expression of the GST fusion 
protein. Ptac directs transcription approximately 11 times more efficiently than the 
de-repressed parental lac UV5 promoter and approximately 3 times more efficiently 
than the trp promoter in the absence of the trp repressor.  
(ii) The gene encoding for the GST tag: The tag is roughly 26 KDa in size, and 
allows separation and purification of GST fusion proteins by binding to agarose 
beads coated with glutathione (known as GST beads). 
(iii) The MCS: This is a sequence of DNA encoded with the recognition sequence 
for a site-specific cleavage (in the case of pGEX-4T-1 a thrombin cleavage site) 
followed by a short segment containing many restriction sites for the introdu ction 
of the sequence for the desired protein. 
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(iv) The gene for ampicillin resistance: Transformed bacteria, unlike their 
untransformed counterparts, continue to grow on a medium containing the antibiotic 
ampicillin, allowing isolation and growth of only cells that have successfully been 
transformed. 
(v) The lac I
q
 E.coli repressor gene: The lac I repressor protein binds to the lac UV5 
promoter region of Ptac, thus repressing its expression. Expression of Ptac is 
induced by the lactose analogue isopropyl -D thiogalactoside (IPTG). IPTG works 
by displacing the lac I repressor protein, allowing expression of Ptac and inducing 
the expression of the GST fusion protein.  
 
Figure 40. pGEX-4T-1 vector. Showing the regions for: (i)  the tac promoter; (ii) the GST tag; 
(iii) the MCS containing the thrombin cleave site, and highlighting the BamH1 and EcoR1 
restriction sites; (iv) the ampicillin resistance gene; and (v) the lac I
q
 E.coli repressor gene. 
 
The pGEX-4T-1 vector containing the cloned human PKB  PH domain (pGEX-
PKB -PH) was kindly donated by the Alessi group, and Dr. P. Free produced the 
mutant pGEX-PKB  PH domain containing plasmid (pGEX-E17A) by using a 
Quikchange II Site-Directed Mutagenesis Kit (Stratagene) to perform in vitro site-
specific mutations using the pGEX-PKB -PH vector as a template for the 
polymerase chain reaction (PCR). Confirmation of the accurate mutation and 
transformation was then obtained through high-resolution electrophoretic gel 
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dsDNA sequencing (carried out by Dr. P. Free, Figure 41). For pGEX-PKB -PH 
position 56 shows the appropriate adenosine (A) base, while position 55 of pGEX-
E17A shows the cytosine (C) mutant base. The shift from 56 to 55 does not show an 
alteration in the actual base positions but instead reflects the differences in 
numbering by the sequencing display program. 
 
A: pGEX-PKB -PH 
 
B: pGEX-E17A 
 
Figure 41. High-resolution electrophoretic gel dsDNA sequencing, provided by Dr. P Free. A 
pGEX-PKB -PH: position 56 shows the appropriate adenosine (A) base (circled in red). B 
pGEX-E17A: position 55 of shows the cytosine (C) mutant base (circled in red).  
 
Initially protein expression was attempted using the BL21 strain of E.coli. It is a 
protease-deficient E.coli host strain ideal for optimal expression of recombinant 
proteins. The BL21 E.coli were transformed with either the  pGEX-PKB -PH or 
pGEX-E17A plasmid by electroporation, and grown on ampicillin LB/Agar plates. 
The transformed cells were then transferred in to lysogeny broth (LB) media 
containing ampicillin. The transformed bacteria were able to grow due to the 
plasmid-conferred ampicillin resistance, while the non-transformed bacteria could 
not survive in those conditions. The potential for protein expression is at a 
maximum during the mid-log phase, and is before overcrowding and nutrient 
competition cause the bacteria to enter their stationary phase. Once the E.coli had 
grown to mid-log phase, treatment with IPTG induced expression of the GST fusion 
protein. After a suitable expression period, the fusion protein was then purified 
from bacterial lysates by immobilized glutathione affinity chromatography. This 
purification process preserves protein antigenicity and function.  
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Protein behavior during purification chromatography with a gel depends upon its 
size, charge and shape, as well as the pore size of the gel. It is possible t o simplify 
these parameters and allow separation of proteins based upon molecular size by 
denaturing the protein. This is achieved by using sodium dodecyl sulfate (SDS) in 
conjunction with disulfide bond reducing agents (such as 2 -ME or DTT) and 
heating. Using SDS – polyacrylamide gel electrophoresis (PAGE) with a Coomassie 
stain it was possible to confirm that a protein of the correct size was being isolated 
(Figure 42).  
 
Figure 42. 12% SDS-PAGE gel, run at 200 volts for 40 min, visualised by Coomassie Blue, 
showing the successful expression of the GST ‐PH fusion protein. Lane 1 – markers; Lane 2 
– wt PH domain on‐bead purification; Lane 3 – E17A PH domain on-bead purification. 
 
The information from the SDS-PAGE combined with the DNA sequencing of the 
pGEX-PKB -PH and pGEX-E17A plasmids, implies that there is successful 
expression of the two PKB  PH domains. To confirm this conclusion the protein 
was tested using a Western blot (also known as a protein immunoblot). The protein 
was isolated using SDS-PAGE, and then transferred on to a polyvinylidene 
difluoride (PVDF) membrane by electroblotting. The PVDF was then washed in a 
dilute solution of non-fat dry milk to block non-specific binding of the antibodies 
used for detection on to the PVDF. The membrane was then incubated with a 
suitable primary antibody, washed, and then incubated with a secondary antibody. 
A range of PKB  PH domain antibodies are commercially available. The choice of 
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antibody is dictated by the E17A mutation, as mutant protein must also be 
detectable by the antibody. Because of this the rabbit anti -Akt proto-oncogene 
product (PKB) polyclonal antibody (Millipore) was employed as the primary 
antibody. This was raised against  a 13 residue synthetic peptide [sequence: 
FHVETPEEREEWT(C)] based on residues 88-100 of the human PKB  isoform, 
with the cysteine (C) residue added to couple the peptide to keyhole limpe t 
hemocyanin (KLH). Because the peptide is designed to interact with only a short 
stretch of the PH domain located at the opposite end of the domain to the E17A 
mutation, both the mutant and wild-type forms of the PH domain could be studied 
using the same antibody. A rabbit anti-KLH antibody conjugated to horseradish 
peroxidase (HRP) was then used as the secondary antibody. The HRP allowed the 
enhanced chemiluminescence (ECL)-based immunodetection technique to be used 
to show that both the wild-type and E17A forms of the PH domain of PKB  were 
successfully expressed (Figure 43). 
 
 wt PKB  PH domain  E17A PH domain 
 
Figure 43. Western blot of wild-type PKB  PH domain and E17A mutant PH domain, using a 
rabbit anti-Akt proto-oncogene product (PKB) polyclonal antibody as a primary antibody.  
 
The next step was to quantify the level of expression. This was done using the 
colorimetric Bradford protein assay. This uses the Coomassie reagent which is 
converted from its red form into its blue form as it complexes with proteins. The 
amount of blue dye present in the solution is a measure of the protein concentration. 
The bound form of the dye has an absorption spectrum maximum at 595 nm. Hence, 
by measuring the increase of absorbance at this wavelength, the amount of bound 
dye and therefore protein concentration of the sample can be calculated.  
Multiple dilutions of the protein solution are often required for two reasons: (i) 
taking readings at various concentrations allows the concentration of the parent 
solution to be confirmed by multiple measurements; and (ii) the assay is only linear 
over a short range (2-120 µg/ml). 
Using the Bradford assay to measure the protein concentrations of the wild -type and 
E17A PH domains of PKB showed the concentration to be below the minimum level 
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accessible by the assay (< 2 µg/ml). It was therefore necessary to consider how the 
level of expression could be increased.  
The first consideration was the strain of E.coli used. Stratagene supply three 
different strains of BL21 competent cells that provide different levels of 
expression: (i) BL21(DE3) competent cells allow high-level protein expression with 
induction, but can suffer from uninduced expression of proteins; (ii) The 
BL21(DE3)pLysS cells provide tighter control of protein expression, but exhibit 
slight inhibition of expression with comparison to the BL21(DE3) cells; and (iii) 
BL21 cells provide the tightest control of protein expression, but the induction 
process is more cumbersome and less efficient than for the DE3 derivatives. 
Since the proteins being expressed are not toxic, the control of expression that the 
BL21 cells afford is not required. It was therefore decided that BL21(DE3) cells 
should be adopted to increase the level of expression.  
The second consideration was the choice of growth media. Expression in LB media 
requires induction by IPTG. The point of induction is determined by monitoring the 
medium until the E.coli reach mid-log phase. The requirement for monitoring can 
be removed by using auto-induction (AI) medium. AI medium has been designed to 
induce expression when the cells reach their optimum stage for expression; it also 
negates the use of ITPG.
181
 AI media works by using glucose lactose and glycerol 
as food sources for the cells. The cells initially consume the glucose; the glucose 
acts to support cell growth and inhibit the entry of the lactose into the cells. Once 
the glucose has been fully consumed the bacteria utilise the glycerol alternative 
food source; this allows the lactose to enter the cells. The presence of lactose 
displaces the lac I repressor protein within the plasmid and causes expression of 
Ptac, thus inducing the expression of the GST fusion protein at optimal cell d ensity. 
These two considerations were combined with using the Ultra Yield™ flask, which 
was kindly donated by Karin Ellis of Thomson Instrument Company. The flask has a 
baffled base and its walls are more vertical than with traditional shake flask designs 
(Figure 44). These flasks have been shown to generate an equivalent amount of 
protein per unit cell culture density as the traditional flasks, but at a substantially 
greater amount per unit volume.
182
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 114 - 
 
Figure 44. The Ultra Yield™ flask, supplied by Thomson Instrument Company . It has a 
baffled base and novel wall construction to increase protein yield.   
 
BL21(DE3) competent cells were transformed using the heat shock protocol to 
insert the pGEX-PKB -PH or pGEX-E17A plasmids. Using the Ultra Yield™ 
flasks, the transformed cells were grown in AI media containing ampicillin. The 
resulting expressed protein was isolated using the same techniques as before, to 
give considerably higher yields of both the wild-type and E17A GST fusion 
proteins bound to GST beads. 
 
6.2 THROMBIN DIGEST 
 
The next stage was to remove the wild-type and E17A mutant PH domains of PKB 
from the GST beads. There are two routes through which this can be achieved: (i) 
thrombin digest, and (ii) glutathione elution. A thrombin digest only gives the 
desired protein, while glutathione elution releases the entire fusion protein from the 
GST beads (Figure 45). The choice of technique is dependent upon how the protein 
is going to be employed. In this case the presence of multiple W residues in the 
GST tag make the fusion protein unsuitable for use in the intrinsic tryptophan 
fluorescence experiments as the additional residues would greatly reduce the 
observed change in emission on binding, hence decreasing the accuracy of any data 
obtained. 
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Figure 45. Cleavage of expressed protein from GST beads. Thrombin digest makes use of 
the thrombin cleavage site within the GST fusion protein to give the isolated protein of 
interest. Glutathione elution disassociates the whole fusion protein from the GST bead.  
 
Because of this thrombin cleavage was employed. The thrombin cleavage site is a 
sequence of six amino acids (LVPRGS) that is used to link the purification tag to 
the protein of interest. It is recognised by the serine protease thrombin, which 
selectively cleaves between the R and G residues in the cleavage site, allowing the 
protein to enter the supernatant, while the GST tag remains bound to the GST 
beads. 
SDS-PAGE showed that cleavage of the two PH domains appeared to proceed with 
good conversion of the fusion proteins to the corresponding bound GST tag and 
cleaved PH domain (Figure 46). However Bradford protein assay of the supernatant 
once more showed only trace levels of the protein. A combination of the Bradford 
assay and SDS-PAGE revealed that the majority of the PH domain was still located 
on the GST beads. Repeated washing of the beads failed to elute any additional 
protein. Since the protein of interest no longer contains a GST tag this was 
attributed to non-specific binding of the protein to the beads. An internet search of 
biochemistry forums for this problem suggested either using a phosphate buffer (pH 
8) or carbonate buffer (pH 11) as a way of breaking the protein bead inte raction. 
Both have their positive and negative aspects. The high pH of the carbonate buffer 
risks denaturing the proteins. There is less risk of this occurring with the lower pH 
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of the phosphate buffer, but the PH domain is an inositol phosphate binding protein, 
so the potential exists for the buffer blocking the binding site for the ligand. It was 
therefore decided to use the carbonate buffer and then use a concentrator to transfer 
the protein into a more suitable buffer.  
 
Figure 46. 12% SDS-PAGE gel, run at 200 volts for 40 mins, visualised by Coomassie Blue, 
showing thrombin cleavage of GST-PH domain fusion proteins. Lane 1 – markers; Lane 2 – 
wt PH domain on‐beads; Lane 3 – wt PH domain beads after thrombin cleavage; Lane 4 – 
supernatant from thrombin cleavage of wt PH domain beads; Lane 5 – E17A PH domain 
on‐beads; Lane 6 – E17A PH domain beads after thrombin cleavage; Lane 7 – supernatant 
from thrombin cleavage of E17A PH domain beads. 
 
6.3 INTRINSIC TRYPTOPHAN FLUORESCENCE 
SPECTROSCOPY 
 
As already discussed Fench et al. have used intrinsic tryptophan fluorescence 
spectroscopy to study the wild-type PH domain of PKB  binding various inositol 
phosphates and phosphoinositides, including Ins(1,3,4,5)P4.
82
 Reproducing these 
results using the synthetic Ins(1,3,4,5)P4 and the expressed wild-type PH domain 
allows direct verification of the use of carbonate buffer for disrupting the non -
specific binding between the PH domain and the GST beads. It also establishes a 
protocol for the subsequent study of the interactions of E17A mutants.  
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 117 - 
Therefore after the wild-type PH domain was removed from the GST beads a 5000 
MW spin concentrator was used to transfer the protein from the carbonate buffer 
into 20 mM HEPES/NaOH, pH 7.0, 10 mM MgCl2. This process led to the 
formation of a protein precipitate, lowering the yield of the PH domain. However 
enough protein remained dissolved in the buffer solution to allow testing to 
proceed. The wild-type PH domain was diluted to a concentration 2.5 g/ml and 
placed in a sample cell in the spectrometer. The fluorescence spectrum of the PH domain 
was obtained at 25 °C by exciting the sample at 290 nm and recording its emission 
spectrum. Comparison of the spectrum to that published (Figure 47) showed the emission 
maximum at a lower wavelength than expected, suggesting that the tryptophans of the 
expressed PH domain are not in the same environment as in Fench‟s research, and that 
the protein has been denatured by the carbonate buffer.  
 
Figure 47. Comparison of literature emission spectrum of PKB  PH domain (black)
92
 with 
the experimentally obtained emission spectrum of the wt PH domain (blue).  
 
To confirm this, binding of the PH domain to Ins(1,3,4,5)P 4 was attempted. If 
binding occurred, a decrease in emission should have been observed. However, no 
decrease was seen and an additional peak with a maximum at 340 nm appeared 
(Figure 48). Addition of Ins(1,3,4,5)P4 to the buffer, in the absence of protein, 
showed this peak to be due to the ligand. There could be two potential reasons for 
this peak: Either trace impurities introduced in the buffer; or it is due to the 
ammonium salt. Re-purification should remove any contaminants, if this does not 
correct the problem, conversion back to the sodium salt should. However, it was 
decided that an alternative approach was needed to isolate the protein so that it is 
not denatured in the process. 
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Figure 48. A Emission spectrum of wt PKB  PH domain with addition of Ins(1,3,4,5)P 4.  
B Emission spectra of isolated of wt PKB  PH domain (blue) and isolated Ins(1,3,4,5)P 4 
(green) super-imposed to show individual components of A. 
 
6.4 GLUTATHIONE ELUTION 
 
As previously discussed, there are two ways to remove the protein from the GST 
beads (Figure 45). Since thrombin cleavage was unsuccessful, glutathione elution 
was utilised. Adding reduced glutathione to the beads in Tris pH 8.0 releases the 
whole GST fusion protein into the solution. Repeated treatment allowed both the 
wild-type and E17A mutant PH domains to be isolated in good yield (Figure 49). 
 
Figure 49. 12% SDS-PAGE gel, run at 200 volts for 40 mins, visualised by Coomassie Blue, 
showing glutathione elution of the GST‐PH fusion proteins. Lane 1 – markers; Lane 2 – wt 
GST-PH domain off the beads; Lane 3 – E17A GST-PH domain off the beads. 
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6.5 ISOTHERMAL TITRATION CALORIMETRY 
 
The presence of the GST tag means that an alternative approach is required as the 
presence of the additional W residues render intrinsic tryptophan fluorescence 
spectroscopy impracticable. As already discussed, isothermal titration calorimetry 
offers a useful alternative technique for the study of protein ligand binding. While 
it has not been previously employed to study the interactions between the PH 
domain of PKB  with various inositol phosphates and phosphoinositides, Lemmon 
et al. have used it to investigate the binding patterns of a wide range of other PH 
domains. 
The first consideration is the amount of protein needed per experiment. As 
discussed in the bio-physical techniques (section 2.3.2) the shape of the binding 
isotherm is determined by the unitless constant c.
94
 
 
c = ([Mtot]n)/Kd (eq. 2) 
 
The recommended minimum value of c is 5. Since experimental values are only 
available for the wild-type protein these were used for initial calculations. For the 
interaction of the PH domain of PKB  with Ins(1,3,4,5)P4, the n value would be 
expected to be 1, and a value of 0.95 has been determined experimentally. The same 
research used intrinsic tryptophan fluorescence spectroscopy to determine the Kd 
value to be 1.5 (±0.2) M.
82
 Adding all these values into the above equation give:  
 
5 = ([Mtot] × 0.95)/1.5 (±0.2) M  (eq. 3) 
 
7.5 (±1.0) M = [Mtot] × 0.95  (eq. 4) 
 
7.9 (±1.1) M = [Mtot]  (eq. 5) 
 
This gives the desired molar concentration for the wild-type PH domain. Both the 
wild-type and E17A mutant PH domains have a molecular weight of ~14 kDa, and 
the GST tag an additional ~25 kDa. This gives a minimum required concentration of ~230 
g/ml per experiment.  
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The wild-type fusion protein was transferred from the Tris pH 8.0 buffer into 25 
mM 3-(N-morpholino)propanesulfonic acid (MOPS), pH 6.8, 100 mM NaCl and 1 
mM dithiothreitol (DTT) prior to the experiment, once again using a 5000 MW spin 
concentrator, and then adjusted to the required concentration. The protein sample 
was then carefully injected into the sample cell and sequential aliquots (10 l) of 
Ins(1,3,4,5)P4 in water were injected, under computer control, to cover a range of 
Ins(1,3,4,5)P4-PH domain molar ratios of 0:1 to 6:1 [taking into account that the 
sample of Ins(1,3,4,5)P4 is racemic]. A control experiment for the heat of dilution 
of the Ins(1,3,4,5)P4 into the buffer was performed in a separate titration, and data 
corrected accordingly (Figure 50).  
 
Figure 50. A Ins(1,3,4,5)P4 injected into 25 mM MOPS, pH 6.8, 100 mM NaCl, 1 mM DTT buffer. B 
Ins(1,3,4,5)P4 injected into 25 mM MOPS, pH 6.8, 100 mM NaCl, 1 mM DTT buffer containing wild-type 
GST-PH domain fusion protein of PKB . Initial concentration of PH domain was 240 g/ml. For both 
experiments Ins(1,3,4,5)P4 was injected in sequential aliquots (10 l) to cover a range of 
Ins(1,3,4,5)P4:PH domain molar ratios of 0:1 to 7:1. The Ins(1,3,4,5)P4 solution was generated by dilution 
of a 10 mM stock solution (in water) into the buffer.  
 
Comparison of these results (Figure 50A vs. Figure 50B) show significant 
differences, implying the potential occurrence of binding, but the relative intensity 
of the observed peak compared to just the background heat of mixing implied either 
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the protein had once more become denatured, or a secondary factor was influencing 
the shape of the observed binding isotherm.  MicroCal report in their user‟s 
manual
94
 that as well as consideration of the c value, the sensitivity of the 
equipment must also be taken into account. The equipment has a limiting sensitivity 
of ~0.1 cal, so each injection into the cell should have an average heat absorbed or evolved 
of 3-5 Cal. Hence if the H value for the interaction is low then the minimum 
concentration of protein can be significantly higher than that implied by calculations from c. 
To investigate whether this could be the cause an increased concentration of protein was 
needed. Attempting to increase the concentration lead to the formation of protein precipitate, 
and no significantly higher protein concentrations could be achieved. This suggests an 
alternative approach is needed to deal with the insolubility issues arising with the protein so 
that the RLE interactions can be investigated. However, due to time restraints this could not 
be fully explored. 
 
6.6 ADDITIONAL BIOLOGICAL TESTING 
 
The following research was carried out in collaboration with Jessica Knott, using 
the Ins(1,3,4,5)P4 analogues synthesised for the RLE studies.  
While the above testing was being attempted, the compounds were also undergoing 
testing as phosphatase inhibitors. Synaptojanin is a type II phosphatase that has 
been shown to be involved in the uncoating of vesicles in neurons.
183
 It is an 
important lipid phosphatase that dephosphorylates the 5-O of PtdIns(3,4,5)P3 and 
PtdIns(4,5)P2, as well as Ins(1,4,5)P3 and Ins(1,3,4,5)P4. It possesses two 
phosphatase domains: A central inositol 5-phosphatase domain (IPPc), that 
dephosphorylates both PtdIns(3,4,5)P3 and PtdIns(4,5)P2, as well as Ins(1,4,5)P3 
and Ins(1,3,4,5)P4; and a phosphatidylinositide phosphatase Sac1 homology domain 
at its N-terminal, of which the main substrate is PtdIns(4)P.
184
 
To investigated the possible models and mechanisms to explain the lipid based 
Sac/IPPc domain co-dependence a suitable IPPc domain inhibitor needed to be 
identified. The 2-O substituted analogues of Ins(1,3,4,5)P4 synthesised for polar 
group exchange RLE of protein kinase B‟s pleckstrin homology domain  (Figure 51), 
were tested as potential synaptojanin inhibitors. Because Ins(1,4,5)P3 and 
Ins(1,3,4,5)P4 are both substrates for only the IPPc domain, it was believed that the 
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analogues would also only selectively interact with the IPPc domain, and not 
interact or inhibit the Sac active site. However their additional functional moieties 
could disrupt the hydrolysis mechanism, leading to inhibition of the active site.  
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Figure 51. Structures of Ins(1,3,4,5)P4 analogues tested as potential IPPc domain 
inhibitors. 
 
Initially it needed to be confirmed that none of these compounds were substrates for 
either the IPPc or Sac domains. Using a malachite green assay, it is possible to 
measure the activity of Sac/IPPc towards each compound compared to the IPPc 
domain hydrolysing Ins(1,4,5)P3 (Figure 52). The malachite green assay measures 
the level of free phosphate released into the solution by inositol phosphate ester 
hydrolysis. 
This showed that within the detection limits of the assay, none of the compounds 
tested exhibited significant formation of free phosphate. Based on this it can be 
assumed that none of them are substrates for IPPc/Sac.  
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Figure 52. Free phosphate levels produced - 
relative to Ins(1,4,5)P3 - from the incubation of 
IPPc/Sac with 200 µM of the inositol phosphate 
analogue compounds. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. The activity of Sac/IPPc on 100µM 
Ins(1,4,5)P3 in the presence of 100 µM inositol 
phosphate analogues (as a percentage of the control). 
The control is the hydrolysis of Ins(1,4,5)P 3 in the 
absence of any inositol phosphate analogue.  
 
 
 
 
 
 
 
 
Once this had been established, each compound‟s ability to inhibit the IPPc domain 
of IPPc/Sac was tested. The compounds were each incubated with the IPPc/Sac 
before the protein‟s activity towards Ins(1,4,5)P3 was measured (Figure 53). 
The activity of the IPPc/Sac phosphatase in the presence of each analogue was 
expressed as a percentage of the domain‟s activity towards just  Ins(1,4,5)P3. Based 
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on these results it can be seen that the 2-O-propyl InsP4 and 2-O-(2-hydroxyethyl) 
InsP4 inhibit the IPPc domain by more than 50% at 100 µM. 
The inhibition mechanism was then investigated using a Lineweaver-Burke plot (Figure 
54) of the Sac/IPPc hydrolysis of Ins(1,4,5)P3 compared to those of Sac/IPPc in the 
presence of the strongest inhibitor - the 2-O-(2-hydroxyethyl) InsP4. If the ligand 
inhibits an enzyme in a competitive manner the plot shows a shift in KM with the 
VMAX value staying constant. For non-competitive inhibition KM stays constant but 
a drop in VMAX is observed. 
Figure 54 shows no shift in the (1/V) axis intercept, corresponding to V MAX 
remaining constant in each case; and a shift in the projected intersect on the (1/[S])  
axis, showing a change in KM. It can therefore be stated that the mechanism of IPPc 
inhibition by 2-O-(2-hydroxyethyl) InsP4 is competitive in nature.  
 
Figure 54. A Lineweaver-Burke plot of the Sac/IPPc hydrolysis of Ins(1,4,5)P3 in the 
presence of (i) 2-O-(2-hydroxyethyl) InsP4 (blue); and (ii) in the absence of an inositol 
phosphate analogue (black).  
 
To determine if these analogues acted as inhibitors in a dose dependent manner, 
increasing concentrations of 2-O-propyl InsP4 and 2-O-(2-hydroxyethyl) InsP4, were 
incubated with the IPPc/Sac protein, and the activity of the IPPc domain towards 
Ins(1,4,5)P3 measured in each case (Figure 55). 
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Figure 55. Dose response of (i) 2-O-propyl InsP4 (red); and (ii) 2-O-(2-hydroxyethyl) InsP4 
(green) as inhibitors of the IPPc domain activity in Sac/IPPc towards 100 µM of Ins(1,4,5)P 3. 
 
The 2-O-propyl InsP4 inhibited up to 50% of IPPc activity, with the level of inhibition 
staying constant after ~100 M. Only the 2-O-(2-hydroxyethyl) InsP4 showed a dose-
dependent behaviour that allowed inhibition of 100% of IPPc‟s activity. 
To validate these compounds‟ potential as selective inhibitors of the IPPc domain in the 
presence of the Sac phosphatase, they were assayed with both the IPPc/Sac active 
synaptojanin and the IPPc-dead and Sac-dead mutants in the presence of either PtdIns(4)P, 
Ins(1,4,5)P3 or O-methyl fluorescein phosphate (OMFP) (Figure 56). 
 
 
 
Figure 56. Inhibition of the Sac 
hydrolysis of PtdIns(4)P and OMFP; and 
that of the IPPc hydrolysis of 
Ins(1,4,5)P3 for Sac/IPPc, Sac-/IPPc 
(Sac dead mutant) and Sac/IPPc- (IPPc 
dead mutant). 
 
 
 
 
 
 
 
In each case the compounds inhibit the IPPc/Sac hydrolysis of PtdIns(4)P by ~35%, and 
similar levels of inhibition are observed in the IPPc dead mutant, showing that these 
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compounds exhibit poor selectivity for just the IPPc domain. It is worth noting however that 
significantly less inhibition is observed using the artificial substrate OMFP. The inhibition 
of the Sac dead mutant and Sac/IPPc hydrolysing Ins(1,4,5)P3 was comparable in each case 
studied, suggesting that the compounds do not bind to the Sac active site, but cause 
additional inhibition via conformational changes upon binding. 
Hence while the 2-O-(2-hydroxyethyl) InsP4 analogue initially seemed promising as an 
inhibitor of the IPPc domain, it is not selective enough to be employed for probing the 
IPPc/Sac protein. 
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7. CONCLUSIONS AND OUTLOOK  
 
The preceding research can be split into three sections: (i) chemical  synthesis of a 
range of 2-O functionalised Ins(1,3,4,5)P4 derivatives; (ii) the expression and 
purification of both the wild-type and E17A mutant forms of the PH domain of 
PKB ; and (iii) bio-physical testing of any interactions between the PH domains 
and the synthetic ligands in order to establish the potential for polar group 
exchange RLE of protein kinase B‟s pleckstrin homology domain.  
The first part can be considered successful with the synthesis of the 2 -O-acetic acid 
Ins(1,3,4,5)P4. Adopting a divergent synthetic strategy allowed the synthetic route 
to be adapted for the synthesis of 2-O-propyl and 2-O-(2-hydroxyethyl) compounds. 
These compounds are designed to act as control molecules to ensure that polar 
group exchange RLE is occurring rather than a steric complementation interaction. 
Using the 2-O-(2-hydroxyethyl) compound also showed potential for further 
functionalisation of the 2-O side-chain. The Mitsunobu reaction was used to convert 
the alcohol selectively into both an azide and a protected guanidinium. However 
further development of the reaction conditions is required to allow purification of the final 
compound. One potential route to overcome this problem could be to employ polymer-
supported triphenylphosphine to allow easier separation of the reagent debris from the 
product. 
Although it was not explored as part of this research, there are two key intermediates that 
would allow for this small library of compounds to be expanded. The first is the 1,3,4,5-O-
tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-inositol (118): The allyl moiety 
can be expanded beyond the ethyl chain length explored here, to propyl, and longer chain 
length, derivatives. The second main derivative is the 1,3,4,5-O-
tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-benzyl-myo-inositol (128): As 
already seen, in combination with the Mitsunobu reaction, this allows the introduction of a 
variety of moieties into this derivative, including phenols, anilines and carbon nucleophiles.  
In addition to these compounds there is the route to Ins(1,4,5)P3 which was discussed in 
section 3.2.2. Applying this methodology to myo-inositol-2-O-allyl-6-O-benzyl-1,3,5-O-
orthobenzoate (108), would allow access to the Ins(1,4,5)P3 analogues similarly to the 
Ins(1,3,4,5)P4 compounds. 
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Expression of both the wild-type and E17A mutant of the PH domain of PKB  was 
successfully achieved, and both proteins isolated in yields comparable to those reported in 
current literature, but subsequent purification was less successful. Trying to use the 
thrombin cleavage site for purification led to non-specific binding of the protein to the GST 
beads, and the conditions that allowed disruption of the binding also caused denaturation of 
the protein. These restrictions meant that the use of intrinsic tryptophan fluorescence 
spectroscopy had to be discarded due to the presence of the GST tag after cleavage with 
reduced glutathione. Theoretically the GST tag could be removed post cleavage, but 
the issues with solubility already encountered suggest that removing the tag – 
which is known to increase protein solubility in many cases – would be unwise. 
Since this solubility issue arose again when trying to probe the interaction using 
ITC, an alternative approach is needed. Ingley and Hemmings have developed a 
large-scale method for the expression and purification of a form of PKB ‟s PH 
domain with increased solubility.
185
 This solubility is conferred on the protein by 
the presence of three additional lysines on the C-terminus of the protein. It is 
proposed that this method is employed to create samples of both the wild-type and 
E17A mutant in significant yields, and at high enough concentrations to facilitate 
study by ITC. Identification and verification of the cause of the observed compound 
peak in intrinsic tryptophan fluorescence spectroscopy should also allow this 
method to be revisited. This approach is going to be continued by Sarah Rosen as 
part of her PhD research. 
While a successful polar group exchange RLE pair has not yet been identified the key 
components are in place. The ligand designed for this purpose has been synthesised. The 
problems with isolation of the expressed proteins have been identified, and a strategy for 
surmounting these problems has been proposed. Both intrinsic tryptophan fluorescence 
spectroscopy and ITC have been shown to be applicable to studying any interaction that 
occurs, and the problems encountered experimentally should be removed by the new 
expression strategy, combined with either re-purification, or changing the salt of the 
Ins(1,3,4,5)P4 analogues. 
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8. EXPERIMENTAL  
 
8.1 CHEMISTRY 
 
8.1.1 General experimental 
 
Unless otherwise stated, the following protocols were used for each reaction: 
 All reactions were conducted under a nitrogen atmosphere, at room temperature and in 
dry glassware. 
 Chemicals were purchased from Sigma-Aldrich Ltd. or Acros Organics, and 
used directly from the supplier‟s container.  
 A water-cooled Büchi rotary evaporator was used for the evaporation of organic 
solvents. 
 Solvents were dried over a suitable reagent, and then dist illed, before use. 
Distilled solvents were stored under nitrogen, and over 4 Å molecular sieves if 
suitable, in sealed containers. 
Depending upon availability, 
1
H-, 
13
C- and 
31
P-NMR spectra were recorded on 
Bruker AV-500, AV-400 or AC-270 spectrometers. Chemical shifts ( ) are recorded 
in parts per million (ppm), referenced to an internal solvent standard, H (CHCl3) 
7.25 ppm, H (d6-DMSO) 2.50 ppm, H (HOD) 4.60 ppm, C (CDCl3) 77.50 ppm, C 
(d6-DMSO) 39.43 ppm, or an external reference, P (H3PO4) 0.00 ppm. Splitting 
patterns are recorded using standard abbreviations:  s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), b (broad) and combinations of the above.  
Coupling constants (J) are quoted in Hertz (Hz). 
13
C peaks are assigned as C 
(quaternary), CH (tertiary), CH2 (secondary) and CH3 (primary). 
1
H- and 
13
C-NMR 
assignments were made with the aid of DEPT-90 and -135, HSQC, COSY and 
NOESY experiments. JPC coupling constants were assigned using resolution 
enhancement in MestRe-C. 
13
C- and 
31
P-NMR spectra are proton decoupled. 
Deuterated solvents were purchased from Merck, with the exception of d6-DMSO 
(Apollo Scientific Ltd.).  
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Mass spectra were recorded on a VG AutoSpec-Q (CI and FAB), a Micromass 
AutoSpec Premier (CI and EI), a  Micromass LCT Premier (ES) or a Micromass MALDI 
micro MX (MALDI). 
Merck silica gel 60 F254 glass-backed plates were used for analytical TLC. The 
plates were visualised using UV light or after treatment with a chemo -selective 
stain. Flash chromatography was carried out using flash silica from Merck. 
A general method was designed for the global deprotection of Ins(1,3,4,5)P 4 and its 
2-O analogues  
 
General method 1: Global deprotection to form Ins(1,3,4,5)P4 and its 2-O 
analogues 
 
1,3,4,5-O-tetrakis(dibenzylphosphoryl)-2,6-O-dibenzyl-myo-inositol (114, 110 mg, 78 mol) 
was taken up in 
t
BuOH-water (6:1 v/v, 14 ml), then sodium bicarbonate (53 mg, 0.62 mmol) 
and Pd-black (167 mg, 1.57 mmol) were added. The reaction vessel was flushed with N2 (  
3) followed by H2 (  3). The reaction mixture was stirred under 1 atm. H2 for 24 h. The 
solution was filtered, and the remaining solids washed with water (15 ml), and the combined 
filtrates evaporated under reduced pressure. The residue was taken up in water (15 ml) and 
washed with CHCl3 (15 ml). The aqueous layer was evaporated under reduced pressure to 
give the sodium salt.  
 
General method 2: Ion exchange of Ins(1,3,4,5)P4 and its 2-O analogues 
 
The sodium salt was passed through a DOWEX 50WX8-200 (H
+
 form) ion exchange 
column, and the acidic fractions of eluent were combined, neutralised with aq. NH3 and then 
freeze dried, giving the ammonium salt. 
 
8.1.2 MRes research 
 
This section contains the characterisation of a selection of compounds that were synthesised 
during the MRes year of research. They are included here as they are involved in the final 
synthetic route to the target compounds. 
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myo-Inositol-1,3,5-O-orthobenzoate (43c) 
O
O
O
OH
HO
HO
Ph
 
myo-Inositol (2, 5.00 g, 28 mmol) was suspended in DMSO (23 ml), then trimethyl 
orthobenzoate (7.2 ml, 42 mmol) and toluene sulfonic acid (55 mg, cat.) were added. The 
suspension was stirred at 100 °C for 5 h. The solution was quenched with Et3N (40 l, 1 
eq./TSA), and the solvents were evaporated under reduced pressure to give the crude 
product. This was purified by recrystalisation from EtOAc to afford the title compound (43c, 
4.28 g, 58%) as colourless crystals. Rf (EtOAc) 0.55; H (500 MHz; d6-DMSO) 7.58-7.53 
(2H, m), 7.37-7.30 (3H, m) (5 × Ph-H), 5.50 (2H, s, Ins 4-OH + Ins 6-OH), 5.32 (1H, d, J 
6.2, Ins 2-OH), 4.40 (2H, t, J 3.6, Ins 4-H + Ins 6-H), 4.20 (1H, tt, J 3.2, 1.6, Ins 5-H), 4.15 
(2H, dq, J 3.6, 1.5, Ins 1-H + Ins 3-H), 4.08 (1H, dt, J 6.2, 1.5, Ins 2-H); C (125 MHz; d6-
DMSO) 137.9 (Ph C), 129.0, 127.5 (2C), 125.4 (2C) (5 × Ph CH), 106.4 (PhCO3), 75.8 
(2C), 70.1, 67.2 (2C), 57.8 (6 × Ins CH); MS (FAB+) m/z (%): [M+H]
+ 
267 (100), [PhCO]
+ 
105 (56); HRMS (FAB+) m/z (%): found [M+H]
+
 267.0878 (100), C13H15O6 requires 
267.0869. 
 
6-O-Benzyl-myo-inositol-1,3,5-O-orthobenzoate (76) 
O
O
O
OH
BnO
HO
Ph
 
Crude myo-inositol-1,3,5-O-orthobenzoate (43c, 1.00 g, 3.8 mmol) was evaporated from 
MeCN (3  5 ml) then taken up in DMF (20 ml). The solution was cooled to -15 °C and 
NaH (60% dispersion in mineral oil, 150 mg, 3.8 mmol) was added. The reaction was stirred 
for 15 min at -15 °C, and a further 30 min at room temperature. Benzyl bromide (434 l, 3.8 
mmol) was added and the reaction stirred overnight. The reaction was quenched with water, 
stirred for a further 20 min, then the solvent was evaporated under reduced pressure. The 
remaining solids were taken up in EtOAc (20 ml) and washed with water (3 × 15 ml), then 
brine (10 ml). The organic layer was dried over MgSO4, filtered and the filtrate evaporated 
under reduced pressure. The residue was fractionated by flash column chromatography, 
eluting with with hexane-EtOAc (1:1 v/v) to give the title compound (76, 1.20 g, 90%) as a 
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colourless oil. Rf (hexane-EtOAc, 1:4 v/v) 0.65; H (500 MHz; d6-DMSO) 7.58-7.53 (2H, 
m), 7.37-7.30 (8H, m) (10 × Ph-H), 5.33 (1H, d, J 6.2, Ins 2-OH), 5.28 (1H, d, J 5.1, Ins 4-
OH), 4.72 (1H, d, J 11.7), 4.58 (1H, d, J 11.7) (OCH2Ph), 4.46 (1H, td, J 3.4, 1.6, Ins 6-H), 
4.43 (1H, dtd, J 6.1, 3.5, 1.4, Ins 4-H), 4.32 (1H, tt, J 3.8, 1.8, Ins 5-H), 4.25 (1H, dq, J 1.7, 
3.3, Ins 1-H), 4.13 (1H, dq, J 3.9, 2.0, Ins 3-H), 4.08 (1H, dt, J 6.0, 1.7, Ins 2-H); C (125 
MHz; d6-DMSO) 138.2, 137.9 (2 × Ph C), 129.1, 128.3 (2C), 127.6 (2C), 127.6 (3C), 125.4 
(2C) (10 × Ph CH), 106.9 (PhCO3), 76.0, 74.1, 73.6 (3 × Ins CH), 70.2 (OCH2Ph), 69.6, 
67.0, 58.2 (3 × Ins CH); MS (FAB+) m/z (%): [M+H]
+ 
357 (100), [PhCO]
+ 
105 (63), 
[PhCH2]
+ 
91 (95); HRMS (FAB+) m/z (%): found [M+H]
+
 357.1333 (100), C20H21O6 
requires 357.1338. 
 
4-O-para-Methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (78)  
O
O
O
OPmb
BnO
HO
Ph
 
6-O-Benzyl-myo-inositol-1,3,5-O-orthobenzoate (76, 11.21 g, 31.5 mmol) was evaporated 
from MeCN (3 × 20 ml) then taken up in DMF (75 ml). The solution was cooled to -15 °C 
and NaH (60% dispersion in mineral oil, 1.26 g, 31.5 mmol) was added. The reaction was 
stirred for 15 min at -15 °C, and a further 30 min at room temperature. para-Methoxybenzyl 
chloride (4.26 ml, 31.5 mmol) was added and the reaction stirred overnight. The reaction 
was quenched with water, stirred for a further 20 min, then the solvent was evaporated under 
reduced pressure (oil pump). The remaining solids were taken up in DCM (30 ml) and 
washed with water (3 × 30 ml), then brine (30 ml). The organic layer was dried over 
MgSO4, filtered and the filtrate evaporated under reduced pressure. The residue was 
fractionated by flash column chromatography, eluting with with hexane-DCM-EtOAc (3:2:1 
v/v/v) to give the title compound (78, 9.03 g, 60%) as a colourless oil. Rf (EtOAc-hexane, 
1:1 v/v) 0.55; H (400 MHz; d6-DMSO) 7.56-7.52 (2H, m), 7.38-7.26 (8H, m), 7.21 (2H, d, J 
8.5), 6.82 (2H, d, J 8.5) (14 × Ar-H), 5.40 (1H, d, J 6.2, ex. → s,  Ins 2-OH), 4.75-4.68 (1H, 
m, Ins 5-H), 4.69 (1H, d, J 11.6), 4.61 (1H, d, J 11.6), 4.60 (1H, d, J 11.2), 4.53 (1H, d, J 
11.2) (2 × OCH2Ar), 4.37-4.26 (4H, m, 4 × Ins-H), 4.06 (1H, bd, J 6.2, ex. → s, Ins 2-H,), 
3.72 (3H, s, OCH3); C (100 MHz; d6-DMSO) 158.7, 138.1, 137.7, 130.0 (4 × Ar C), 129.3 
(2C), 129.1, 128.2 (2C), 127.6 (2C), 127.6 (2C), 127.5, 125.4 (2C), 113.6 (2C) (14 × Ar 
CH), 107.1 (PhCO3), 73.9, 73.1, 73.6, 73.3 (4 × Ins CH), 70.5, 70.3 (2 × OCH2Ar), 67.8, 
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58.5 (2 × Ins CH), 55.0 (OCH3); MS (FAB+) m/z (%): [M+H]
+
 477 (54), [MeOC6H4CH2]
+
 
121 (100), [PhCH2]
+
 91 (46); HRMS (FAB+) m/z (%): found [M+H]
+
 477.1934 (100), 
C28H29O7 requires 477.1913. 
 
2-O-Allyl-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate 
(79) 
O
O
O
OPmb
BnO
O
Ph
 
4-O-para-Methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (78, 9.03 g, 18.9 
mmol) was evaporated from MeCN (3 × 20 ml) then taken up in DMF (50 ml). The 
solution was cooled to -15 °C and NaH (60% dispersion in mineral oil, 1.13 
g, 28.4 mmol) was added.  The reaction was stirred for 15 min at -15 °C, and a further 
30 min at room temperature. Allyl bromide (2.45 ml, 28.4 mmol) was added, and the 
reaction stirred overnight. The reaction was quenched with water, stirred for a further 20 
min, then the solvent was evaporated under reduced pressure (oil pump). The remaining 
solids were taken up in DCM (20 ml) and washed with water (3 × 15 ml), then brine (15 ml). 
The organic layer was dried over MgSO4, filtered and the filtrate evaporated under reduced 
pressure. The residue was fractionated by flash column chromatography, eluting with with 
hexane-DCM-EtOAc (3:2:1 v/v/v) to give the title compound (79, 9.30 g, 95%) as a 
colourless oil. Rf (hexane-EtOAc, 1:1 v/v) 0.65; H (400 MHz; d6-DMSO) 7.53-7.49 (2H, 
m), 7.39-7.30 (8H, m), 7.24 (2H, d, J 8.6), 6.86 (2H, d, J 8.6) (14 × Ar-H), 5.92 (1H, ddt, J 
17.2, 10.5, 5.3, OCH2CHCH2), 5.30 (1H, dq, J 17.2, 1.6), 5.17 (1 H, dq, J 10.4, 1.2) 
(OCH2CHCH2), 4.73-4.68 (1H, m, Ins 5-H), 4.70 (1H, d, J 11.6), 4.64 (1H, d, J 11.6), 4.63 
(1H, d, J 11.3), 4.56 (1H, d, J 11.3) (2 × OCH2Ar), 4.52 (1H, dq, J 3.5, 1.7), 4.49 (1H, dq, J 
3.5, 1.7), 4.41-4.34 (2H, m) (4 × Ins-H), 4.03-4.15 (2H, m, OCH2CHCH2), 3.89 (1H, bs, Ins 
2-H), 3.75 (3H, s, OCH3); C (100 MHz; d6-DMSO) 159.3, 138.6, 138.0 (3 × Ar C), 135.7 
(OCH2CHCH2), 130.5 (Ar C), 129.8 (2C) , 129.7, 128.7 (2C), 128.2 (2C), 128.1 (2C), 128.0, 
125.7 (2C) (12 × Ar CH), 117.3 (OCH2CHCH2), 114.1 (2C, Ar CH), 107.5 (PhCO3), 74.0, 
73.7, 71.6, 71.5 (4 × Ins CH), 71.1, 70.9, 69.5 (3 × CH2), 68.6, 66.4 (2 × Ins CH), 55.5 
(OCH3); MS (FAB+) m/z (%): [M+H]
+
 517 (28), [MeOC6H4CH2]
+
 121 (100), [PhCH2]
+
 91 
(31); HRMS (FAB+) m/z (%): found [M+H]
+
 517.2223 (100), C31H33O7 requires 517.2226. 
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8.1.3 PhD research 
 
4-O-Allyl-myo-inositol-1,3,5-O-orthobenzoate (93) 
O
O
O
OAllyl
HO
HO
Ph
 
Crude myo-inositol-1,3,5-O-orthobenzoate (43c, 3.00 g, 11.2 mmol) was evaporated from 
MeCN (3  5 ml) then taken up in DMF (30 ml). The solution was cooled to -15 °C and 
NaH (60% dispersion in mineral oil, 450 mg, 11.2 mmol) was added. The reaction was 
stirred for 15min at -15 °C, and then stirred for a further 30 min at room temperature. Allyl 
bromide (972 l, 11.2 mmol) was added, and the reaction stirred overnight. The reaction 
was quenched with water, stirred for a further 20 min, then the solvent was evaporated under 
reduced pressure. The remaining solids were then taken up in DCM (20 ml) and washed 
with water (3  20 ml) and then with brine (20 ml). The organic layer was dried over 
MgSO4, filtered and the filtrate evaporated under reduced pressure. The residue was 
fractionated by flash column chromatography, eluting with with hexane-EtOAc (1:1 v/v) to 
give the title compound (93, 3.06 g, 89%). Rf (EtOAc) 0.70; H (400 MHz; CDCl3) 7.66-7.60 
(2H, m), 7.42-7.26 (3H, m) (5 × Ph-H), 5.90 (1H, ddt, J 16.3, 10.3, 5.9, OCH2CHCH2), 5.36 
(1H, dq, J 10.3, 1.2), 5.30 (1H, dq, J 10.0, 1.2) (OCH2CHCH2), 4.61 (1H, dtd, J 10.0, 4.1, 
1.2, Ins 6-H), 4.55-4.49 (2H, m), 4.42-4.44 (2H, m) (4 × Ins-H), 4.23 (1H, ddt, J 12.2, 5.8, 
1.2), 4.21 (1H, ddt, J 12.2, 5.8, 1.2) (OCH2CHCH2), 4.15 (1H, bd, J 9.5, Ins 2-H), 3.76 (1H, 
d, J 10.0, Ins 6-OH), 3.26 (1H, bd, J 9.5, Ins 2-OH); C (100 MHz; CDCl3) 136.5 (Ph C), 
132.6 (OCH2CHCH2), 129.7, 128.5 (2C), 125.2 (2C) (5 × Ph CH), 119.6 (OCH2CHCH2), 
107.4 (PhCO3), 76.0, 74.0, 73.5 (3 × Ins CH), 72.0 (OCH2CHCH2), 68.2, 67.7, 59.9 (3 × Ins 
CH); HRMS (ES+) m/z (%): found [M+H]
+
 307.1193 (100), C16H19O6 requires 307.1182.  
 
2,6-O-Dibenzyl-4-O-allyl-myo-inositol-1,3,5-O-orthobenzoate (94) 
O
O
O
OAllyl
BnO
BnO
Ph
 
4-O-Allyl-myo-inositol-1,3,5-O-orthobenzoate (93, 2.50 g, 8.14 mmol) was evaporated from 
MeCN (5 ml) then taken up in DMF (25 ml). The solution was cooled to -15 °C and NaH 
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(60% dispersion in mineral oil, 977 mg, 24.4 mmol) was added. The reaction was stirred for 
15 min at -15 °C, and then stirred for a further 30 min at room temperature. Benzyl bromide 
(2.90 ml, 24.4 mmol) was added to the reaction, which was then stirred overnight. The 
reaction was carefully quenched with water (5 ml) and stirred for a further 20 min and then 
the solvent was evaporated. The remaining solids were taken up in DCM (20 ml) and 
washed with water (3 × 15 ml), then brine (15 ml). The organic layer was dried over 
MgSO4, filtered and the filtrate evaporated under reduced pressure. The residue was 
fractionated by flash column chromatography, eluting with hexane-EtOAc (9:1 v/v) to give 
the title compound (94, 3.81 g, 96%). Rf (hexane-EtOAc, 9:1 v/v) 0.35; H (500 MHz; 
CDCl3) 7.71-7.66 (2H, m), 7.45 (2H, bd, J 7.2), 7.40-7.29 (11H, m) (15 × Ph-H), 5.87 (1H, 
ddt, J 17.0, 10.7, 5.5, OCH2CHCH2), 5.26 (1H, dq, J 17.4, 1.5), 5.20 (1H, dq, J 10.4, 1.4) 
(OCH2CHCH2), 4.77-4.71 (2H, m), 4.68 (1H, d, J 11.8) (3 × OCHHPh), 4.58-4.53 (2H, m, 2 
× Ins-H), 4.55 (1H, d, J 12.1, OCHHPh), 4.50 (1H, dq, J 3.7, 1.8, Ins-H), 4.47 (1H, td, J 3.7, 
1.6, Ins-H), 4.42 (1H, td, J 3.6, 1.6, Ins-H), 4.13 (1H, ddt, J 12.7, 5.4, 1.3, OCHHCHCH2), 
4.10 (1H, t, J 1.6, Ins 2-H), 4.04 (1H, ddt, J 12.7, 5.6, 1.2, OCHHCHCH2); C (125 MHz; 
CDCl3) 138.2, 137.8, 137.2 (3 × Ph C), 134.2 (OCH2CHCH2), 129.4, 128.5 (5C), 128.0 
(2C), 127.9 (3C), 127.8, 127.6, 125.4 (2C) (15 × CH), 117.6 (OCH2CHCH2) 107.9 (PhCO3), 
73.9, 73.8, 72.1, 71.9 (4 × Ins CH), 71.5, 71.3, 70.7 (3 × CH2), 69.1, 66.4 (2 × Ins CH); 
HRMS (CI+) m/z (%): found [M+H]
+
 487.2130 (100), C30H31O6 requires 487.2121. 
 
2,6-O-Dibenzyl-4-O-(prop-Z-1-enyl)-myo-inositol-1,3,5-O-orthobenzoate (95) 
O
O
O
O
Ph
BnO
BnO
 
2,6-O-Dibenzyl-4-O-allyl-myo-inositol-1,3,5-O-orthobenzoate (94, 3.00 g, 6.17 mmol) was 
evaporated from MeCN (3  3 ml) then taken up in DMSO (6.15 ml). Potassium tert-
butoxide (1.38 g, 12.3 mmol) was then added and the solution stirred at 100 °C for 3 h. The 
reaction was allowed to cool, was quenched with water, and then the solvent was 
evaporated. The remaining solids were taken up in EtOAc (20 ml). The organic layer was 
washed with water (4  15 ml) and brine (15 ml). The combined aqueous layers were then 
back extracted with EtOAc (20 ml), and the previous washing procedure repeated. The 
combined organic layers were dried over MgSO4, filtered and the filtrate evaporated under 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 136 - 
reduced pressure. The crude title compound (95, 3.00 g, 100%) was isolated as a yellow oil. 
Rf (hexane-EtOAc, 1:1 v/v) 0.76; H (400 MHz; CDCl3) 7.61-7.68 (2H, m), 7.22-7.46 (13H, 
m) (15 × Ph-H), 6.03 (1H, dq, J 6.1, 1.7, OCHCHCH3,), 4.72 (2H, s, OCH2Ph), 4.67-4.62 
(1H, m, Ins-H), 4.66 (1H, d, J 11.8), 4.50 (1H, d, J 11.8) (OCH2Ph), 4.57-4.42 [5H, m, (4  
Ins-H) + OCHCHCH3], 4.06 (1H, t, J 1.6, Ins 2-H), 1.39 (3H, dd, , J 6.8, 1.5, 
OCHCHCH3); C (100 MHz; CDCl3) 143.3 (OCHCHCH3), 137.8, 137.6, 136.9 (3 × Ph C), 
129.4, 128.4 (2C), 128.3 (2C), 128.0 (2C), 127.9 (2C), 127.8 (2C), 127.5 (2C), 125.4 (2C) 
(15 × Ph CH), 107.8 (PhCO3), 104.0 (OCHCHCH3), 75.2, 73.5, 71.9, 71.7 (4 × Ins CH), 
71.5, 71.1 (2 × OCH2Ph), 69.1, 65.6 (2 × Ins CH), 14.2 (OCHCHCH3); HRMS (CI+) m/z 
(%): found [M+H]
+
 487.2130 (100), C30H31O6 requires 487.2121. 
 
2,6-O-Dibenzyl-myo-inositol-1,3,5-O-orthobenzoate (96) 
O
O
O
OH
BnO
BnO
Ph
 
2,6-O-Dibenzyl-4-O-(prop-Z-1-enyl)-myo-inositol-1,3,5-O-orthobenzoate (95, 3.00 g, 6.17 
mmol) was taken up in MeCN-water (9:1 v/v, 18 ml). pTSA (117 mg, 0.617 mmol) was 
added to the vigorously stirred solution. After 48 h pTSA (117 mg, 0.617 mmol) was added 
again and the reaction stirred for a further 24 h. The reaction was quenched with Et3N, then 
taken up in EtOAc (20 ml), washed with sat. aq. NaHCO3 (15 ml), water (2  15 ml) and 
brine (15 ml). The organic layer was dried over MgSO4, filtered and the filtrate evaporated 
under reduced pressure. The residue was fractionated by flash column chromatography, 
eluting with hexane-DCM-EtOAc (6:2:1 v/v/v) to give the title compound (96, 2.20 g, 80%) 
as a waxy colourless solid. Rf (hexane-EtOAc, 4:1 v/v) 0.50; H (400 MHz; CDCl3) 7.69-
7.66 (2H, m), 7.47-7.34 (11H, m), 7.24-7.21 (2H, m) (15 × Ph-H), 4.82 (1H, d, J 12.4), 4.71 
(1H, d, J 12.4) (OCH2Ph), 4.61-4.55 [4H, m, (2 × Ins-H) + OCH2Ph], 4.54-4.45 (2H, m, 2 × 
Ins-H), 4.41 (1H, tt, J 3.5, 1.7, Ins 5-H), 3.97 (1H, bs, Ins 2-H), 3.65 (1H, d, J 9.8, Ins 6-
OH); C (100 MHz; CDCl3) 137.9, 136.9, 136.0 (3 × Ph C), 129.5, 128.9 (2C), 128.8, 128.6 
(2C), 128.2 (2C), 128.0 (5C), 125.4 (2C) (15 × Ph CH), 107.4 (PhCO3), 74.5, 73.5 (2 × Ins 
CH), 73.0 (OCH2Ph), 71.3 (Ins CH), 71.0 (OCH2Ph), 68.7, 68.0, 65.1 (3 × Ins CH); MS 
(FAB+) m/z (%): [M+H]
+ 
447 (16), [PhCH2]
+ 
91 (100); HRMS (FAB+) m/z (%): found 
[M+H]
+
 447.1822 (100), C27H27O6 requires 447.1808. 
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2,6-O-Dibenzyl-myo-inositol (99) 
OBn
OHHO
OH
OBnHO
 
2,6-O-Dibenzyl-myo-inositol-1,3,5-O-orthobenzoate (96, 500 mg, 1.12 mmol) was dissolved 
in TFA-water (4:1 v/v, 10 ml), and stirred overnight. The reaction mixture was then 
evaporated to dryness and re-evaporated from MeOH (3 × 5 ml). The residue was taken up 
in MeOH (10 ml), NaOMe (25 wt. % solution in MeOH) was added drop-wise until the 
reaction solution attained pH 11, then the reaction was stirred overnight. The solution was 
neutralised by the dropwise addition of 0.1 M HCl and the solvent was evaporated. The 
crude product was partitioned between CHCl3 (10 ml) and water (10 ml), and the aqueous 
layer collected. The organic layer was then washed with water (3 × 10 ml), and the 
combined aqueous layers evaporated to dryness. The crude product was then taken up in 
MeOH (10 ml). The solution was filtered, and the filtrate evaporated to afford the title 
compound (99, 403 mg, 100%) as a colourless oil, which was used without further 
purification. Rf (EtOAc) 0.25; H (400 MHz; CD3OD) 7.46-7.40 (4H, m), 7.33-7.27 (4H, m), 
7.26-7.21 (2H, m) (10 × Ph-H), 4.90-4.87 (2H, m), 4.86 (1H, d, J 10.9), 4.83 (1H, d, J 10.9) 
(2 × OCH2Ph), 4.89 (1H, t, J 2.5, Ins 2-H), 3.70 (1H, t, J 9.6), 3.66 (1H, t, J 9.3), 3.58 (1H, 
dd, J 9.8, 2.5), 3.42 (1H, dd, J 9.9, 2.5) (4 × Ins-H), 3.31 (1H, t, J 9.4, Ins 5-H); C (100 
MHz; CD3OD) 140.6, 140.5 (2 × Ph C), 129.3 (2C), 129.2 (2C), 129.1 (2C), 128.9 (2C), 
128.5, 128.3 (10 × Ph CH), 83.4, 82.8, 76.8 (3 × Ins CH), 76.4, 76.0 (2 × OCH2Ph), 74.9, 
73.8, 73.7 (3 × Ins CH); HRMS (ES+) m/z (%): found [M+Na]
+
 383.1486 (100), 
C20H24O6Na requires 383.1471. 
 
2,6-O-Dibenzyl-4-O-(tert-butyldimethylsilyl)-myo-inositol-1,3,5-O-orthobenzoate 
(101a) 
O
O
O
OTbdms
BnO
BnO
Ph
 
2,6-O-Dibenzyl-myo-inositol-1,3,5-O-orthobenzoate (96, 300 mg, 0.672 mmol) and 
imidazole (99 mg, 1.48 mmol) were evaporated from MeCN (3  1 ml), then taken up in 
DMF (5 ml) and Et3N (93 l, 0.672 mmol) was added. The solution was cooled to 0 °C, 
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before adding TbdmsCl (0.152 g, 1.01 mmol). The temperature was then raised to 100 °C 
and the reaction stirred for 48 h. The reaction was quenched with water (1 ml), stirred 
for a further 20 min and the solvent was evaporated. The remaining solids were taken up 
in DCM (10 ml) and washed with sat. aq. NaHCO3 (10 ml), water (10 ml), then brine (10 
ml). The organic layer was dried over Na2SO4, filtered and the filtrate evaporated under 
reduced pressure. The residue was fractionated by flash column chromatography, eluting 
with hexane-DCM (9:1  5:5 v/v), when the title compound (101a, 286 mg, 76%) eluted 
hexane-DCM (6:4 v/v). Rf (hexane-DCM, 1:2 v/v) 0.55; H (400 MHz; CDCl3) 7.72-7.67 
(2H, m), 7.47-7.43 (2H, m), 7.40-7.29 (9H, m), 7.28-7.22 (2H, m) (15 × Ph-H), 4.77 
(1H, d, J 12.6), 4.73 (1H, d, J 12.6) (OCH2Ph), 4.67-4.63 (1H, m, Ins-H), 4.64 (1H, d, J 
11.8, OCHHPh), 4.51-4.49 (1H, m, Ins-H), 4.49 (1H, d, J 11.8, OCHHPh), 4.44 (1H, td, 
J 3.7, 1.6, Ins-H), 4.38-4.33 (2H, m, 2 × Ins-H), 4.12 (1H, t, J 1.5, Ins 2-H), 0.80 [9H, s, 
SiC(CH3)3], 0.06 [6H, s, Si(CH3)2]; C (100 MHz; CDCl3) 138.1, 137.8, 137.3 (3 × Ph 
C), 129.4, 128.5 (2C), 128.4 (2C), 128.1 (2C), 128.0 (2C), 127.9, 127.8, 127.6 (2C), 
125.4 (2C) (15 × Ph CH), 107.7 (PhCO3), 74.3, 74.1, 72.0 (3 × Ins CH), 71.5 (OCH2Ph), 
71.2 (Ins CH), 71.0 (OCH2Ph), 68.3, 65.3 (2 × Ins CH), 25.6 (3C, SiC(CH3)3), 17.8 
(SiC(CH3)3), -4.8, -5.1 (Si(CH3)2); HRMS (ES+) m/z (%): found [M+H]
+
 561.2677 (83), 
C33H41O6Si requires 561.2672, found [M+Na]
+
 583.2501 (100), C33H40O6SiNa requires 
583.2492. 
 
2,6-O-Dibenzyl-4-O-(tert-butyldiphenylsilyl)-myo-inositol-1,3,5-O-orthobenzoate 
(101b) 
O
O
O
OTbdps
BnO
BnO
Ph
 
2,6-O-Dibenzyl-myo-inositol-1,3,5-O-orthobenzoate (96, 500 mg, 1.12 mmol) and 
imidazole (164 mg, 2.46 mmol) were evaporated from MeCN (3  1 ml), then taken up 
in DMF (3 ml) and Et3N (155 l, 1.12 mmol) was added. The reaction was cooled to 0 
°C, before adding TbdpsCl (1.16 ml, 4.48 mmol). The reaction was heated to 100 °C and 
stirred for 72 h. The reaction was quenched with water (0.5 ml), stirred for a further 20 
min and the solvent was evaporated. The remaining solids were taken up in DCM (10 
ml) and washed with sat. aq. NaHCO3 (10 ml), water (10 ml), then brine (10 ml). The 
organic layer was dried over Na2SO4, filtered and the filtrate evaporated. The residue 
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was fractionated by flash column chromatography, eluting with hexane-EtOAc (9:1 v/v), 
followed by sublimation of the residual TbdpsOH contaminant (oil pump, heat gun) to 
give the title compound (101b, 645 mg, 84%). Rf (hexane-EtOAc, 4:1 v/v) 0.52; H (500 
MHz; CDCl3) 7.71-7.67 (2H, m), 7.66-7.63 (4H, m), 7.52-7.47 (4H, m), 7.46-7.32 (13H, 
m), 7.31-7.27 (2H, m) (25 × Ph-H), 4.70 (1H, td, J 3.9, 1.7, Ins-H), 4.70 (1H, d, J 12.2), 
4.67 (1H, d, J 12.6), 4.60 (1H, d, J 12.0) (3 × OCHHPh), 4.48 (1H, dq, J 3.9, 1.9, Ins-H), 
4.48 (1H, d, J 12.0, OCHHPh), 4.39 (1H, td, J 3.6, 1.6, Ins-H), 4.24 (1H, tt, J 3.5, 1.7, 
Ins 5-H), 4.22 (1H, t, J 1.7, Ins 2-H), 4.19 (1H, dq, J 3.9, 1.9, Ins-H), 0.97 (9H, s, 
SiC(CH3)3); C (125 MHz; CDCl3) 138.1, 137.7, 137.2 (3 × Ph C), 135.8 (2C), 135.7 
(2C) (4 × Ph CH), 133.2, 133.1 (2 × Ph C), 130.2, 130.1, 129.4, 128.6 (2C), 128.5 (2C), 
128.2 (2C), 127.9 (8C), 127.8 (2C), 125.4 (2C) (21 × Ph CH), 107.6 (PhCO3), 74.4, 73.6 
(2 × Ins CH), 72.1 (OCH2Ph), 72.0 (Ins CH), 71.0 (OCH2Ph), 70.9, 68.7, 65.3 (3 × Ins 
CH), 26.8 (3C, SiC(CH3)3), 19.14 (SiC(CH3)3); HRMS (ES+) m/z (%): found [M+Na]
+
 
707.2792 (94), C43H44O6SiNa requires 707.2805, found [M+H]
+
 685.2970 (100), 
C43H45O6Si requires 685.2985. 
 
2-O-Allyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (108) 
O
O
O
OH
BnO
O
Ph
 
2-O-Allyl-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (79, 
1.90 g, 3.6 mmol) was taken up in MeCN-water (9:1, 100 ml). The solution was cooled to 0 
°C and CAN (8.0 g, 14.7 mmol) was added. The reaction was stirred for 5 min at 0 °C, and 
then a further 45 min at room temperature. The solvent was evaporated, and the reaction 
mixture then taken up in CHCl3 (50 ml). This solution was washed with water (3  50 ml), 
then sat. aq. NaHCO3 (2  50 ml) and finally with brine (50 ml). The organic layer was dried 
over MgSO4, filtered and the filtrate evaporated. The residue was fractionated by flash 
column chromatography, eluting with hexane-DCM-EtOAc (6:2:1 v/v/v) to give the title 
compound (108, 1.04g, 72%) as a waxy colourless solid. Rf (hexane-DCM-EtOAc, 3:2:1 
v/v/v) 0.33; H (400 MHz; CDCl3) 7.67-7.63 (2H, m), 7.45-7.28 (8H, m) (10 × Ph-H), 6.02 
(1H, ddt, J 15.7, 10.2, 5.2, OCH2CHCH2), 5.39 (1H, dq, J 15.7, 2.1), 5.28 (1H, dq, J 10.2, 
2.1) (OCH2CHCH2), 4.73 (1H, d, J 12.1), 4.68 (1H, d, J 12.1) (OCH2Ph), 4.62 (1H, dtd, J 
10.1, 3.7, 1.8, Ins 4-H), 4.57-4.52 (3H, m, 3 × Ins-H), 4.43 (1H, tt, J 3.5, 1.8, Ins 5-H), 4.23 
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(1H, ddt, J 13.1, 5.5, 1.5), 4.18 (1H, ddt, J 13.1, 5.5, 1.5) (OCH2CHCH2), 3.95 (1H, t, J 1.7, 
Ins 2-H), 3.72 (1H, d, J 10.0, Ins 6-OH); C (100 MHz; CDCl3) 136.9, 136.2 (2 × Ph C), 
134.7 (OCH2CHCH2), 129.5, 129.0 (2C), 128.9, 128.2 (2C), 128.0 (2C), 125.4 (2C) (9 × Ph 
CH), 117.8 (OCH2CHCH2), 107.4 (PhCO3), 74.7, 73.5 (2 × Ins CH), 73.3 (OCH2Ph), 71.4 
(OCH2CHCH2), 70.4, 68.7, 68.0, 65.4 (4 × Ins CH); MS (FAB+) m/z (%): [M+H]
+ 
397 (47), 
[PhCO]
+ 
105 (55), [PhCH2]
+ 
91 (100); HRMS (FAB+) m/z (%): found [M+H]
+
 397.1657 
(100), C23H25O6
 
requires 397.1651. 
 
2-O-Allyl-6-O-benzyl-myo-inositol (109) 
OAllyl
OHHO
OH
OBnHO
 
Method 1: 2-O-Allyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (79, 500 mg, 1.26 
mmol) was dissolved in TFA-water (4:1 v/v, 10 ml) and stirred overnight. The reaction 
mixture was then evaporated to dryness and re-evaporated from MeOH (3  5 ml). The 
residue was taken up in MeOH (10 ml), NaOMe (25 wt. % solution in MeOH) was added 
dropwise until the reaction solution attained pH 11, then the reaction was stirred overnight. 
The solution was neutralised by the dropwise addition of 0.1 M HCl and the solvent was 
evaporated. The crude product was partitioned between CHCl3 (10 ml) and water (10 ml), 
and the aqueous layer separated collected. The organic layer was then washed with water (3 
× 10 ml), and the combined aqueous layers evaporated to dryness. The crude product was 
taken up in MeOH (10 ml). The solution was filtered, and the filtrate evaporated. to afford 
the title compound (109, 391mg, 100%) as a colourless oil, which was used without further 
purification. 
Method 2: 2-O-Allyl-4-O-para-methoxybenzyl-6-O-benzyl-myo-inositol-1,3,5-O-
orthobenzoate (108, 9.30 g, 18.0 mmol) was dissolved in TFA-water (4:1 v/v, 50 ml) and 
stirred overnight. The reaction mixture was evaporated to dryness and then re-evaporated 
from MeOH-CHCl3 (1:1 v/v, 3 × 20 ml). The residue was taken up in MeOH-CHCl3 (1:1 
v/v, 50 ml), NaOMe (25 wt. % solution in MeOH) was added dropwise until the reaction 
solution attained pH 11, and the reaction was stirred overnight. The solution was neutralised 
by the dropwise addition of 0.1 M HCl and the solvent was evaporated. The crude product 
was partitioned between CHCl3 (25 ml) and water (25 ml), and the aqueous layer collected. 
The organic layer was then washed with water (3 × 20 ml), and the combined aqueous layers 
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evaporated to dryness. The crude product was taken up in MeOH (10 ml). The solution was 
filtered, and the filtrate evaporated to afford the title compound (109, 5.59 g, 100%) as a 
colourless oil, which was used without further purification. Rf (EtOAc) 0.25; H (400 MHz; 
CD3OD) 7.43 (2H, bd, J 7.2), 7.30 (2H, bt, J 7.2), 7.24 (1H, tt, J 7.2, 1.4) (5 × Ph-H), 6.00 
(1H, ddt, J 17.3, 10.4, 5.7, OCH2CHCH2), 5.25 (1H, dq, J 17.3, 1.8), 5.11 (1H, ddt, J 10.4, 
2.1, 1.3) (OCH2CHCH2), 4.86 (1H, d, J 10.7), 4.84 (1H, d, J 10.7) (OCH2Ph), 4.37-4.29 
(2H, m, OCH2CHCH2), 3.77 (1H, t, J 2.6, Ins 2-H), 3.64 (1H, t, J 9.5), 3.60 (1H, t, J 9.4), 
3.52 (1H, dd, J 9.8, 2.6), 3.38 (1H, dd, J 9.9, 2.6) (4 × Ins-H), 3.29 (1H, t, J 9.1, Ins 5-H); C 
(100 MHz; CD3OD) 140.5 (Ph C), 137.2 (OCH2CHCH2), 129.2 (2C), 129.1 (2C), 128.5 (5 × 
Ph CH), 116.5 (OCH2CHCH2), 83.5 (Ins CH), 82.3 (Ins 2 CH), 76.7 (Ins 5 CH), 76.0 
(OCH2Ph), 75.6 (OCH2CHCH2), 74.8, 73.6, 73.6 (3 × Ins CH); MS (FAB+) m/z (%): 
[M+H]
+
 333 (100), [PhCH2]
+
 91 (29); HRMS (ES+) m/z (%): found [M+Na]
+
 333.1317 (70), 
C16H22O6Na requires 333.1314. 
 
1-H-Tetrazole (34) 
N
N N
N
H
 
 
 
Figure 57. Sublimation apparatus. 
 
Sodium nitrite (69 g, 1.0 mol) in water (200 ml) was slowly added to a mechanically stirred 
suspension of 5-aminotetrazole monohydrate (103 g, 1.0 mol) and 50% aqueous 
hypophosphous acid (120.5 ml, 1.1 mol) in water (500 ml). The reaction mixture was 
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maintained at 35 °C (initially by cooling, then by heating) for 30 min after addition of the 
sodium nitrite. After cooling the pH was adjusted to ~3.5 with 5 M sodium hydroxide 
solution, and the reaction mixture evaporated to dryness. The residue was refluxed for 15 
min in EtOAc (250 ml), and then the supernatant was decanted. Extraction by refluxing and 
decantanting was repeated (4 × 100 ml), and the extracts were combined, then evaporated to 
dryness to afford crude 1-H-tetrazole. A drying pistol with its end cap filled with 
batches of ~2 g crude 1-H-terazole – with glass wool to hold it in place – was 
attached to a high vacuum oil pump, and heated using a Kugelröhr heater (Figure 57). 
Careful control the temperature (< 130 °C), and pressure (~0.01 mmHg) allowed the 
crude 1-H-terazole to be sublimed to afford the pure product (34).  
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-myo-inositol (114) 
OBn
OO
O
OBnO
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn  
2,6-O-Dibenzyl-myo-inositol (99, 50 mg, 0.14 mmol) was evaporated from MeCN (2  1 
ml) and then tetrazole (246 mg, 1.94 mmol) was added and the mixture evaporated again 
from MeCN (1 ml). The mixture was taken up in MeCN (2.5 ml) and N,N-diisopropyl 
dibenzyl phosphoramidite (320 l, 0.97 mmol) in DCM (2.5 ml) was added drop-wise. The 
reaction was stirred for 2 h. The reaction was cooled to -20 °C, before adding mCPBA (77% 
max., 435 mg, 1.94 mmol) in DCM (2.5 ml). The solution was then stirred for a further 1 h 
at 0 °C. The reaction mixture was taken up in DCM (15 ml) and washed with 10% aq. 
sodium thiosulfate (2  10 ml), sat. aq. NaHCO3 (2  7.5 ml), water (7.5 ml), then brine (7.5 
ml). The organic layer was dried over Na2SO4, filtered and the filtrate evaporated. The 
residue was fractionated by flash column chromatography, eluting with hexane-EtOAc (1:1 
v/v), to give the title compound (114, 101 mg, 52%). Rf (hexane-EtOAc, 2:3 v/v) 0.55; H 
(500 MHz; CDCl3) 7.39-7.36 (2H, m), 7.29-7.09 (46H, m), 6.98-6.96 (2H, m) (50 × Ph-H), 
5.09-4.73 [20H, m, (19 × OCHHPh) + Ins 4-H], 4.69 (1H, t, J 1.9, Ins 2-H), 4.64 (1H, dd, J 
11.8, 8.8, POCHHPh), 4.46 (1 H, q, J 9.2, Ins 5-H), 4.32 (1H, td, J 9.8, 1.9, Ins 1-H), 4.25 
(1H, td, J 9.4, 1.6, Ins 3-H), 4.09 (1H, t, J 9.5, Ins 6-H); P (162 MHz; CDCl3) -0.05, -0.29, -
0.47, -0.80; C (125 MHz; CDCl3) 138.1, 138.0, 136.1 (d, J 7.5), 136.0 (d, J 6.9), 135.9 (d, J 
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7.4), 135.7 (d, J 7.1), 135.6 (d, J 6.9), 135.5 (2C, d, J 7.2), 135.4 (d, J 6.7) (10 × Ph C), 
128.6-127.1 (m, 50 × Ph CH), 78.1-77.9 (m, Ins 5 CH), 77.7 (d, J 7.7, Ins 6 CH), 77.2 (Ins 2 
CH), 77.1 (d, J 5.8, Ins 1 CH), 76.0 (dt, J 8.6, 5.3, Ins 4 CH), 75.8 (OCH2Ph), 75.4-75.3 (m, 
Ins 3 CH), 74.6 (OCH2Ph), 69.75 (d, J 5.7), 69.58 (d, J 5.4), 69.52 (d, J 5.6), 69.50 (d, J 
5.7), 69.48 (2C, d, J 5.6), 69.28 (d, J 5.4), 69.22 (d, J 5.2) (8 × POCH2Ph); MS (FAB+) m/z 
(%): [M+H]
+
 1401 (56), [M-PhCH2]
+
 1310 (30), [PhCH2]
+
 91 (100). 
 
myo-Inositol-1,3,4,5-O-tetrakisphosphate (115) 
OH
OO
O
OHO
P
O
-
O
P
O
O
-
P
O
O
-
P
O
-
O
O
-
O
-
-
O
O
-
8NH4
+
 
Hydrogenolysis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-myo-inositol 
(114, 110 mg, 79 mol) was effected using general method 1 followed by general method 2 
to give the ammonium salt of the title compound (115, 53 mg, 100%). H (500 MHz; D2O) 
4.26 (1H, q, J 9.5, Ins 4-H), 4.25 (1H, t, J 2.7, Ins 2-H), 3.98 (1H, td, J 9.8, 2.8, Ins 3-H), 
3.92 (1H, td, J 9.3, 2.5, Ins 1-H), 3.91 (1H, q, J 9.2, Ins 5-H), 3.77 (1H, t, J 9.6, Ins 6-H); P 
(202 MHz; D2O) 1.49, 1.13, 0.59, 0.42; C (125 MHz; D2O) 78.2 (dd, J 6.1, 3.1, Ins 5 CH), 
76.0 (ddd, J 6.5, 4.8, 3.1, Ins 4 CH), 74.5 (d, J  5.5, Ins 1 CH), 74.3 (dd, J 5.7, 2.1, Ins 3 
CH), 70.9 (dd, J 5.8, 2.8, Ins 6 CH), 70.5 (Ins 2 CH); HRMS (ES-) m/z (%): found [M-H]
-
 
498.9274 (100), C6H15O18P4 requires 498.9209. 
 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-myo-inositol (116) 
OBn
OBnO
O
OBnO
P
O
OBn
P
O
OBn
P
OBnO
OBn
BnO
OBn  
2,3,6-O-Dibenzyl-myo-inositol (105, 76 mg, 0.17 mmol) was evaporated from MeCN (2  1 
ml) and then tetrazole (118 mg, 1.68 mmol) was added and the mixture evaporated again 
from MeCN (1 ml). The mixture was taken up in MeCN (2 ml) and N,N-diisopropyl 
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dibenzyl phosphoramidite (277 l, 0.84 mmol) in DCM (2 ml) was added drop-wise. The 
reaction was stirred for 2 h. The reaction was cooled to -20 °C, before adding mCPBA (77% 
max., 245 mg, 1.09 mmol) in DCM (2 ml). The solution was then stirred for a further 1 h at 
0 °C. The reaction mixture was taken up in DCM (10 ml) and washed with 10% aq. sodium 
thiosulfate (2  10 ml), sat. aq. NaHCO3 (2  7.5 ml), water (7.5 ml), then brine (7.5 ml). 
The organic layer was dried over Na2SO4, filtered and the filtrate evaporated. The residue 
was fractionated by flash column chromatography, eluting with hexane-EtOAc (1:1 v/v), to 
give the title compound (116, 114 mg, 55%). Rf (hexane-EtOAc, 1:2 v/v) 0.52; H (500 
MHz; CDCl3) 7.38-7.34 (3H, m), 7.33-7.16 (31H, m), 7.15-7.08 (9H, m), 6.98-6.96 (2H, m) 
(45 × Ph-H), 5.06-4.74 [15H, m, (14 × OCHHPh) + Ins 4-H], 4.70-4.63 (2H, m, 2 × 
OCHHPh), 4.55 (1H, q, J 9.2, Ins 5-H), 4.54 (1H, d, J 11.6), 4.47 (1H, d, J 11.6) (OCH2Ph), 
4.35 (1H, t, J 2.3, Ins 2-H), 4.27 (1H, ddd, J 9.8, 7.5, 2.4, Ins 1-H), 4.12 (1H, t, J 9.5, Ins 6-
H), 3.47 (1H, dd, J 9.9, 2.2, Ins 3-H); P (202 MHz; CDCl3) -1.64, -1.80, -2.03; C (125 
MHz; CDCl3) 138.22, 138.20, 137.3, 136.13 (d, J 7.4), 136.11 (d, J 7.6), 136.09 (d, J 7.7), 
135.8 (d, J 7.3), 135.53 (d, J 7.0), 135.49 (d, J 7.0) (9 × Ph C), 128.5-127.1 (m, 45 × Ph 
CH), 79.1-78.9 (m, Ins 5 CH), 78.0-77.9 (m, 3 × Ins CH), 77.8 (Ins 3 CH), 75.2 (OCH2Ph), 
75.1 (Ins 2 CH), 74.5, 72.3 (2 × OCH2Ph), 69.45 (d, J 6.0), 69.41 (d, J 6.1), 69.36 (d, J 5.5), 
69.28 (d, J 5.3), 69.12 (d, J 5.0), 69.08 (d, J 5.0) (6 × POCH2Ph); MS (ES+) m/z (%): 
[M+Na]
+
 1253 (100), [M+H]
+
 1231 (93). 
 
myo-Inositol-1,4,5-O-trisphosphate (117) 
OH
OHO
O
OHO
P
O
O
-
P
O
O
-
P
O
-
O
O
-
-
O
O
-
6NH4
+
 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-myo-inositol (116, 88 mg, 72 mol) 
was taken up in 
t
BuOH-water (6:1 v/v, 7 ml), then sodium bicarbonate (36 mg, 0.43 mmol) 
and Pd-black (114 mg, 1.07 mmol) were added. The reaction vessel was flushed with N2 (  
3) followed by H2 (  3). The reaction mixture was stirred under 1 atm. H2 for 24 h. The 
solution was filtered, the remaining solids washed with water (15 ml), and the combined 
filtrates evaporated under reduced pressure. The residue was taken up in water (15 ml) and 
washed with CHCl3 (15 ml). The aqueous layer was evaporated under reduced pressure to 
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give the sodium salt. Using general method 2 then gave the ammonium salt of the title 
compound (117, 53 mg, 100%). H (400 MHz; D2O) 4.15 (1H, t, J 2.8, Ins 2-H), 4.15 (1H, q, 
J 9.2, Ins-H), 3.90 (1H, td, J 9.7, 2.7, Ins 1-H), 3.89 (1H, q, J 8.9, Ins-H), 3.79 (1H, t, J 9.5, 
Ins 6-H), 3.61 (1H, dd, J 9.8, 2.7, Ins 3-H); P (162 MHz; D2O) 2.06, 1.32, 0.20; C (125 
MHz; CDCl3) 78.1 (t, J 5.3), 76.5 (dd, J 6.1, 3.4), 75.0 (d, J 5.6), 71.1 (t, J 4.5), 70.6-70.5 
(2C, m) (6 × Ins CH); HRMS (ES-) m/z (%): found [M-H]
-
 418.9566 (100), C6H14O15P3 
requires 418.9546. 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-inositol (118) 
O
OO
O
OBnO
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn  
2-O-Allyl-6-O-benzyl-myo-inositol (109, 380 mg, 1.22 mmol) was evaporated from MeCN 
(2  2 ml) and then tetrazole (1.20 g, 17.15 mmol) was added and the mixture evaporated 
again from MeCN (2 ml). The mixture was taken up in MeCN (10 ml) and N,N-diisopropyl 
dibenzyl phosphoramidite (2.82 ml, 8.58 mmol) in DCM (10 ml) was added. The reaction 
was stirred for 2 h, then cooled to -20 °C, before adding mCPBA (77% max., 2.46 g, 11.03 
mmol) in DCM (10 ml). The solution was then stirred for a further 1 h at 0 °C. The 
reaction mixture was taken up in DCM (20 ml) and washed with 10% aq. sodium thiosulfate 
(2  15 ml), sat. aq. NaHCO3 (2  10 ml), water (10 ml), then brine (10 ml). The organic 
layer was dried over Na2SO4, filtered and the filtrate evaporated. The residue was 
fractionated by flash column chromatography, eluting with hexane-EtOAc (1:1 v/v), to give 
the title compound (118, 721 mg, 44%). Rf (hexane-EtOAc, 1:2 v/v) 0.45; H (400 MHz; 
CDCl3) 7.39-7.35 (2H, m), 7.32-7.09 (41H, m), 6.99-6.95 (2H, m) (45 × Ph-H), 5.84 (1H, 
ddt, J 17.2, 10.6, 5.3, OCH2CHCH2), 5.17 (1H, dq, J 17.2, 1.7, OCH2CHCHH), 5.09-4.73 
[19H, m, (17 × OCHHPh) + OCH2CHCHH + Ins 4-H], 4.66 (1H, dd, J 11.8, 8.8, 
POCHHPh), 4.53 (1H, t, J 2.3, Ins 2-H), 4.43 (1H, q, J 9.2, Ins 5-H), 4.25 (1H, ddd, J 9.9, 
7.4, 2.5, Ins 1-H), 4.24-4.21 (2H, m, OCH2CHCH2), 4.17 (1H, ddd, J 9.9, 7.5, 2.4, Ins 3-H), 
4.05 (1H, t, J 9.5, Ins 6-H); P (162 MHz; CDCl3) -0.68, -0.95, -1.11, -1.45; C (100 
MHz; CDCl3) 138.1, 136.08 (d, J 7.6), 136.07 (d, J 6.8), 135.96 (d, J 7.4),135.79 (d, J 7.1), 
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135.62 (d, J 6.9), 135.56 (d, J 7.4), 135.54 (d, J 7.4), 135.49 (d, J 7.1) (9 × Ph C), 134.51 
(OCH2CHCH2), 128.6-127.2 (m, 45 × Ph CH), 116.6 (OCH2CHCH2), 78.2-78.0 (m, Ins 5 
CH), 77.72 (d, J 7.2, Ins 6 CH), 77.16 (d, J 6.0, Ins 1 CH), 76.8 (Ins 2 CH), 76.2-75.8 (m, 
Ins 4 CH), 75.6-75.3 (m, Ins 3 CH), 74.7, 74.6 (2 × CH2), 69.75 (d, J 5.9), 69.61 (d, J 5.4), 
69.54-69.47 (3C, m), 69.53 (d, J 5.5), 69.31 (d, J 5.9), 69.25 (d, J 6.1) (8 × POCH2Ph); MS 
(FAB+) m/z (%): [M+H]
+
 1351 (15), [PhCH2]
+
 91 (56). 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2,3-epoxypropyl)-6-O-benzyl-myo-
inositol (119) 
O
OO
O
OBnO
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn
O
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-inositol (118, 66 mg, 
49 mol) was dissolved in CHCl3 (1 ml), and cooled to 0 °C. mCPBA (77% max., 33 mg, 
147 mol) was added, and the reaction mixture allowed to warm to room temperature. The 
solution was then stirred for 48 h. The reaction mixture was taken up in DCM (5 ml) and 
washed with 10% aq. sodium thiosulfate (2  5 ml), sat. aq. NaHCO3 (2  5 ml), water (5 
ml), then brine (5 ml). The organic layer was dried over Na2SO4, filtered and the filtrate 
evaporated. The residue was fractionated by flash column chromatography, eluting with 
hexane-EtOAc (1:2 v/v), to give an inseparable ~2:1 mixture of diastereoisomers of the title 
compound (118, 24 mg, 35%). Rf (hexane-EtOAc, 1:2 v/v) 0.30; H (400 MHz; CDCl3) 7.41-
7.36 (2H, m), 7.34-7.10 (41H, m), 7.01-6.96 (2H, m) (45 × Ph-H), 5.12-4.60 [19H, m, (18 × 
OCHHPh) + Ins 4-H], 4.55 (1H, s , Ins 2-H), 4.45 (1H, q, J 9.2, Ins 5-H), 4.26 (1H, td, J 
10.0, 2.2, Ins-H), 4.18 (1H, td, J 8.6, 2.0, Ins-H), 4.07 (0.3H, t, J 9.4, Ins 6-H), 4.06 (0.7H, t, 
J 9.6, Ins 6-H), 3.90 (0.3H, dd, J 11.4, 3.3), 3.88 (0.7H, dd, J 11.4, 3.3), 3.65 (0.7H, dd, J 
11.4, 5.6), 3.55 (0.3H, dd, J 11.2, 5.3) (OCH2CHOCH2), 3.10-3.05 (1H, m, OCH2CHOCH2), 
2.66 (1H, t, J 4.4), 2.45 (0.7H, dd, J 5.0, 2.7), 2.40 (0.3H, dd, J 5.0, 2.6) (2 × 
OCH2CHOCH2); P (162 MHz; CDCl3) -1.32 (1P), -1.58 (1P), -1.85 (0.3P), -1.79 (0.7P), 
-2.16 (1P); MS (FAB+) m/z (%): [M+H]
+
 1368 (100). 
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myo-Inositol-1,3,4,5-O-tetrakisphosphate-2-O-propyl (120) 
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O
-
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+
 
Hydrogenolysis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-
inositol (118, 50 mg, 37 mol) was effected using general method 1 followed by general 
method 2, to give the ammonium salt of the title compound (120, 25 mg, 100%). H (500 
MHz; D2O) 4.36 (1H, q, J 9.4, Ins 4-H), 4.16 (1H, t, J 2.6, Ins 2-H), 4.05 (1H, td, J 9.9, 2.6, 
Ins 3-H), 3.98 (1H, q, J 9.0, Ins 5-H), 3.97 (1H, td, J 9.5, 2.8, Ins 1-H), 3.82 (1H, t, J 9.6, Ins 
6-H), 3.78-3.70 (2H, m, OCH2CH2CH3), 1.55 (2H, sextet, J 7.1, OCH2CH2CH3), 0.85 (3H, t, 
J 7.4, OCH2CH2CH3); P (202 MHz; D2O) 0.66, 0.52, -0.12, -0.41; C (125 MHz; D2O) 78.4 
(dd, J 6.8, 3.0, Ins 5 CH), 78.1 (Ins 2 CH), 76.5 (dt, J 6.0, 3.3, Ins 4 CH), 75.9 
(OCH2CH2CH3), 74.7 (d, J 5.4, Ins 1 CH), 74.4 (dd, J 5.9, 2.1, Ins 3 CH), 71.1 (dd, J 6.3, 
2.8, Ins 6 CH), 22.6 (OCH2CH2CH3), 9.9 (OCH2CH2CH3); HRMS (ES-) m/z (%): found [M-
H]
-
 540.9670 (100), C9H21O18P4
 
requires 540.9678. 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-acetaldehyde-6-O-benzyl-myo-
inositol (122) 
O
OO
O
OBnO
P
O
BnO
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O
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P
O
OBn
P
OBnO
OBn OBn
BnO
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O
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-inositol (118, 754 
mg, 0.558 mmol) was taken up in acetone-water (9:1 v/v, 8 ml) and N-methylmorpholine-N-
oxide (226 mg, 1.67 mmol), followed by OsO4 (4% in water, 226 l) was added. The 
reaction was stirred for 16 h. The solvent was evaporated and the residue suspended in ether 
(10 ml), then washed with water (2  10 ml), then brine (10 ml). The organic layer was dried 
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over Na2SO4, filtered and the filtrate evaporated. This crude mixture was disolved in 
dioxane (9 ml) and sat. aq. NaIO4 (3 ml) was added. The solution was stirred for 1 h. The 
solvent was evaporated, and the residue was taken up in DCM (20 ml) and washed with sat. 
aq. NaHCO3 (3  20 ml), then brine (20 ml). The organic layer was dried over Na2SO4, 
filtered and the filtrate evaporated. The residue was fractionated by flash column 
chromatography, eluting with DCM-EtOAc (9:1 v/v), to give the title compound (122, 619 
mg, 82%). Rf (DCM-EtOAc, 9:1 v/v) 0.65; H (400 MHz; CDCl3) 9.61 (1H, bs, OCH2CHO), 
7.44-7.41 (2H, m), 7.40-7.12 (41H, m), 7.06-7.03 (2H, m) (45 × Ph-H), 5.15-4.68 [19H, m, 
(9 × OCH2Ph) + Ins 4-H], 4.62 (1H, t, J 2.0, Ins 2-H), 4.60 (1H, q, J 9.2, Ins 5-H), 4.32 (1H, 
td, J 8.7, 2.0, Ins 1-H), 4.24 (1H, td, J 8.6, 1.9, Ins 3-H), 4.22 (2H, s, OCH2CHO), 4.15 (1H, 
t, J 9.6, Ins 6-H); P (162 MHz; CDCl3) -1.26, -1.51, -1.71, -2.08; C (100 MHz; CDCl3) 
199.9 (CHO), 138.0, 136.2 (d, J 7.6), 136.02 (d, J 7.0), 135.98 (d, J 7.4), 135.8 (d, J 7.0), 
135.6 (d, J 6.8), 135.44 (d, J 7.0), 135.41 (2C, m) (9 × Ph C), 128.7-127.3 (45 × Ph CH), 
78.9 (OCH2CHO), 78.8 (Ins 2 CH), 78.1-77.9 (m, Ins 5 CH), 77.6 (d, J 8.7, Ins 6 CH), 76.9 
(d, J 6.8, Ins 1 CH), 75.9 (dt, J 9.2, 4.8, Ins 4 CH), 75.1 (d, J 3.9, Ins 3 CH), 74.8 (OCH2Ph), 
70.0 (d, J 5.7), 69.9 (d, J 5.4), 69.8 (d, J 5.6), 69.66-69.63 (3C, m), 69.62 (d, J 5.4), 69.4 (d, 
J 5.2) (8 × POCH2Ph); MS (MALDI+) m/z (%): [M+K]
+
 1416 (82), [M+Na]
+
 1376 (100).  
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-acetic acid-6-O-benzyl-myo-inositol 
(121) 
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OBn OBn
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-acetaldehyde-6-O-benzyl-myo-inositol 
(122, 20 mg, 15 mol) was taken up in 
t
BuOH (0.7 ml). 2-Methyl-2-butene (2 M in THF, 
0.35 ml) was added, and the solution cooled to 0 °C. „Pinnick‟ oxidant (Stock solution: 
NaClO2, 6.1 g; NaH2PO4, 4.3 g; water, 100 ml) was added drop-wise until TLC showed 
complete consumption of the starting material. The solution was taken up in DCM (5 ml) 
and washed with sat. aq. NaHCO3 (3  5 ml), then brine (5 ml). The organic layer was dried 
over Na2SO4, filtered and the filtrate evaporated. The title compound (121, 14 mg, 68%) was 
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used with no further purification. Rf (DCM-EtOAc, 9:1 v/v) 0.15; H (400 MHz; CDCl3-d-
acetic acid) 7.38-7.09 (43H, m), 7.03-6.98 (2H, m) (45 × Ph-H), 5.10-4.64 [19H, m, (9 × 
OCH2Ph) + Ins 4-H], 4.59 (1H, bs, Ins 2-H), 4.60-4.52 (1H, bs, Ins 5-H), 4.40-4.25 (2H, m, 
2 × Ins-H), 4.35 (2H, s, OCH2COOH), 4.17 (1H, t, J 9.5, Ins 6-H); P (162 MHz; CDCl3) -
2.06, -2.18, -2.47, -2.71; C (100 MHz; CDCl3) 177.5 (OCH2COOH), 138.0, 135.8-135.2 
(8C, m) (9 × Ph C), 128.7-127.3 (45 × Ph CH), 78.5 (Ins 2 CH), 78.1-77.9 (m, Ins 5 CH), 
77.5 (dd, J 7.6, 1.9, Ins 6 CH), 76.9 (d, J 5.9, Ins 1 CH), 76.0 (dt, J 8.2, 4.5, Ins 4 CH), 75.0-
74.9 (m, Ins 3 CH), 74.8 (OCH2Ph), 70.7 (OCH2COOH), 70.3 (d, J 5.9), 70.2 (d, J 5.6), 
70.12-70.01 (2C, m), 70.00 (d, J 5.8), 69.93-69.87 (2C, m), 69.75 (d, J 5.3) (8 × POCH2Ph); 
MS (ES+) m/z (%): [M+Na]
+
 1391 (40), [M+H]
+
 1369 (93).  
 
myo-Inositol-1,3,4,5-O-tetrakisphosphate-2-O-acetic acid (1) 
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Hydrogenolysis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2-O-acetic acid-6-O-benzyl-
myo-inositol (121, 14 mg, 10 mol) was effected using general method 1 followed by 
general method 2, to give the ammonium salt of the title compound (1, 8 mg, 100%). H 
(500 MHz; D2O) 4.25 (1H, q, J 9.3, Ins 4-H), 4.24 (1H, d, J 15.4), 4.17 (1H, d, J 15.4) 
(OCH2COOH), 4.10 (1H, t, J 2.1, Ins 2-H), 3.94 (1H, td, J 9.9, 2.6, Ins 3-H), 3.91-3.81 (3H, 
m, 3 × Ins-H); P (202 MHz; D2O) 3.49, 3.33, 3.05, 2.85; C (100 MHz; D2O) 178.5 
(OCH2COOH), 79.0 (Ins 2 CH), 78.3 (dd, J 6.2, 3.1, Ins 5 CH), 76.1 (dt, J 5.9, 4.6, Ins 4 
CH), 74.2 (d, J 5.3, Ins 1 CH), 74.0 (dd, J 5.8, 2.0, Ins 3 CH), 72.6 (OCH2COOH), 71.5 (dd, 
J 5.2, 2.2, Ins 6 CH); HRMS (ES-) m/z (%): found [M-H]
-
 556.9276 (65), C8H17O20P4 
requires 556.9264. 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-benzyl-myo-
inositol (128) 
O
OP(OBn)2(BnO)2PO
OP(OBn)2
OBn(BnO)2PO
OO
O
O
OH
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-acetaldehyde-6-O-benzyl-myo-inositol 
(122, 482 mg, 0.36 mmol) was taken up in MeOH (30 ml). Acetic acid (300 l) wads added, 
followed by NaBH3CN (1 M in THF, 356 l, 0.36 mmol). The solution was stirred for ~2 h, 
monitoring extent of reaction by TLC and staining with 2,4-DNP. When the reaction had 
gone to completion it was taken up in DCM (20 ml), washed with sat. aq. NaHCO3 (2  15 
ml), and brine (15 ml). The organic layer was dried over MgSO4, filtered and the filtrate 
evaporated. The title compound (128, 309 mg, 64%) was used with no further purification. 
Rf (DCM-EtOAc, 9:1 v/v) 0.65; H (500 MHz; CDCl3) 7.41-7.37 (2H, m), 7.34-7.13 (41H, 
m), 7.04-7.01 (2H, m) (45 × Ph-H), 5.10-4.67 [19H, m, (9 × OCH2Ph) + Ins 4-H], 4.57 (1H, 
t, J 2.4, Ins 2-H), 4.46 (1H, q, J 9.3, Ins 5-H), 4.29 (1H, ddd, J 10.1, 7.5, 2.5, Ins 1-H), 4.21 
(1H, ddd, J 9.8, 7.5, 2.3, Ins 3-H), 4.08 (1H, t, J 9.3, Ins 6-H), 3.88-3.82 (2 H, m, 
OCH2CH2O), 3.65 (2 H, t, J 4.4, OCH2CH2O); P (202 MHz; CDCl3) -1.22, -1.64, -1.73, -
2.03; C (125 MHz; CDCl3) 138.0, 136.02 (d, J 7.3), 135.98 (d, J 7.2), 135.94 (d, J 7.4), 
135.78 (d, J 7.0), 135.58 (d, J 6.9), 135.54 (d, J 7.2), 135.50 (d, J 7.4), 135.45 (d, J 7.0) (9 × 
Ph C), 128.6-127.3 (m, 45 × Ph CH), 78.0-77.9 (m, Ins 5 CH), 77.8 (d, J 6.4, Ins 6 CH), 77.2 
(d, J 6.1, Ins 1 CH), 76.9 (Ins 2 CH), 76.0 (dt, J 8.3, 5.0, Ins 4 CH), 75.41 (OCH2CH2O), 
75.35 (d, J 4.7, Ins 3 CH), 74.7 (OCH2Ph), 69.93 (d, J 5.6), 69.85 (d, J 5.3), 69.71 (d, J 5.5), 
69.61 (2C, d, J 5.8), 69.59 (d, J 5.9), 69.56 (d, J 5.8), 69.38 (d, J 5.1) (8 × POCH2Ph), 61.9 
(OCH2CH2O); MS (ES+) m/z (%):[M+Na]
+
 1377 (95), [M+H]
+
 1355 (100).  
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myo-Inositol-1,3,4,5-O-tetrakisphosphate-2-O-(2-hydroxyethyl) (129) 
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Hydrogenolysis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-
benzyl-myo-inositol (128, 80 mg, 59 mol) was effected using general method 1 followed 
by general method 2, to give the ammonium salt of the title compound (129, 40 mg, 100%). 
H (400 MHz; D2O) 4.31 (1H, q, J 9.4, Ins 4-H), 4.12 (1H, t, J 2.6, Ins 2-H), 4.02 (1H, td, J 
9.9, 2.6, Ins 3-H), 3.96 (1H, td, J 9.9, 2.5, Ins 1-H), 3.91 (1H, q, J 9.0, Ins 5-H), 3.84 (2H, t, 
J 4.6, OCH2CH2O), 3.82 (1H, t, J 9.4, Ins 6-H), 3.70-3.60 (2H, m, OCH2CH2O); P (162 
MHz; D2O) 2.75, 2.49, 1.71, 1.41; C (100 MHz; D2O) 78.7 (Ins 2 CH), 78.3 (dd, J 6.3, 2.8, 
Ins 5 CH), 76.2 (dt, J 5.8, 2.9, Ins 4 CH), 74.7 (d, J 5.4, Ins 1 CH), 74.5 (OCH2CH2O), 74.3 
(dd, J 6.0, 1.9, Ins 3 CH), 71.1 (dd, J 6.0, 2.8, Ins 6 CH), 61.0 (OCH2CH2O); HRMS (ES-) 
m/z (%): found [M-H]
-
 542.9456 (92), C8H19O19P4 requires 542.9471. 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2-methanesulfonyloxyethyl)-6-O-
benzyl-myo-inositol (130) 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-benzyl-myo-inositol 
(128, 105 mg, 78 mol) was taken up in pyridine (1 ml), and cooled to 0 °C. MsCl (7.80 l, 
97 mol) was added, and the solution stirred for 2 h at room temperature. The solvent was 
evaporated, and the residue resuspended in DCM (10 ml), then washed with sat. aq. 
NaHCO3 (10 ml), water (10 ml), then brine (10 ml). The organic layer was dried over 
MgSO4, filtered and the filtrate evaporated. The residue was fractionated by flash column 
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chromatography, eluting with hexane-EtOAc (1:3 v/v), to give the title compound (130, 34 
mg, 31%). Rf (hexane-EtOAc, 1:3 v/v) 0.80; H (400 MHz; CDCl3) 7.46-7.11 (43H, m), 
7.02-6.99 (2H, m) (45 × Ph-H), 5.10-4.65 [19H, m, (9 × OCH2Ph) + Ins 4-H], 4.57 (1H, t, J 
2.2, Ins 2-H), 4.44 (1H, q, J 9.3, Ins 5-H), 4.26 (1H, ddd, J 10.1, 7.4, 2.4, Ins 1-H), 4.21-4.14 
(3H, m, OCH2CH2O + Ins 3-H), 4.03 (1H, t, J 9.3, Ins 6-H), 3.94-3.83 (2H, m, OCH2CH2O), 
2.99 (3H, s, SO2CH3); P (162 MHz; CDCl3) -1.29, -1.58, -1.77, -2.03; C (100 MHz; 
CDCl3) 138.0, 135.97 (d, J 6.8), 135.93 (d, J 6.7), 135.92 (d, J 6.9), 135.72 (d, J 7.0), 
135.54-135.46 (2C, m), 135.43 (d, J 6.9), 135.42-135.37 (m) (9 × Ph C), 129.5-127.3 (45 × 
Ph CH), 78.0-77.9 (m, Ins 5 CH), 77.7 (Ins 6 CH), 77.5 (d, J 8.3, Ins 1 CH), 77.3 (Ins 2 CH), 
77.0 (d, J 8.3, Ins 4 CH), 75.0 (d, J 4.7, Ins 3 CH), 74.8 (OCH2Ph), 71.4 (OCH2CH2O), 
69.98 (d, J 5.7), 69.90 (d, J 5.6), 69.75 (d, J 5.7), 69.62 (2C, d, J 5.7), 69.60 (2C, d, J 5.7), 
69.39 (d, J 5.3) (8 × POCH2Ph), 68.8 (OCH2CH2O), 37.5 (SO2CH3); MS (ES+) m/z (%): 
[M+Na]
+
 1455 (100), [M+H]
+
 1433 (87). 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2-azidoethyl)-6-O-benzyl-myo-
inositol (131) 
O
OO
O
OBnO
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn
N3
 
DIAD (52.9 l, 0.27 mmol) was added dropwise to a cooled (-5 °C) solution of Ph3P (65 
mg, 0.25 mmol) in THF (0.4 ml). After 30min, a solution of 1,3,4,5-O-
tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-benzyl-myo-inositol (128, 140 
mg, 0.10 mmol) in THF (0.3 ml) was added. After a further 10 min, diphenyl 
phosphorazidate (DPPA, 52.5 l, 0.24 mmol) was added and the reaction mixture was 
allowed to attain room temperature. After stirring overnight, the reaction was taken up in 
DCM (10 ml) and washed with sat. aq. NaHCO3 (2  10 ml), then brine (10 ml). The organic 
layer was dried over Na2SO4, filtered and the filtrate evaporated. The residue was 
fractionated by flash column chromatography, eluting with hexane-EtOAc (1:3 v/v), to give 
the title compound (131, 68 mg, 48%). Rf (hexane-EtOAc, 1:1 v/v) 0.50; H (400 MHz; 
CDCl3) 7.42-7.38 (2H, m), 7.35-7.12 (41H, m), 7.01-6.98 (2H, m) (45 × Ph-H), 5.13-4.79 
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[18H, m, (17 × OCHHPh) + Ins 4-H], 4.66 (1H, dd, J 11.8, 8.9, POCHHPh), 4.57 (1H, t, J 
2.5, Ins 2-H), 4.46 (1H, q, J 9.3, Ins 5-H), 4.28 (1H, ddd, J 10.0, 7.7, 2.3, Ins 1-H), 4.20 (1H, 
ddd, J 9.9, 7.5, 2.4, Ins 3-H), 4.08 (1H, t, J 9.6, Ins 6-H), 3.90 (1H, ddd, J 10.3, 5.8, 3.5), 
3.81 (1H, ddd, J 10.4, 7.0, 3.4) (CH2CH2), 3.27 (1H, ddd, J 13.4, 7.1, 3.5), 3.16 (1H, ddd, J 
13.4, 5.8, 3.4) (CH2CH2); P (162 MHz; CDCl3) -1.37, -1.52, -1.81, -2.07; C (100 MHz; 
CDCl3) 138.1, 136.02 (2C, d, J 7.5), 135.94 (d, J 7.9), 135.73 (d, J 7.0), 135.53 (d, J 6.4), 
135.48 (d, J 7.2), 135.46 (d, J 7.2), 135.41 (d, J 6.9) (9 × Ph C), 128.6- 127.1 (45 × Ph CH), 
78.0-77.9 (m, Ins 5 CH), 77.7 (Ins 2 CH), 77.5 (dd, J 8.0, 1.8, Ins 6 CH), 76.8 (d, J 5.7, Ins 1 
CH), 75.9 (dt, J 8.5, 5.5, Ins 4 CH), 75.3 (dt, J 5.5, 1.9, Ins 3 CH), 74.7 (OCH2Ph), 73.1 
(CH2CH2), 69.84 (d, J 5.7), 69.73 (d, J 5.5), 69.59 (d, J 5.8), 69.53 (d, J 5.7), 69.52 (2C, d, J 
5.8), 69.41 (d, J 5.5), 69.25 (d, J 5.2) (8 ×POCH2Ph), 50.7 (CH2CH2); MS (ES+) m/z (%): 
[M+Na]
+
 1402 (54), [M+H]
+
 1380 (44). 
 
myo-Inositol-1,3,4,5-O-tetrakisphosphate-2-O-(2-aminoethyl) (138) 
O
OO
O
OHO
P
O
-
O
P
O
O
-
P
O
O
-
P
O
-
O
O
-
O
-
-
O
O
-
8Na
+
NH2
 
Hydrogenolysis of 1,3,4,5-O-tetrakis(dibenzyloxyphosphoryl)-2-O-(2-azidoethyl)-6-O-
benzyl-myo-inositol (131, 80 mg, 59 mol) was effected using general method 1, to give the 
sodium salt of the title compound (139, 40 mg, 100%). H (400 MHz; D2O) 4.26 (1H, q, J 
9.2, Ins 4-H), 4.18 (1H, bs, Ins 2-H), 4.07-3.98 (2H, m, CH2CH2), 3.98-3.76 (4H, m, 4 × Ins-
H), 3.17-3.07 (2H, m, CH2CH2); P (162 MHz; D2O) 3.33, 3.20, 2.76, 1.46; HRMS (ES-) 
m/z (%): found [M-H]
-
 541.9625 (100), C8H20NO18P4 requires 541.9631, found [M+Na-2H]
-
 
563.9452 (32), C8H19NO18P4Na requires 563.9450. 
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N,N’-Bis(benzyloxycarbonyl)guanidine (140) 
H2N
NCbz
NHCbz  
N,N’-Bis(benzyloxycarbonyl)-S-methylisothiourea (1.0 g, 2.79 mmol) was dissolved in 
MeOH (27 ml) and 0.88 ammonia (3 ml), and stirred overnight. The precipitate was 
separated from the supernatant, then recrystallised from MeOH-DCM to give the title 
compound (141, 731 mg, 80%). H (400 MHz; CDCl3) 9.50-8.00 (2H, bs, NH2), 7.58-7.12 
(10H, m, 10 × Ph-H), 5.10 (4H, s, 2 × OCH2Ph); C (100 MHz; CDCl3) 158.90 (2C, 2 × 
CO), 135.58 (2C, 2 × Ph C), 128.52 (4C), 128.28 (2C), 128.01 (4C) (10 × Ph CH), 67.45 
(2C, 2 × OCH2Ph); mp 148 – 150 °C; HRMS (ES+) m/z (%): found [M+H]
+
 328.1309 (100), 
C17H18N3O4 requires 328.1297. 
 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-{2-[N,N’-
bis(benzyloxycarbonyl)guanidino]ethyl}-6-O-benzyl-myo-inositol (141) 
O
OO
O
OBnO
P
O
BnO
P
O
OBn
P
O
OBn
P
OBnO
OBn OBn
BnO
OBn
N
NCbzCbzN
H
H
 
DIAD (39.1 l, 0.20 mmol) was added dropwise to a cooled (-5 °C) solution of Ph3P (48 
mg, 0.18 mmol) in THF (0.3 ml). After 30min, a solution of 1,3,4,5-O-
tetrakis(dibenzyloxyphosphoryl)-2-O-(2-hydroxyethyl)-6-O-benzyl-myo-inositol (128, 100 
mg, 74 mol) in THF (250 l) was added. After a further 10 min, N,N’-
bis(benzyloxycarbonyl)guanidine (141, 58 mg, 0.18 mmol) was added and the reaction 
mixture was allowed to attain room temperature. After stirring overnight, the reaction was 
taken up in DCM (10 ml) and washed with sat.aq.  NaHCO3 (2  10 ml), then brine (10 ml). 
The organic layer was dried over Na2SO4, filtered and the filtrate evaporated. The residue 
was fractionated by flash column chromatography, eluting with hexane-EtOAc (1:3 v/v), to 
give the impure title compound (141, 49 mg, 40%). Rf (hexane-EtOAc, 1:1 v/v) 0.45; H 
(400 MHz; CDCl3) 7.42-7.02 (53H, m), 6.93-6.90 (2H, m) (55 × Ph-H), 5.33 (1H, d, J 12.3), 
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5.24 (1H, d, J 12.3) (OCH2Ph), 5.12-4.52 [21H, m, (10 × OCH2Ph) + Ins 4-H], 4.46-4.38 
(2H, m, Ins 2-H + Ins 5-H), 4.27-4.19 (3H, m, CH2CH2 + Ins 1-H), 4.20 (1H, ddd, J 10.0, 
7.9, 2.4, Ins 3-H), 3.93-3.85 (3H, m, CH2CH2 + Ins 6-H); P (162 MHz; CDCl3) -0.03, -0.33, 
-0.44, -0.65; C (100 MHz; CDCl3) 163.5, 160.4, 155.8 [(2 × CO) + C=N], 138.2, 136.7, 
136.00 (d, J 7.5), 135.95 (d, J 7.9), 135.86 (d, J 7.0), 135.85 (d, J 6.4), 135.51-135.46 (m), 
135.45-135.41 (m), 135.41-135.37 (m), 135.37-135.33 (m), 135.0 (11 × Ph C), 128.7-127.0, 
(55 × Ph CH), 78.1-78.0 (m), 77.8-77.7 (m), 77.23-77.15 (m), 77.13-77.04 (m), 76.2-76.1 
(m), 75.2-75.1 (m) (6 × Ins CH), 74.6, 72.1 (2 × OCH2Ph), 69.84 (d, J 5.7), 69.74 (d, J 5.5), 
69.65-69.59 (m), 69.58-69.54 (m), 69.53-69.49 (m), 69.49-69.45 (m), 69.44-69.38 (m), 
69.27 (d, J 5.1) (8 ×POCH2Ph), 69.1 (OCH2Ph), 667.0 (CH2CH2), 44.6 (CH2CH2); MS 
(ES+) m/z (%): [M+H]
+
 1664.6 (100). 
 
8.2 BIOCHEMISTRY 
 
The following protocols where either: Adapted from the standard protocols used 
within the Mann group; adapted from those provided by G.  Rosenberg (née Busch); 
or protocols provided with the the reagents. 
 
8.2.1 Transformation by electroporation 
  
Transformation of BL21 E.coli, with either the pGEX-PKB -PH or pGEX-E17A 
plasmids were carried out using the electroporation protocol:  
 
 Take out E.coli BL21 from -80 °C freezer and thaw on ice. 
 Put cuvettes on ice. 
 Switch on the electroporation machine. Set to 25, 200 (black knob) and set 
the voltage to 2.2-2.3.  
 Calibrate machine by applying a pulse across the empty cuvette holder.  
 Take 1 l of DNA and add it into the 50 l aliquot of E.coli.  
 Set the Gilson to about 60 l, mix carefully and transfer into chilled 
cuvettes. Make sure not to get bubbles. If you get this wrong or there is too 
much salt it will spark. If you have a spark then the cuvette must be thrown 
away. 
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 Set up the cuvettes on the electroporation machine (make sure bottom is 
covered with mixture) and apply the pulse.  
 Add 1ml of LB into the cuvettes, mix and transfer back into an Eppendorf 
tube.  
 Spin and remove about a half of supernatant, then resuspend the rest.  
 Plate it onto LB + ampicillin and leave in 37 °C overnight. Clean cuvettes 
thoroughly and dry in the 37 °C room. 
 
8.2.2 Transformation by heat shock 
  
Transformation of BL21(DE3) E.coli, with either the pGEX-PKB -PH or pGEX-
E17A plasmids were carried out using the heat shock protocol:  
 
 Take out E.coli BL21(DE3) from -80 °C freezer and thaw on ice. 
 Take 1 l of DNA, add it into the 50 l aliquot of E.coli and swirl gently. 
 Incubate the reactions on ice for 30 min.  
 Preheat 1 ml LB in a 42 °C water bath. 
 Heat-pulse each transformation reaction in a 42 °C water bath for 45 s. The 
duration of the heat pulse is critical for optimal transformation efficiencies. 
 Incubate the reactions on ice for 2 min.  
 Add 0.9 ml of preheated (42 °C) LB to the transformation reaction and 
incubate the reactions at 37 °C for 1 h with shaking at 225–250 rpm. 
 Using a sterile spreader, plate ≤ 200 μl onto LB + ampicillin and leave in 37 
°C overnight.  
 
8.2.3 LB preparation of GST fusion protein 
 
GST fusion proteins where expressed and isolated from BL21 E.coli in LB: 
 
Bacterial expression 
 
 Incubate a colony of transformed BL21 E.coli in three litres of LB, 
containing 100 μg/ml ampicillin, at 30 °C and 225 rpm for 16 h.  
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 Induce protein expression by adding 1 ml/l of 1M IPTG (in freezer). 
 Incubate for a further 16h at 18 °C and 225 rpm. 
 
GST fusion protein isolation 
 
 Collect the cells from the LB into a single sample: 
o Spin samples for 5 min at 5000 rpm, 4 ºC.  
o Remove supernatant and collect pellet.  
 Resuspend pellet in NETN and vortex. N.B. As NETN contains detergent 
(i.e. NP-40), it could develop foam. Try not to get the flask full of bubbles.  
 Keep on ice and sonicate at power 18 for 2 × 30 s.  
 Spin for 5 min at 5000 rpm at 4 ºC (If the sonication has worked well the 
pellet volume should be reduced compared to the initial big pellet and the 
supernatant solution should be brown/yellow).  
 In the meantime, equilibrate glutathione sepharose beads (from Amersham). 
o Take 1.5 ml of beads from the stock into 50 ml Falcon tube. 
o Add 50ml of NETN . 
o Spin 2000 rpm, 4 ºC, 2 min. Remove supernatant.  
 To these beads add the supernatant from the lysed culture.  
 Mix on the wheel at 4 ºC for at least 1 h.  
 Perform 3 × washes.  
 Spin to 2000 rpm for 1 min at 4 ºC. 
 Remove supernatant. 
 Add 40ml NETN 
 Mix by inversion and repeat. 
 Resuspend the beads into 15 ml of NETN and transfer into a fresh Falcon 
tube. 
 Pulse down microfuge (up to 13000 rpm and stop immediately) 
 Reduce the volume to about 2-3 ml of NETN. 
 Add an equal volume of 80% glycerol.  
 Let it sit on ice for about 30 min so that glycerol will be distributed evenly 
throughout the liquid volume, preventing the protein from freezing.  
 Store at -20 °C unless running on a gel. 
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Component of NETN 
solution 
Volume of stock per 1 l 
of NETN (ml) 
Stock concentration 
0.5% NP40 50 10% 
20 mM Tris-HCl, pH 8 10 2 M 
0.1 M NaCl 20 5 M 
1 mM EDTA 2 0.5 M 
 
8.2.4 AI media preparation of GST fusion protein 
 
GST fusion proteins where expressed and isolated from BL21(DE3) E.coli in AI 
media: 
 
Bacterial expression 
 
 Incubate a colony of transformed BL21(DE3) E.coli in three litres of AI 
media (40 mM Na2HPO4, 20 mM KH2PO4, 90 mM NaCl, 2% w/v tryptone, 
0.5% w/v yeast extract), containing 100 μg/ml ampicillin and 0.6% v/v 
glycerol, 0.05% w/v glucose, and 0.2% w/v lactose, at 30 °C and 225 rpm for 
16 h. 
 Incubate for a further 16 h at 18 °C and 225 rpm.  
 
GST fusion protein isolation 
 
As for previous (section 8.2.3) 
 
8.2.5 Thrombin digest 
 
 Wash ~100 l of GST prep (containing ~50 l beads) 3-4 times in assay 
buffer. 
 Adjust final volume to 200 l. 
 Add 0.5U (2 l) of thrombin to sample. 
 Incubate at room temperature for 2-3 h. 
 Pulse down and remove supernatant from beads.  
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 Pulse supernatant down once more and remove to ensure no beads are left in 
sample. 
 Adjust so all protein samples are stored in 50% glycerol.  
 
Thrombin Assay Buffer (made up fresh on day of use) 
 
 20mM Tris pH 8.0 
 150mM NaCl 
 2.5mM CaCl2 
 10% Glycerol 
 
8.2.6 SDS-PAGE and Western blot 
 
 
Resolving 
gel 12.5% 
(ml) 
  
Stacking 
gel (ml) 
Total vol. 10  Total vol. 5 
Ac 4.25  Ac 0.85 
Tris 8.8 1.9  Tris 6.8 0.3 
H2O 3.65  H2O 3.8 
10% SDS 0.2  10% SDS 0.05 
 
 
 Load samples (2-40 l), and markers (3 l). 
 Run at 200 volts in running buffer (can be run at lower voltage to extend the 
time). 
 
Staining gels 
 
 After running the gel, disassemble the apparatus and remove the stacking 
gel.  
 Place gel in staining solution (Coomassie Brilliant  Blue) for 30 min. 
 Rinse the gel with warm water. 
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Semi-dry Western blot transfer procedure 
 
 Cut 6-10 sheets of Whatman 3MM filter paper the same size as the PAGE 
gel. 
 Cut membrane (PVDF) to the size of the gel.  
 Membrane activation: 
o Wet PVDF membrane in methanol for 15 s. 
o Transfer to a container of ddH2O for 5 min. 
o Soak membrane in 1 × transfer buffer for 10 min while preparing 
transfer sandwich. 
 Soak Whatman filter paper in transfer buffer for several minutes to avoid 
trapping of air bubbles. 
 Assemble sandwich (bottom up on the surface of wet semi-transfer plate): 
o 3-5 sheets of wet Whatman filter paper 
o Membrane 
o Gel 
o 3-5 sheets of wet Whatman filter paper 
 Use a roller to roll over sandwich gently to remove trapped air butbbles.  
 Apply a few ml of transfer buffer on top of sandwich to avoid drying out 
membrane during transfer. 
 Transfer at 14 volts for 40-60 min. 
 
Westerns 
 
 After transferring the protein to membrane, the membrane can be cut (best 
whilst wet and then allowed to dry).  
 Make up milk solution 5% milk powder in PBST. 
 Place membrane in the milk solution and then add primary antibody (1:500-
1:2000 dilution of anti-Akt1/PKB, PH Domain) and incubate overnight at 4 
°C. 
 Rinse membrane in water. 
 Make milk solution 5% milk powder in PBST. 
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 Incubate the membrane in the secondary reagent (a goat anti-rabbit HRP 
conjugated IgG) in PBST-milk for 1.5 h at room temperature. 
 Rinse twice with water. 
 Wash the membrane in PBS-0.1% Tween 20 for 3-5 minutes. 
 Rinse the membrane in 4-5 changes of water. 
 Prepare ECL reagent - Black first then White (do not cross contaminate).  
 Also need: tissue, tweezers, Saran wrap and timer. 
 Check Fuji SLA-3000 is on and cooled. 
 Remove PBS and add ECL to the membrane for 1 min.  
 Remove excess ECL by blotting membrane on tissue.  
 Wrap in Saran wrap. 
 Set exposure times 1 or 2 min and then assess if you need longer exposure.  
 Take a white light image so that the markers can be visualized (F2.8 
exposure 1/100 s). 
 
SDS PAGE loading buffer 
 
50 ml 2×  10 ml 5× 
1.6 ml 2M Tris pH6.8 0.8 ml 
6 ml 80% glycerol 3 ml 
10 ml 10% SDS 5 ml 
2.5 ml -mercaptoethanol 1.25 ml 
30 ml water 0 
1-2 drops bromophenol blue 1-2 drops 
 
Running buffer 
 
For 2.5 l of 10× 
75 g Tris base 
360 g glycine 
25 g SDS (measure in fume cupboard) 
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Transfer buffers 
 
ETB 
For 2.5 l of 10× 
75 g Tris base 
360 g glycine 
25 ml 10% SDS 
for 1× need to add 10% methanol 
 
Carbonate 
 
For 2 l of 10× 
6.36 g disodium carbonate 
16.8 g sodium hydrogen carbonate 
20 ml 10% SDS 
for 1 × need to add 10% methanol 
 
Coomassie Blue Stain 
 
0.25%  Coomassie Blue Dye (be careful it gets everywhere and it stains)  
10%  Methanol 
10%  Acetic Acid 
Use dH2O – must be added before adding acid 
 
Destain 
  
10%  Methanol 
10%  Acetic Acid 
Use dH2O – must be added before adding acid 
 
PBST 
 
Add 2 ml of Tween 20 to make up 2 l of PBST (i.e. 0.1%). Use a glass pipette and 
when adding Tween 20, pipette up and down to wash the inside of pipette.  
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Make PBS as normal (200 ml of 10× PBS and make up to 2 l with dH2O). 
 
8.2.7 Bradford assay 
 
To prepare in advance: 
 
1× stock of Bradford reagent 
 
 Dilute stock in fridge 1:5 with distilled water.  
 Keep in tin foil to protect from light.  
 Make on day of use. 
 
BSA standards 
 
 Range of known BSA concentrations from 0.125-1 mg/ml. 
 Make up in distilled water. 
 
Sample protein stock dilutions 
 
 Dilute your sample over a range so that optimum concentrations can be 
obtained. 
 For high concentrations dilute up to 1:100/1:1000.  
 
Method 
 
 Add 5 μl of each BSA standard to 3 wells of a clear 96 well plate.  
 Add 5 μl of sample protein, including the neat stock and dilut ions, into 3 
wells (i.e. each sample in triplicate).  
 Add 250 μl of 1× Bradford stock to each well.  
 Incubate at room temperature for 5 min.  
 Take to plate reader and measure absorbance at 595 nm.  
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8.2.8 Glutathione elution 
 
 Wash beads in 100 mM Tris pH8 2×.  
 Elute in 300 l 20 mM reduced glutathione (in 100 mM Tris pH 8) for 5 min 
at room temperature, vortexing once or twice.   Make sure the pH of the Tris 
is 8 and that the glutathione is made up freshly just before use.  
 Pulse down the beads and transfer the supernatant into a fresh tube. 
 Repeat elution several times (3-4) and check which fractions are best on a 
gel - also check the beads to see what is left on them (can be lots).  
 Dialyze against your favorite buffer to remove the glutathione/Tris if 
necessary. 
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9. APPENDIX A – ITC EQUATIONS  
 
Taken from the ITC Data Analysis in Origin® Tutorial Guide: 
 
Equations used for fitting ITC data 
 
General considerations 
 
It will be assumed throughout that the macromolecule M is in the cell at an initial 
bulk concentration M0t (mol/l) before the first injection, and the ligand X to be 
injected is initially at zero concentration in the cell. The working volume (cross -
hatched area below) of the lollipop-shaped cell is V0, the size of the i
th
 injection is 
V i and the total liquid which has been injected at any point during the experiment, 
V, is simply the sum of the individual V i for all injections. 
 
 
Figure 58. Initial volume (V0), and increase in volume ( V) on addition of ligand to sample 
cell. 
 
At the beginning of an experiment, both the cell and the long communication tube 
are filled with macromolecule solution, but it is only that contained within V0 that is 
sensed calorimetricallly, Because of the total-fill nature of the cell each injection 
acts to drive liquid out of the working volume and up into the inactive tube as 
shown by the darkened portion representing V. Thus, the concentration of 
macromolecule in V changes a small amount with each injection since the total 
number of moles of macromolecule initially in V (i.e. M0t times V0) at the beginning 
of the experiment is later distributed in a larger volume, V0 + V. Since the average 
bulk concentration of macromolecule in V is the mean of the beginning 
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concentration M0t and the present concentration Mt in the active volume, then 
conservation of mass requires that:  
 
M
0
tV0 = MtV0 +  ½(Mt + M
0
t) V (eq. 6) 
 
so that: 
 
Mt = M
0
t{[1 – ( V/2V0)]/[1 + ( V/2V0)]} (eq. 7) 
 
Using similar reasoning, it is easily shown that the actual bulk concentration of 
ligand in V0, Xt, is related to the hypothetical bulk concentration X
0
t (assuming that 
all of the injected ligand remained in V0) as follows: 
 
X
0
tV0 = XtV0 + ½Xt V (eq. 8) 
 
X = X
0
t[1 – ( V/2V0)]  (eq. 9) 
 
The above expressions for Mt and X t are used by Origin to correct for displaced 
volume effects which occur with each injection.  
 
Single Set of Identical Sites 
 
In the following equations, 
 
Kb = Binding constant; 
 
n = number of sites; 
 
V0 = active cell volume; 
 
Mt and [M] are bulk and free concentration of macromolecule in V0; 
 
Xt and [X] are bulk and free concentration of ligand, and 
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 = fraction of sites occupied by ligand X. 
 
Kb = /((1 – )[X])  (eq. 10) 
 
Xt = [X] + n Mt  (eq. 11) 
 
Combining equations (eq. 10) and (eq. 11) above gives: 
 
2 – [1 + (Xt/nMt) + (1/nKbMt)] + (Xt/nMt) = 0  (eq. 12) 
 
The total heat content Q of the solution contained in V0 (determined relative to zero 
for the unliganded species) as fractional saturation  is: 
 
Q = n Mt HV0  (eq. 13) 
 
where H is the molar heat of ligand binding. Solving the quadratic equation ( eq. 
12) for  and then substituting into eq. 13 gives: 
 
Q = (nMt HV0/2){1 + (X t/nMt) + (1/nKbMt) – [{(1+ (Xt/nMt) + (1/nKbMt)}
2
 – (4Xt/nMt)]
½
}
   
 
(eq. 14) 
 
The value of Q above can be calculated (for any designated values of n, Kb, and ΔH) 
at the end of the i
th
 injection and designated Q(i). The parameter of interest for 
comparison with experiment, however, is the change in heat content from the 
completion of the i-1
th
 injection to completion of the i
th
 injection. The expression 
for Q in equation (eq. 14) only applies to the liquid contained in volume V0. 
Therefore, after completing an injection, it is obvious that a correction must be 
made for displaced volume (i.e., V i = injection volume) since some of the liquid in 
V0 after the i-1
th
 injection will no longer be in V0 after the i
th
 injection, even though 
it will contribute to the heat effect (assuming the kinetics of reaction and mixing 
are fast) before it passes out of the working volume V0. The liquid in the displaced 
volume contributes about 50%  as much heat effect as an equivalent volume 
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remaining in V0
1
 The correct expression then for heat released, ΔQ(i), from the ith 
injection is: 
 
ΔQ(i) = Q(i) + (dV i/V0)((Q(i)+ ΔQ(i – 1))/2) – Q(i – 1)  (eq. 15) 
 
The process of fitting experimental data then involves: (i) initial guesses (which 
most often can be made accurately enough by Origin) of n, Kb, and H; (ii) 
calculation of Q(i) for each injection and comparison of these values with the 
measured heat for the corresponding experimental injection; (iii) improvement in 
the initial values of n, Kb, and ΔH by standard Marquardt methods; and (iv) iteration 
of the above procedure until no further significant improvement in fi t occurs with 
continued iteration. 
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10. APPENDIX B – NMR DATA   
 
The spectra included here are presented as illustrations of the characteristic signals 
observed in the 
1
H-, and 
31
P-NMR spectra of compounds at various stages of the 
synthesis. They were taken on either 270 MHz, 400 MHz or 500 MHz machines, 
depending on availability. Because of the differences in the machines there are 
noticeable difference in the quality of the spectra and therefore the quality of the 
possible interpretation. The spectra of the following compounds  have been 
supplied: 
 myo-Inositol-1,3,4,5-tetrakisphosphate-2-O-acetic acid (1) 
 2,6-O-Dibenzyl-4-O-(tert-butyldiphenylsilyl)-myo-inositol-1,3,5-O-
orthobenzoate (101b) 
 2-O-Allyl-6-O-benzyl-myo-inositol-1,3,5-O-orthobenzoate (108) 
 2-O-Allyl-6-O-benzyl-myo-inositol (109) 
 myo-Inositol-1,3,4,5-tetrakisphosphate (115) 
 myo-Inositol-1,4,5-trisphosphate (117) 
 1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-allyl-6-O-benzyl-myo-
inositol (118) 
 myo-Inositol-1,3,4,5-tetrakisphosphate-2-O-propyl (120) 
 1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-acetaldehyde-6-O-benzyl-
myo-inositol (122) 
 myo-Inositol-1,3,4,5-tetrakisphosphate-2-O-(2-hydroxyethyl) (129) 
 1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-(2-azidoethyl)-6-O-benzyl-
myo-inositol (131) 
 myo-Inositol-1,3,4,5-tetrakisphosphate-2-O-(2-aminoethyl) (138) 
 1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2-O-{2-[N,N’-
bis(benzyloxycarbonyl)guanidino]ethyl}-6-O-benzyl-myo-inositol (141) 
 
 
 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 170 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 171 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 172 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 173 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 174 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 175 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 176 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 177 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 178 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 179 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 180 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 181 - 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 182 - 
 
 
 
Polar group exchange receptor-ligand engineering of protein kinase B‟s pleckstrin homology domain  
 
- 183 - 
11. APPENDIX C – SYNAPTOJANIN ASSAYS 
 
These are the assays that were employed for the study of the Ins(1,4,5)P 3 and 
Ins(1,3,4,5)P4 analogues in section 4.6. 
 
Malachite Green Assay 
 
The activity of the phosphatases was determined by evaluating the levels of phosphate 
released during the course of the reaction with a malachite green dye. 
 Compounds and enzyme (SAL) were incubated at room temperature for 15 
min with 100 mM Tris, 4 mM MgCl2, pH7.4. 
 Boiled enzyme was used as a negative control.  
 The final volume of the assay was 80 l. 
 Ins(1,4,5)P3 was added to start the reaction and samples were incubated for 
30 min at 37 °C. 
 To stop the enzyme reaction, an equal volume of the acidic malachite green 
dye was added. 
 The mixture was allowed to develop for 5 min.  
 An ELISA reader was used to read the absorption of the dye at a wavelength of 625 
nm. 
 
O-Methyl Fluorescein Phosphate (OMFP) Fluorescence Assay 
 
The activity of the phosphatases towards OMFP was determined by measuring the 
fluorescence of O-methyl fluorescein (OMF), excitating at 485 nm and detecting emission at 
525 nm. 
 Compounds and enzyme were incubated at room temperature for 15 min with 
100 mM Tris, 4 mM MgCl2, pH 7.4. 
 Boiled enzyme was used as a negative control.  
 OMFP was added to start the reaction.  
 Continuously monitoring the fluorescence, with the assay thermostatted at 37 °C on a 
Cary Eclipse fluorimeter was used to study the reaction. 
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